INDEX OF EXHIBITS

Introduction
Exhibit 1.1: Approximate combined health insurance premium and out-of-pocket spending relative to income for a family of three 11

Overview of Trends in Spending and Care Delivery
Exhibit 2.1: Annual growth in per capita health care spending, MA and the U.S., 2002-2015 14
Exhibit 2.2: Annual growth in health insurance premium spending per enrollee, MA and the U.S., 2005-2015 14
Exhibit 2.3: Annual growth in commercial spending per enrollee, by spending category, 2010-2015 15
Exhibit 2.4: Growth in per person spending for major public coverage programs in Massachusetts, 2013-2015 16
Exhibit 2.5: Original Medicare (FFS) spending per beneficiary in Massachusetts and in the U.S., by category, 2015 16
Exhibit 2.6: Share of MassHealth LTSS spending on institutional care and community-based care, MA and the U.S., 2001-2014 18
Exhibit 2.7: Average annual family premiums and employee contributions, by wage quartile of employer in Massachusetts, 2015 19
Exhibit 2.8: Annual out-of-pocket spending for Massachusetts residents in the lowest and highest income areas in the state, 2014 19
Exhibit 2.9: Massachusetts hospitals performance on each component of CMS’ Hospital 5 Star Ratings, 2015 20
Exhibit 2.10: Distribution of beds, by nursing facility quality and median zip code income, 2016 21
Exhibit 2.11: Percentage of nursing facility beds in four or five star quality facilities, by HPC region, 2016 21

The Massachusetts Provider Market: Status And Trends
Exhibit 3.1: Primary care physician primary sites of practice reported to the RPO program, 2015 23
Exhibit 3.2: Summary data on the largest Massachusetts provider organizations, 2015 24
Exhibit 3.3: Physician employment status among Massachusetts’ largest provider systems, 2015 25
Exhibit 3.4: Frequency of providers involved in Material Change Notices consisting of corporate or contracting affiliations, 2013-2016 26
Exhibit 3.5: Frequency of provider alignment types for which the HPC received Material Change Notices, 2013-2016 26
Exhibit 3.6: Inpatient discharges from the top five networks, 2015 27
Exhibit 3.7: Inpatient relative price for one major commercial payer compared to inpatient net patient service revenue per case-mix-adjusted discharge across all payers, 2014 28
Exhibit 3.8: Hospital inpatient relative prices in Medicaid Managed Care Organization networks, 2014 29
Exhibit 3.9: Number of retail clinics and urgent care centers in Massachusetts, 2008-2016 31

Prescription Drug Spending
Exhibit 4.1: Growth in commercial spending categories and proportion of total medical expenses, 2013-2015 33
Exhibit 4.2: Flow of payments and prescription medications 34
Exhibit 4.3: Prescription drug growth, with and without rebates, 2014-2015 34
Exhibit 4.4: Year to year changes in pharmaceutical spending by category (in billions of US$) 35
Exhibit 4.5: Average spending and cost sharing for branded and generic drugs, per claim and per member year, 2012-2014 36
Exhibit 4.6: Distribution of cost sharing, per claim, 2012-2014 36
Exhibit 4.7: Spending and cost sharing by gender, per claim and per member per year, 2012-2014
Exhibit 4.8: Average spending and cost sharing, per claim, on Mylan's EpiPen epinephrine injector in Massachusetts, 2012-2014

**Hospital Utilization**

Exhibit 5.1: Hospital use in Massachusetts and the U.S., 2010-2014
Exhibit 5.2: ED visits per 1,000 population, by type, 2011-2015
Exhibit 5.3: Median length of stay in the ED, 2015
Exhibit 5.4: Percent of patients with an ED length of stay of 12 hours or more, 2011-2015
Exhibit 5.5: Rate of opioid-related ED visits per 100,000 population, by state, 2014
Exhibit 5.6: Inpatient discharges per 1,000 population, by age category, 2011-2015
Exhibit 5.7: Thirty-day readmission rates, Massachusetts and the U.S., 2011-2015
Exhibit 5.8: Share of community appropriate discharges, by hospital type, 2011-2015
Exhibit 5.9: Discharges at Lahey and Winchester hospitals, by type of discharge, 2012-2015

**Post-Acute Care**

Exhibit 6.1: PAC discharges, all DRGs, all payers, 2013
Exhibit 6.2: Adjusted percentage of discharges to post-acute care, all DRGs, 2010-2015
Exhibit 6.3: Original Medicare adjusted spending per beneficiary on PAC by setting, 2014
Exhibit 6.4: PAC discharge destination following joint replacement among Original Medicare patients, 2013

**Variation in Spending by Primary Care Provider Group**

Exhibit 7.1: HSA TME, by PCP group, 2012-2015
Exhibit 7.2: Annual HSA TME growth rate by PCP group, 2012-2015
Exhibit 7.3: APM uptake and HSA TME growth in the next year, by PCP group, 2013-2015
Exhibit 7.4: Indexed rates of non-recommended care, by provider group, 2013
Exhibit 7.5: Rates of non-recommended care for two selected measures, by HPC region, 2013-2014

**Alternative Payment Methods**

Exhibit 8.1: Proportion of member months under alternative payment methods (APMs) by insurance category, 2013-2015

**Demand-Side Incentives**

Exhibit 9.1: Adjusted premiums by market segment, fully-insured market, 2013-2015
Exhibit 9.2: Broker fees, per member per month, by group size
Exhibit 9.3: Plan offerings by firm size in Massachusetts, 2014
Exhibit 9.4: Full premium costs in Massachusetts compared to other states in the Massachusetts Health Connector (top) and in the small employer-group market (bottom)

**Policy Recommendations**

Exhibit 10.1: Dashboard of HPC system performance metrics
# INDEX OF ACRONYMS

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACA</td>
<td>Affordable Care Act</td>
</tr>
<tr>
<td>ACO</td>
<td>Accountable Care Organizations</td>
</tr>
<tr>
<td>ADL</td>
<td>Activities of Daily Living</td>
</tr>
<tr>
<td>AGO</td>
<td>Attorney General’s Office</td>
</tr>
<tr>
<td>AHRQ</td>
<td>Agency for Healthcare Research and Quality</td>
</tr>
<tr>
<td>AMC</td>
<td>Academic Medical Centers</td>
</tr>
<tr>
<td>APCD</td>
<td>All-Payer Claims Database</td>
</tr>
<tr>
<td>APM</td>
<td>Alternative Payment Methods</td>
</tr>
<tr>
<td>BCBS</td>
<td>Blue Cross Blue Shield</td>
</tr>
<tr>
<td>BCPI</td>
<td>Bundled Payments for Care Improvement Initiative</td>
</tr>
<tr>
<td>BH</td>
<td>Behavioral Health</td>
</tr>
<tr>
<td>BID</td>
<td>Beth Israel Deaconess</td>
</tr>
<tr>
<td>BIDCO</td>
<td>Beth Israel Deaconess Care Organization</td>
</tr>
<tr>
<td>BMC</td>
<td>Boston Medical Center</td>
</tr>
<tr>
<td>CAUTIs</td>
<td>Catheter-associated urinary tract infection</td>
</tr>
<tr>
<td>CCT</td>
<td>Complex Care Team</td>
</tr>
<tr>
<td>CHART</td>
<td>Community Hospital Acceleration, Revitalization, and Transformation Investment Program</td>
</tr>
<tr>
<td>CHF</td>
<td>Congestive Heart Failure</td>
</tr>
<tr>
<td>CHIA</td>
<td>Center for Health Information and Analysis</td>
</tr>
<tr>
<td>CLABSI</td>
<td>Central line-associated bloodstream infection</td>
</tr>
<tr>
<td>CMIR</td>
<td>Cost and Market Impact Reviews</td>
</tr>
<tr>
<td>CMS</td>
<td>Center for Medicare and Medicaid Services</td>
</tr>
<tr>
<td>COPD</td>
<td>Chronic Obstructive Pulmonary Disease</td>
</tr>
<tr>
<td>CP</td>
<td>Community Partners</td>
</tr>
<tr>
<td>CPC</td>
<td>Comprehensive Primary Care</td>
</tr>
<tr>
<td>DSRIP</td>
<td>Delivery System Reform Incentive Program</td>
</tr>
<tr>
<td>DSTI</td>
<td>Delivery System Transformation Initiatives</td>
</tr>
<tr>
<td>ED</td>
<td>Emergency Department</td>
</tr>
<tr>
<td>EHR</td>
<td>Electronic Health Record</td>
</tr>
<tr>
<td>EHS</td>
<td>Health and Human Services</td>
</tr>
<tr>
<td>EMR</td>
<td>Electronic Medical Record</td>
</tr>
<tr>
<td>FFS</td>
<td>Fee-For-Service</td>
</tr>
<tr>
<td>GE</td>
<td>General Electric</td>
</tr>
<tr>
<td>GIC</td>
<td>Group Insurance Commission</td>
</tr>
<tr>
<td>HCV</td>
<td>Hepatitis C Virus</td>
</tr>
<tr>
<td>HEDIS</td>
<td>Healthcare Effectiveness Data and Information Set</td>
</tr>
<tr>
<td>HMFP</td>
<td>Harvard Medical Faculty Physicians</td>
</tr>
<tr>
<td>HMO</td>
<td>Health Maintenance Organization</td>
</tr>
<tr>
<td>HNE</td>
<td>Health New England</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>HPC</td>
<td>Health Policy Commission</td>
</tr>
<tr>
<td>HPHC</td>
<td>Harvard Pilgrim Health Care</td>
</tr>
<tr>
<td>HSA</td>
<td>Health Status-Adjusted</td>
</tr>
<tr>
<td>IMPACT</td>
<td>Improving Medicare Post-Acute Care Transformation</td>
</tr>
<tr>
<td>IRF</td>
<td>Inpatient Rehabilitation Facility</td>
</tr>
<tr>
<td>IVC</td>
<td>Inferior Vena Cava</td>
</tr>
<tr>
<td>KFF</td>
<td>Kaiser Family Foundation</td>
</tr>
<tr>
<td>LTCH</td>
<td>Long-Term Care Hospital</td>
</tr>
<tr>
<td>LTSS</td>
<td>Long-Term Services and Supports</td>
</tr>
<tr>
<td>MACIPA</td>
<td>Mount Auburn Cambridge Independent Practice Association</td>
</tr>
<tr>
<td>MACRA</td>
<td>Medicare Access and CHIP Reauthorization Act</td>
</tr>
<tr>
<td>MCN</td>
<td>Notice of Material Change</td>
</tr>
<tr>
<td>MCO</td>
<td>Managed Care Organization</td>
</tr>
<tr>
<td>MedPAC</td>
<td>Medicare Payment Advisory Commission</td>
</tr>
<tr>
<td>MGH</td>
<td>Massachusetts General Hospital</td>
</tr>
<tr>
<td>MIPS</td>
<td>Merit-Based Incentive Payment System</td>
</tr>
<tr>
<td>MRSA</td>
<td>Methicillin-resistant staphylococcus aureus</td>
</tr>
<tr>
<td>MSSP</td>
<td>Medicare Shared Savings Program</td>
</tr>
<tr>
<td>NASHP</td>
<td>National Academy for State Health Policy</td>
</tr>
<tr>
<td>NCPHI</td>
<td>Net Cost of Private Health Insurance</td>
</tr>
<tr>
<td>NEQCA</td>
<td>New England Quality Care Alliance</td>
</tr>
<tr>
<td>NHE</td>
<td>National Health Expenditure</td>
</tr>
<tr>
<td>PAC</td>
<td>Post-Acute Care</td>
</tr>
<tr>
<td>PBM</td>
<td>Pharmacy Benefit Management</td>
</tr>
<tr>
<td>PCA</td>
<td>Personal Care Attendants</td>
</tr>
<tr>
<td>PCC</td>
<td>Primary Care Clinician</td>
</tr>
<tr>
<td>PCP</td>
<td>Primary Care Physician</td>
</tr>
<tr>
<td>PCPRI</td>
<td>Primary Care Payment Reform Initiative</td>
</tr>
<tr>
<td>PMPM</td>
<td>Per Member Per Month</td>
</tr>
<tr>
<td>PMPY</td>
<td>Per Member Per Year</td>
</tr>
<tr>
<td>POS</td>
<td>Point Of Service</td>
</tr>
<tr>
<td>PPO</td>
<td>Preferred Provider Organization</td>
</tr>
<tr>
<td>PQRS</td>
<td>Physician Quality Reporting System</td>
</tr>
<tr>
<td>RPO</td>
<td>Registration of Provider Organizations</td>
</tr>
<tr>
<td>SNF</td>
<td>Skilled Nursing Facility</td>
</tr>
<tr>
<td>SUD</td>
<td>Substance Use Disorder</td>
</tr>
<tr>
<td>THCE</td>
<td>Total Health Care Expenditures</td>
</tr>
<tr>
<td>THP</td>
<td>Tufts Health Plan</td>
</tr>
<tr>
<td>TME</td>
<td>Total Medical Expenditures</td>
</tr>
</tbody>
</table>
EXECUTIVE SUMMARY
Section I: Introduction

Consistent with the statutory mandate of the Massachusetts Health Policy Commission (HPC), the 2016 Cost Trends Report presents an overview of health care spending and delivery trends in Massachusetts, evaluates progress in key areas, and makes recommendations for strategies to increase quality and efficiency in the Commonwealth.

HPC reports have identified four areas of opportunity: fostering a value-based market; promoting an efficient, high-quality healthcare delivery system; advancing aligned and effective financial incentives; and enhancing data and measurement for transparency and accountability.

The HPC continues to emphasize these opportunities in its analysis, recommendations, and strategic priorities.

This Executive Summary presents a concise overview of the findings and recommendations detailed in this report.

FINDINGS

TRENDS IN SPENDING AND THE DELIVERY SYSTEM

Trends in spending
- Massachusetts exceeded the benchmark in 2015 for the second year in a row, with growth in total health care expenditures (THCE) of 4.1 percent, similar to growth from 2013 to 2014 (4.2 percent).
- Contributors to growth exceeding the benchmark included prescription drug spending across all sectors (accounting for roughly a third of per capita spending growth for the second year in a row), hospital spending, enrollment changes, and spending on long-term services and supports.
- Even with several years of commercial and Medicare growth rates below national trends, Massachusetts continues to be a high cost health care state. Massachusetts commercial health care spending is roughly 6-9 percent higher than the national average, with premium costs among the highest in the nation.
- These costs disproportionately impact low-to-middle income residents and result in persistent health care affordability concerns for individuals, families, employers, and government in Massachusetts.
  - Massachusetts’ level of household health care spending relative to average statewide household income is comparable to national standards, but low and middle income households bear a very high burden of spending, as premiums and out-of-pocket spending do not vary significantly by income. The roughly $20,000 premium and cost sharing total for family coverage amounts to 30 percent of household income for family of three living at three times the federal poverty level.
  - Recent information suggests rising premium costs in 2016 and beyond. After 12 quarters of growth below 4 percent, the Division of Insurance (DOI) reported base rate increases in the small group and individual markets in Massachusetts of between 5.4 and 8.3 percent from the end of 2015 through the first quarter of 2017.
- Hospital care accounts for a substantial share of total health care spending – and the rate of growth in hospital spending is increasing. Spending in this category accounted for 41 percent of total commercial spending growth in 2015, up from 18 percent in 2014.

Trends in provider markets
- Analysis of the Registration of Provider Organizations (RPO) dataset, a first-in-the-nation initiative, shows key features of the eight largest provider systems in the Commonwealth (representing about 85 percent of physicians practicing in Massachusetts), including
practices regarding direct employment of physicians, geographic reach, and organizational structure and corporate complexity.

- The majority of care in the Commonwealth is now provided by a relatively small number of large provider systems. In 2015, the five largest health systems in the state accounted for 59.9 percent of hospital discharges for commercially insured patients, an increase from 54.6 percent in 2012.

- The number of new urgent care centers entering the market in Massachusetts has grown significantly in recent years, from 8 in 2010 to 90 in 2016.

**Prescription drugs**

- While moderating somewhat in 2015, prescription drug spending continues to grow more rapidly than any other commercial category of service. Continued growth is projected.

- Drug spending has grown faster than overall commercial trends in the past three years and now accounts for more than 20 percent of commercial spending in Massachusetts when including medical drugs.

- Generic drugs represent an increasing share of the drug claims prescribed in Massachusetts (82 percent in 2012 to 84 percent in 2014), yet account for a decreasing proportion of the drug spending in the state (30 percent to 27 percent from 2012 to 2014).

- While total commercial drug spending has grown significantly in Massachusetts from 2012 to 2014, out-of-pocket spending decreased 9 percent, from $219 to $198 per member per year.

- A key factor in lower out-of-pocket spending on prescription drugs has been the Affordable Care Act’s (ACA) mandate of zero cost sharing for certain preventative drugs, including contraception. The percentage of prescription drug claims with no cost sharing among women increased dramatically between 2012 and 2014, from 3.2 percent to 13.4 percent.

- Commercial spending on Mylan’s EpiPen in Massachusetts jumped over $100 per claim in two years, from $244 in 2012 to $362 in 2014.

- Transparency on pricing trends, rebates, discounts, and pharmaceutical benefit managers is lacking.

**CARE DELIVERY PERFORMANCE: OPPORTUNITIES TO IMPROVE QUALITY AND EFFICIENCY**

**Hospital utilization**

- Hospital use declined in Massachusetts from 2010 to 2014; emergency department (ED) and hospital outpatient visits declined by 2 percent, and inpatient discharges declined by 11 percent. However, Massachusetts continues to use hospitals at a higher rate than national averages. Compared to the U.S., in 2014 Massachusetts hospital utilization rates were 50 percent higher for hospital outpatient visits, 10 percent higher for ED visits, and 8 percent higher for inpatient discharges.

- While hospital use has steadily declined in Massachusetts in recent years, in 2015 inpatient discharges increased by almost 2 percent. This growth was entirely due to increases in discharges by patients ages 65 and older.

- Massachusetts did not make progress in reaching the HPC target of a 20 percent reduction in all-cause, all-payer 30-day hospital readmissions relative to the 2013 level. The statewide all-payer readmission rate remained unchanged from 2013 to 2014 at 15.3 percent and increased to 15.8 percent in 2015.

- Inpatient care that could safely and effectively be provided in community hospitals is increasingly being provided by teaching hospitals. However, the trend is not universal. For example, at Winchester Hospital, following acquisition by the Lahey Health System in 2014, the volume of community appropriate discharges increased while community appropriate discharges decreased at Lahey Hospital and Medical Center, the system’s anchor teaching hospital.

- Despite declines in overall ED utilization, the share of visits considered avoidable has remained relatively unchanged since 2011 (42 percent of all visits).

- The number of behavioral health-related ED (including opioid-related ED use) visits per Massachusetts resident has grown steadily, increasing 13 percent from 2011 to 2015.

- ED “boarding” disproportionately impacts behavioral health patients and rates of behavioral-health related ED “boarding” are increasing. In 2015 almost a quarter of all ED patients with a primary behavioral health-related condition had a length of
stay in the ED of more than 12 hours, compared to only 1 percent of patients without a primary behavioral health-related condition.

Post-Acute Care
- Massachusetts continues to discharge patients to institutional post-acute care (PAC) settings (SNFs, IRFs, LTCHs) at a higher rate than the U.S. average, with 21.8 percent of patients in Massachusetts discharged to institutional care in 2013 compared to 17.1 percent in the U.S. overall.
- Adjusting for changes in patient acuity, institutional discharges remained relatively constant between 2010 and 2015, while discharges to home health increased somewhat over the same period.
- Rates of discharge to PAC following joint replacements have declined substantially in Massachusetts, but remain far higher than in the U.S. overall. In 2013, just 3.5 percent of Medicare joint replacements were discharged to home compared to 20.4 percent nationally.

Primary care provider group spending
- Total medical expenses (TME) per patient for the 10 largest provider groups have generally converged between 2012 and 2015, with the exception of Partners which has remained high at 7 percent above the next-highest group.
- Across all groups, health status adjusted TME grew 0.4 percent annually between 2012 and 2015, while unadjusted TME grew 3.5 percent annually, as members were reported to be roughly 3 percent sicker each year on average.
- Higher adoption of APMs is associated with lower TME growth in the subsequent year(s). Those with lower rates of APM adoption in 2013 had spending growth more than double groups with higher rates of APM adoption.
- Rates of non-recommended care, defined as services the medical community agrees provide few benefits to patients, vary in Massachusetts by provider group and by geographic region.

PROGRESS IN ALIGNING INCENTIVES FOR EFFICIENT AND HIGH QUALITY CARE

Alternative payment methods (APMs)
- Progress stalled in 2015 among both commercial and public payers in expanding use of APMs. However, there are several potentially promising developments for 2016 and beyond:
  - Expansion of APMs into commercial preferred provider organization (PPO) products, with the three largest commercial insurers reporting growth in the numbers of PPO members in global budget contracts in 2016; and expansion of quality and risk-based payments in Medicare with implementation of Medicare Access and CHIP Reauthorization Act (MACRA), adoption of the Next Generation ACO program with higher levels of downside risk than in previous ACO options, and introduction of new bundled payment initiatives.
  - Comprehensive payment and delivery system initiatives in MassHealth, with the launch of its global-budget based ACO program in 2016 as a pilot and full program in 2017.

Demand-side incentives
- Adoption of tiered network plans was unchanged from 2014 to 2015 (16 percent) and use of limited network plans grew slightly but remained low (3.0 percent to 3.2 percent).
- Fully-insured health insurance premiums varied by market segment, with premiums paid by members of the Group Insurance Commission (GIC) and those obtaining insurance through the Connector lower than those who obtain insurance in group markets. Connector premiums in the individual market were below the national average, unlike those in the small group market, which were above national averages.
- Smaller businesses pay higher broker fees and administrative costs for their insurance coverage than do larger businesses, and most do not offer employees a choice of insurance plan (unlike larger businesses). Surveyed small employers stated they were unaware of the Connector and that they don't have enough employees to offer plan choice.
RECOMMENDATIONS

In light of these findings, as well as the HPC’s other analytic and policy work throughout the year, the HPC makes the following recommendations to advance the goal of better care and better health at a lower cost for the people of the Commonwealth.

RECOMMENDATIONS TO FOSTER A VALUE-BASED MARKET

1 Health Care Equity and Affordability: The Commonwealth should examine how health care costs are differentially allocated to individuals, families, and businesses across Massachusetts, and should further consider opportunities to promote equity and affordability, including tracking and monitoring differences in health care spending, insurance costs, and member cost-sharing across a range of characteristics (e.g., socio-economic profile, employer size and industry, health status, etc.).

2 Prescription Drug Spending: The Commonwealth should take action to reduce increases in drug spending including by enhancing the transparency of drug prices and spending, and payers and providers should consider further opportunities to maximize value.

3 Out-of-Network Billing: Efforts to address out-of-network billing issues continue to gain momentum across the nation. Massachusetts has not taken comprehensive action on this issue. The Commonwealth should implement safeguards for consumers and improve market functioning related to out-of-network billing by enhancing out-of-network billing protections and establishing reasonable reimbursement for services.

4 Provider Price Variation: Extensive variation in prices paid to health care providers for the same sets of services is a persistent issue in the Commonwealth, driving increased health care spending and perpetuating inequities in health care resources. The Commonwealth should take action to reduce unwarranted variation in provider prices by continuing to monitor and analyze price variation, including by factors identified as “warranted” and “unwarranted”.

5 Facility Fees: The Commonwealth should take action to limit newly-licensed and existing sites that can bill as hospital outpatient departments and equalize payments for select services for similar patients between hospital outpatient departments and physician offices.

6 Community-Appropriate Care: The Commonwealth, payers, and providers should work to redirect community-appropriate care to high value, community settings.

RECOMMENDATIONS TO PROMOTE AN EFFICIENT, HIGH-QUALITY HEALTH CARE DELIVERY SYSTEM

7 Unnecessary Hospital Use and Other Institutional Care: The Commonwealth should continue to focus on strengthening partnerships between the health care delivery system and community-based organizations in order to reduce the unnecessary utilization of institutional care, including hospital readmissions, behavioral health-related ED visits, and institutional post-acute care.

8 Substance Use Disorder Treatment: The Commonwealth, payers, and providers should continue to improve treatment of substance use disorder, particularly including opioid use disorder.

9 Adherence to Evidence-Based Care: The Commonwealth, payers, and providers should work to focus on the highest possible adherence to evidence-based care, including putting systems in place to track and reduce the provision of non-recommended care.

RECOMMENDATIONS TO ADVANCE ALIGNED AND EFFECTIVE INCENTIVES

10 Adoption of Alternative Payment Methods (APMs): Payers and providers should continue to focus on increasing the adoption of alternative payment methods (APMs). The Commonwealth should set APM adoption targets for HMO and PPO patients, and MassHealth members.

11 Alignment and Improvement of APMs: Payers should align and improve features of APMs in order to increase their effectiveness in promoting high quality, efficient care, including through improving quality measurement, reducing disparities in spending levels, inclusion of behavioral health, and adopting HPC’s ACO certification standards.
12 Demand-Side Incentives: Payers and employers should continue to enhance strategies that empower consumers to make high-value choices, including increasing the transparency of comparative prices and quality to enhance the selection of value-based providers.

RECOMMENDATIONS TO ENHANCE DATA AND MEASUREMENT FOR TRANSPARENCY AND ACCOUNTABILITY

13 Data and Measurement: Center of Health Information and Analysis (CHIA) should continue to improve and document its data resources and develop key spending measures on drug rebates, Total Medical Expenditures (TME) for PPO populations, provider-level measures of spending growth, and ambulatory quality measures. CHIA should also evaluate the impact on the All-Payer Claims Database (APCD) of the expected loss of data due to the Gobielle decision.
INTRODUCTION
Section I: Introduction

The Health Policy Commission (HPC), created in 2012, is charged with monitoring health care spending growth in Massachusetts and providing data-driven policy recommendations on health care delivery and payment system reform (see Sidebar: “What is the role of the Health Policy Commission?”). In this fourth annual Cost Trends Report, the HPC examines key cost and market trends and evaluates the state’s progress in meeting certain cost containment, care delivery, and payment system goals. The Report includes a set of policy recommendations and targets for the Commonwealth to consider in our collective work toward a high-value, well-functioning health system.

The HPC’s work is driven by the following principles:

- **Fostering a value-based market** in which payers and providers openly compete, and in which providers are supported and equitably rewarded for providing high-quality and affordable services;

- **Promoting an efficient, high-quality, health care delivery system** that improves health by delivering coordinated, patient-centered health care that accounts for patients’ behavioral, social and medical needs;

- **Advancing aligned and effective financial incentives** for providers to deliver high-quality, cost effective care and for consumers and employers to make high-value choices for their care and coverage;

- **Enhancing transparency through publicly available data and information on health care system performance** necessary for providers, payers, patients, employers, and policymakers, including state agencies and the Legislature, to successfully implement reforms and evaluate performance over time.

The context in which this Report is published is one of both challenge and promise. Massachusetts has the lowest rate of uninsured residents in the nation, having undertaken health reform long before the Affordable Care Act was passed. According to the Commonwealth Fund’s state health system scorecard, Massachusetts ranks among the top five states overall.¹

Massachusetts, however, continues to have high health care spending that places a significant burden on residents, particularly on low and middle-income residents. As Exhibit 1.1 shows, total spending on health care, including contributions made by the employer, is as high as 30 percent of income for someone in a family of three living at three times the federal poverty level. Roughly a quarter of Massachusetts families have household income around this level (between 200 and 400 percent of the federal poverty level).

Further, significant delivery system challenges persist, leading to higher overall spending. In the HPC’s first Cost Trends Report, we found that of total health care spending in Massachusetts, an estimated 21 to 39 percent could be considered wasteful (translating to $12.1 to $22.4 billion in 2015).² This spending could be eliminated without harming

---

1 Commonwealth Fund, State Health System Scorecard, 2014.

2 Commonwealth Fund, State Health System Scorecard, 2014.
consumers or diminishing quality, but Massachusetts has failed to make significant progress and continues to underperform compared to most states on key efficiency measures. For example, Massachusetts continues to have high hospital use and the Commonwealth Fund ranks Massachusetts 31st in the nation in avoidable hospital use. These performance trends are further detailed in this Report.

Recognizing that excessive health care costs are crowding out spending on other needs for government, households, and businesses alike, Chapter 224 set a statewide target for a sustainable rate of growth of total health care expenditures. From 2014 to 2015, the growth in total health care spending in Massachusetts was 4.1 percent, exceeding the state’s benchmark of 3.6 percent. While 2015 marks the second year that the growth in total health care spending exceeded the benchmark, reflecting particular areas of high spending growth, there are areas of marked achievement in lower spending. Through the analyses and research developed for this Report, the HPC seeks to enhance the state’s understanding of spending trends and market dynamics that impacted the Commonwealth’s ability to meet the benchmark in 2015 and identify opportunities for improving the quality and efficiency of the Commonwealth’s health care system moving forward.

HOW THIS REPORT IS ORGANIZED

The HPC’s fourth annual Report is informed by annual reports of the Attorney General’s Office (AGO) and the Center for Health Information and Analysis (CHIA), as well as by testimony submitted during the HPC’s 2016 Annual Cost Trends Hearing.

In this Report, Section II: “Trends in spending and the delivery system” (Chapters 2 through 4) compares health care cost growth in 2015 against the Chapter 224 benchmark, discusses trends and levels of health care spending as well as affordability and quality of care in Massachusetts and the nation overall; trends in provider markets and factors driving market performance; trends in prescription drug spending; and provides a brief outlook for future success in meeting the benchmark.

Section III: “Care delivery performance” (Chapters 5 through 7) examines opportunities to improve quality and efficiency of care, highlighting the need to refocus care toward primary and community-based care settings, rather than institutions, including avoidable hospital and emergency department utilization, maximize value and quality in post-acute care, and analyze variation among provider groups in total medical expenses and use of non-recommended care.

Section IV: “Progress in aligning incentives” (Chapters 8 and 9) evaluates progress made in two key areas of focus: improving incentives for providers through alternative payment methods (APMs) and improving the opportunities for employers and consumers to save money by making high-value care choices.

Section V: “Recommendations” (Chapter 10) contains the HPC’s recommendations for accelerating efficiency in health care spending in Massachusetts and improving quality of care, as well as a dashboard summarizing performance in the Commonwealth on key measures.

What Is the role of the Health Policy Commission?

The Health Policy Commission (HPC) is an independent state agency that develops policy to reduce health care cost growth and improve the quality of patient care. The HPC’s mission is to advance a more transparent, accountable, and innovative health care system through its independent policy leadership and investment programs. The HPC’s goal is better health and better care – at a lower cost – across the Commonwealth.

The agency’s main responsibilities are led by HPC staff (divided into six departments) and overseen by an 11-member Board of Commissioners. HPC staff and commissioners work together collaboratively to monitor the performance of the health care system, including setting the health care cost growth benchmark; creating standards for care delivery systems that are accountable to better meet patients’ medical, behavioral, and social needs; analyzing the impact of health care market transactions on cost, quality, and access; and investing in community health care delivery and innovations.

REFERENCES

OVERVIEW OF TRENDS IN SPENDING AND CARE DELIVERY

Section II: Trends in Spending and Care Delivery

Through Chapter 224 of the Acts of 2012, the Commonwealth established a benchmark against which annual growth in health care spending is evaluated, recognizing that containing spending growth is critical to easing this burden on households, businesses, and the state economy. Chapter 224 directs the Health Policy Commission (HPC) and the Center for Health Information and Analysis (CHIA) to annually monitor health care spending growth relative to the Commonwealth’s economic growth. The benchmark is tied to potential gross state product with the intention of maintaining a roughly constant share of the state economy devoted to health care spending. From 2013 to 2017, the benchmark has been set at 3.6 percent.

This chapter, in keeping with the legislative mandate to monitor spending against the benchmark and the broader mandate to monitor overall health system value and performance, discusses the state’s performance relative to the benchmark in 2015, broad trends affecting health care spending in the Commonwealth, and the quality of the Massachusetts health care system overall.

SPENDING GROWTH FROM 2014 TO 2015

The measure of spending growth compared to the benchmark is defined as the change in total health care expenditures (THCE, as defined by CHIA) per state resident. THCE includes health care spending incurred by individuals, the state, and the federal government via Medicaid (MassHealth) and Medicare, as well as commercial spending as reported by health insurers to CHIA. CHIA reported initial per capita growth in total spending (THCE) in Massachusetts from 2014 to 2015 to be 4.1 percent, exceeding the state’s benchmark of 3.6 percent. Total spending increased from $54.8 billion for 2014 to $57.4 billion in 2015, while the state’s population was estimated to have grown from 6.76 million to 6.79 million residents over the same time period, resulting in an increase in per capita spending from $8,109 to $8,441. Hospital spending grew faster in 2015 than in 2014 and continues to represent a considerable portion of total commercial spending at 42 percent. Additionally, for the second year in a row, prescription drug spending contributed significantly to spending growth; although prescription drugs account for roughly 14 percent of overall health care spending in Massachusetts, the increase in prescription drug spending in 2015 accounted for roughly one third of total spending growth between 2014 and 2015 (not factoring in rebates). While exceeding the benchmark, the 4.1 percent increase in spending per Massachusetts resident was below the Center for Medicare and Medicaid Services’ (CMS) estimate of 5.1 percent per capita growth in personal health care spending across the entire U.S. for 2015 (see Exhibit 2.1). Overall, health care spending growth per resident in Massachusetts has been similar to or below national spending growth since 2012, after exceeding national growth rates from 2002 to 2008.

---

i 2013 and 2014 spending were revised from $51.3 billion and $54.0 billion to $52.2 billion and $54.8 billion, respectively, based on new data provided to CHIA from United Healthcare and final settlements between payers and providers, which reduced 2013-2014 growth of THCE per capita from the initially-reported 4.8 percent to 4.2 percent.

ii This figure is preliminary.

iii The estimate of 5.1 percent is based on the subset of national health spending called personal health care expenditures, which is most similar to THCE.
COMMERCIAL SPENDING

The commercial sector, composed of individuals covered by private health insurance, represents roughly 40 percent of health care spending accounted for by THCE in Massachusetts. As shown in Exhibit 2.2, annual growth in commercial health insurance premium spending per enrollee in Massachusetts has been roughly 2 percent per year since 2012, significantly below national trend through 2015. However, this aggregate figure masks important differences between the individual and employer markets due to a large influx of individual members (e.g. former CommonwealthCare enrollees) who enrolled in low-cost plans in 2015. Excluding individual purchasers, fully insured premiums grew 3.6 percent in 2015. More recent premium rate filing data suggest even higher premium growth in late 2015 through 2017. The Massachusetts Division of Insurance reported rate increases for premiums in the small group and individual markets of between 5.4 and 8.3 percent from the end of 2015 through the first quarter of 2017 (see “Future Outlook”).

As in prior years, large commercial payers in Massachusetts reported that spending growth in 2015 was primarily driven by increases in unit costs (prices) rather than by utilization.1

---

Exhibit 2.1: Annual growth in per capita health care spending, MA and the U.S., 2002-2015

![Graph showing annual growth in per capita health care spending, MA and the U.S., 2002-2015.](image)


Exhibit 2.2: Annual growth in health insurance premium spending per enrollee, MA and the U.S., 2005-2015

![Graph showing annual growth in health insurance premium spending per enrollee, MA and the U.S., 2005-2015.](image)

Notes: U.S. data includes Massachusetts. Data show spending growth from previous year to year indicated. Center for Health Information and Analysis data are for the fully-insured market only. Sources: Centers for Medicare and Medicaid Services, State and National Healthcare Expenditure Accounts, Private Health Insurance Expenditures and Enrollment (U.S. and MA 2005-2009); Center for Health Information and Analysis Annual Reports (MA 2009-2015)

---

1 These spending figures exclude out-of-pocket spending but include the net cost of private health insurance, which includes insurer administrative expenses, prescription drug rebates and other related spending.
Overall, lower growth rates in commercial spending per enrollee over the last several years have brought Massachusetts commercial spending per person closer to the U.S. average. Currently, Massachusetts commercial spending per person is roughly 6 percent above national levels after being 12-13 percent higher in 2009. Average employer-sponsored premiums for family coverage in Massachusetts are now the fifth highest among states in the U.S. after being the highest in 2009.

By category of commercial spending (see Exhibit 2.3), spending growth for physician and professional services and hospital care remained relatively low and below U.S. averages in 2015. However, growth in hospital spending was faster than in 2014 (2.6 percent versus 1.6 percent); for more information, see Chapter 5: “Hospital Utilization.” Because hospital inpatient and outpatient spending represent a considerable portion of total commercial spending (42 percent), spending in this category contributed 41 percent of total commercial spending growth in 2015, up from 18 percent in 2014.  

As noted above, growth in prescription drug spending in Massachusetts per commercial enrollee remained relatively high at 8.8 percent, far outpacing the other categories of commercial health care spending in Massachusetts in 2015, and accounting for half of commercial spending growth in 2015, excluding the impact of rebates. Prescription drug spending growth in Massachusetts was similar to growth in the U.S. overall of 6.3 percent in 2015 (prescription drug spending figures in Massachusetts are pre-rebate estimates, while U.S. spending estimates are net of drug rebates).

A more detailed discussion on prescription drug spending appears later in this report in Chapter 4: “Prescription Drug Spending.”

**PUBLIC PROGRAM SPENDING**

Growth in spending per enrollee among Medicare beneficiaries in Massachusetts was higher than in the past few years but still below the benchmark rate of 3.6 percent. Combined growth per enrollee for residents receiving coverage through

---

v This is based on a comparison of single and family commercial employer-based premiums as estimated by the Agency for Healthcare Research and Quality and an independent assessment provided to the HPC from Milliman actuarial consulting.

vi Physician and professional spending contributed 27 percent of growth. The combined contribution of prescription drug spending, hospital and physician spending is greater than 100 percent because of a substantial decrease in non-claims spending (e.g. settlements with respect to global budgets), which offset spending growth by 20 percent.
MassHealth’s Primary Care Clinician (PCC) and managed care organization (MCO) programs was negative, meaning per enrollee spending fell in 2015 (see Exhibit 2.4).

MassHealth experienced a substantial increase in enrollment in both programs in 2015 (9 percent for MCO and 18 percent for PCC), partly due to the dissolution of the MassHealth Temporary Coverage program, which had enrolled roughly 250,000 people in 2014. In addition, the increase in MassHealth enrollment in 2015 is reflective of a long-term growth trend, driven by the implementation of the Affordable Care Act and other market dynamics. Notably, the growth in MassHealth enrollment over the past few years coincides with decreased enrollment among commercial plans. Given the large enrollment shifts, it is difficult to draw conclusions about the reasons for the decline in per person spending.

In the Medicare program, the 3.3 percent growth in Medicare spending per enrollee combines 0.5 percent growth among enrollees in Medicare Advantage (17 percent of Massachusetts Medicare beneficiaries) and 3.9 percent among those enrolled in Original Medicare (fee-for-service). The 3.9 percent growth rate was above the national rate of 3.1 percent for all Original Medicare beneficiaries, driven by higher growth in Massachusetts in prescription drug spending (Part D) per enrollee (10.9 percent versus 6.3 percent nationwide) and home health spending per beneficiary (6.6 percent compared to 1.8 percent).

Following this high growth in 2015, the amount of spending per Original Medicare beneficiary in Massachusetts was $14,300 in 2015 compared to the U.S. average of $13,400 (see Exhibit 2.5), a difference of 6.5 percent.

Because program features and prices paid for services under the Original Medicare program are relatively uniform across the US, the comparison of spending in Exhibit 2.5 is particularly useful in understanding utilization of care patterns in Massachusetts compared to the national average. In 2015, Massachusetts spending continued to be particularly higher for hospital inpatient and outpatient care and post-acute care, which are discussed further in Chapter 5: “Hospital Utilization” and Chapter 6: “Post-Acute Care.”

Exhibit 2.4: Growth in per person spending for major public coverage programs in Massachusetts, 2013-2015

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicare</td>
<td>1.0%</td>
<td>1.4%</td>
<td>1.6%</td>
</tr>
<tr>
<td>MassHealth (MCOs+PCC) (61.1% of MassHealth members)</td>
<td>3.3%</td>
<td>3.6%</td>
<td></td>
</tr>
</tbody>
</table>

Source: Centers for Medicare and Medicaid Services (Medicare) and Center for Health Information and Analysis (MassHealth), 2016

Exhibit 2.5: Original Medicare (FFS) spending per beneficiary in Massachusetts and in the U.S., by category, 2015

<table>
<thead>
<tr>
<th>Category</th>
<th>MA</th>
<th>U.S.</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital inpatient</td>
<td>$4,000</td>
<td>$3,200</td>
<td>$3,680 (6.5%)</td>
</tr>
<tr>
<td>Hospital outpatient</td>
<td>$2,000</td>
<td>$1,600</td>
<td>$1,840 (9%)</td>
</tr>
<tr>
<td>Physician &amp; other professional</td>
<td>$2,000</td>
<td>$1,600</td>
<td>$1,840 (9%)</td>
</tr>
<tr>
<td>Home health</td>
<td>$1,000</td>
<td>$800</td>
<td>$920 (11%)</td>
</tr>
<tr>
<td>Skilled nursing</td>
<td>$1,000</td>
<td>$800</td>
<td>$920 (11%)</td>
</tr>
<tr>
<td>Other</td>
<td>$1,000</td>
<td>$800</td>
<td>$920 (11%)</td>
</tr>
<tr>
<td>Drugs</td>
<td>$1,000</td>
<td>$800</td>
<td>$920 (11%)</td>
</tr>
<tr>
<td>Overall</td>
<td>$15,000</td>
<td>$12,000</td>
<td>$13,680 ($888)</td>
</tr>
</tbody>
</table>

Notes: FFS = fee-for-service. Prescription drug spending is calculated per enrollee in Medicare Part D. All other categories are per beneficiary enrolled in either Part A or Part B.

Source: Centers for Medicare and Medicaid Services, 2015

---

vii The MassHealth Temporary Coverage program offered comprehensive coverage paid on a fee-for-service basis through MassHealth to individuals seeking to enroll in the subsidized coverage through the MassHealth Connector for the 2014 open enrollment period due to website difficulties involved in merging the existing Connector with the new requirements and eligibility under the ACA. It was phased out in early 2015 as Connector operations resumed.

viii One exception, as noted in the HPC’s 2015 Cost Trends Report is inpatient hospital care. Due to the combination of Massachusetts’ exceptionally high number of medical residents and a higher wage adjustment that is factored into Medicare’s formulas, a significant portion of Massachusetts’ higher inpatient hospital spending is due to prices rather than higher utilization.
Overall performance against the state cost growth benchmark in 2015

As shown in Exhibits 2.2 and 2.4, despite high rates of growth in spending on prescription drugs, growth in spending per enrollee was below the benchmark rate for Massachusetts’ Medicare, Commercial, and MassHealth PCC and MCO enrollees (as was also the case in 2014). Yet overall, spending growth per Massachusetts resident exceeded the benchmark rate. In 2014, part of the reason for exceeding the benchmark was that, on net, more state residents appeared to be enrolled in any form of coverage (with an implied reduction in the uninsured). This does not appear to be the case in 2015.\(^ix\)

A number of other factors contributed to spending growth in excess of the benchmark in 2015, some of which are detailed in CHIA’s 2016 Annual Report.\(^5\) One factor is an increase in the net cost of private health insurance (NCPHI). Another is enrollment in Medicare; enrollment increased among those in Original Medicare and Medicare Advantage (2 percent, or 22,000 individuals) and in the One Care and Senior Care Options programs, which provide comprehensive care for Medicare beneficiaries who are dually eligible for MassHealth and who are non-elderly disabled or elderly, respectively. The increase in Medicare enrollment, amounting to roughly $300 million in additional spending in 2015 if these new beneficiaries are assumed to have similar spending as average beneficiaries, is significant but not unexpected given that the elderly population in Massachusetts is expected to grow by roughly 30,000 individuals each year between now and 2030.\(^4\)

An additional factor was an increase in spending on long-term services and supports (LTSS). MassHealth provides such additional services to many residents who have primary coverage under Medicare or commercial insurance, but this spending is counted under MassHealth and not Medicare or commercial coverage. This category of spending is discussed in Sidebar: “Long-term services and supports.”

---

**Long-term services and supports**

Many people living with cognitive or physical disabilities or impairments require supports such as assistance with preparing meals, bathing, and other activities of daily living (ADLs). These long-term services and supports (LTSS) can be delivered in a range of institutional and community settings, including nursing facilities, assisted living facilities, or in a client’s home where nursing providers or other aides assist individuals with these activities.

**Spending**

MassHealth is the primary payer of LTSS, covering nearly half (45 percent) of LTSS spending in Massachusetts, as neither Medicare nor commercial health insurance covers most long-term services.\(^x\) \(^x\) Direct MassHealth spending on LTSS totaled over $4.7 billion in FY 2015, roughly 8 percent of total health care expenditures (THCE) in Massachusetts. In FY2015, MassHealth spent about $2.0 billion on community-based LTSS, $1.5 billion on institution-based LTSS, and $1.3 billion on enrollees in Senior Care Options, PACE, and OneCare.\(^x\) \(^x\) This spending represents growth compared to 2014 of 15 percent, -1 percent, and 27 percent, respectively. Together, LTSS spending rose 12 percent (about $510 million) in FY 2015, a considerable amount given that total MassHealth spending growth reported by CHIA was $706 million from CY 2014 to 2015.

In the fee-for-service (FFS) program, growth in 2015 was due solely to growth in spending on community-based LTSS, driven by a 37 percent increase in home health spending. Much of the increase in home health spending was due to an increase in users (23 percent growth), but per member spending also increased by about 12 percent in 2015. During the same time period, institutional LTSS spending shrank by about 1 percent. While spending per member rose slightly by about 1 percent, the number of users declined by 3 percent.

LTSS spending growth in 2015 appears to be relatively high compared to prior years. From FY 2009 to 2014, LTSS spending grew an average 7 percent per year, including an 11 percent average annual growth rate in community-based LTSS, an annual decline of 2 percent in institutional LTSS spending, and 23 percent annual growth in Senior Care Options, PACE, and OneCare. Controlling community-based LTSS spending has been a priority for MassHealth since 2015, as described below.

Furthermore, true LTSS spending in Massachusetts is higher than the totals captured by THCE. THCE does not include claims from long-term care insurance nor personal spending on LTSS (not attached to a claim). Personal spending on LTSS is substantial; out-of-pocket expenditures are estimated to account for 17 percent of the spending on LTSS in Massachusetts, in addition to care provided by unpaid caregivers.\(^5\) Time spent by informal caregivers in Massachusetts helping adult family members with activities of daily living is valued at about $11.6 billion annually.\(^6\)

\(^ix\) Although it is not possible to arrive at precise enrollment figures, this conclusion is supported by the drop in the percentage of emergency department visits in Massachusetts attributable to the uninsured in 2014 (from 8.7 percent to 7.2 percent) followed by a rise in 2015 (to 9.0 percent) based on an HPC analysis of Emergency Department discharge data from the Center for Health Information and Analysis.

\(^x\) Medicare Parts A and B cover home health services designed to assist people who are recovering from an acute care event. While some Medicare beneficiaries receive covered home health benefits for prolonged periods, Medicare does not intend for this service to be used as a substitute for long-term services and supports.

\(^xi\) These managed care programs include LTSS in the capitated rate.

\(^xii\) HPC analysis of data provided by MassHealth.
Use of community-based versus institutional care

Nursing facility care is typically more expensive than community-based services, especially in the Commonwealth. In Massachusetts, the median annual cost in 2016 of semi-private nursing facility services (including spending from all payers) was $135,050 versus the national average of $82,125. The median cost of a full time home health aide was $57,200 annually compared to a national median of $46,332, although spending can vary widely based on the hours of care needed. However, this difference in cost between nursing facility care and community-based care is moderated by the inclusion of other medical services covered under the nursing home reimbursement.

While some individuals with high care needs require the more intensive services that a nursing facility can offer, many others with lower care needs can continue to live in the community with a lower level of support. MassHealth has made significant efforts in recent years to rebalance the share of LTSS provided in nursing facilities versus in the community. The Supreme Court’s Olmstead v. L.C. ruling in 1999 held that individuals with disabilities have the right to live in the community rather than in institutions when appropriate. Since the Olmstead decision, there has been a national shift in Medicaid LTSS spending from institutional to community-based care. Massachusetts was a leader in this trend, with the share of spending devoted to community-based LTSS exceeding the share of institutional spending earlier than in the U.S. overall. In 2014, MassHealth spent 57 cents of every LTSS dollar on community-based services, compared to 53 cents of every LTSS dollar in the U.S. overall (see Exhibit 2.6). From 2010 to 2014, Massachusetts had a 4.2 percent reduction in the number of Massachusetts residents living in nursing homes.

Some remain concerned that institutional LTSS spending has not declined sufficiently to offset the increase in spending on community-based care. To ensure sustainability in spending, MassHealth has pursued a number of strategies. Through the new 1115 waiver, MassHealth is enhancing the coordination and integration of LTSS with other health care services (see Chapter 8: “Alternative Payment Methods”). MassHealth has also focused on actions to strengthen program integrity. Following a recent audit that identified nine home health agencies that improperly billed MassHealth for $23 million, MassHealth implemented a moratorium on new home health agencies that improperly bill MassHealth. It also increased its monitoring of home health agencies that improperly bill MassHealth.

MassHealth is also investing in electronic visit verification tools for home health visits. Despite the large growth in home health enrollment, MassHealth members receiving care from personal care attendants continued to outnumber members receiving services through a home health agency (about 24,400 and 18,900, respectively). MassHealth has also sought to lower spending growth through establishing an overtime cap for personal care attendants. As a result of these efforts, MassHealth estimates reduced community-based LTSS spending growth for FY17 (an estimated 8 percent spending growth).

Considerations for future LTSS spending and delivery

A number of considerations will shape the trajectory of LTSS spending and delivery, including the aging of the population and LTSS service capacity. The Massachusetts population is aging faster than the US overall, with the number of seniors expected to grow by 61 percent from 2010 to 2030. When combined with medical and technological advances and longer life-span, the number of people with long-term care needs is expected to grow significantly. More than half of all adults turning 65 today are expected to need long-term care services. As the population ages, and as an increasing number of seniors in Massachusetts elect to receive care in their homes or community, it will become especially important to ensure that there is a capable and sufficient workforce to provide community-based LTSS. By 2020, it has been estimated that Massachusetts will require 32 percent more direct care workers than were employed in 2010. It will be important for stakeholders and state agencies to consider strategies to maintain access to high-quality care for all residents requiring LTSS.

Exhibit 2.6: Share of MassHealth LTSS spending on institutional care and community-based care, MA and the U.S., 2001-2014

Source: HPC analysis of LTSS expenditures data from Medicaid.gov, FY 2001-2014
ACCESS TO AND AFFORDABILITY OF CARE

Massachusetts continues to perform well compared to other states on some state-wide measures of access to and affordability of care, although other states have closed the gap with the coverage expansions due to the Affordable Care Act (ACA). In terms of insurance coverage, Massachusetts continued to have the lowest rate of uninsured in the U.S. at 3 percent in 2015 compared to a national average that dropped from 15 percent in 2013 to 9 percent in 2015. The percentage of adults who went without care in the past year because of cost increased from 8 percent to 9 percent in 2015 while the national average dropped from 14 percent to 13 percent. The percentage of at-risk adults with a doctor visit in the past two years remained at 93 percent compared to a national average of 87 percent, and the percentage of individuals under age 65 who spent more than 10 percent of income on out-of-pocket expenses for health care (not including premiums) was 11 percent, compared to 14 percent across the U.S.\(^{16}\)

These aggregate measures, however, mask underlying access and affordability problems for many of the state’s residents. Although Massachusetts has higher average income than the nation, Massachusetts also ranks seventh highest among states in the degree of income inequality.\(^{17}\) Approximately one million Massachusetts residents (15 percent of the state) have income levels between the poverty line and twice the poverty line, and another 1.6 million (24 percent of residents) have incomes between twice and four times the poverty level.\(^{18}\) Importantly, the high costs of health care are felt by low- and high-income residents alike. Average total premiums for employer-based family coverage in Massachusetts were $16,300 per year for employees in firms with the lowest average wages in the state and $19,300 for employees in firms with the highest wages (see Exhibit 2.7).\(^{19}\) Although some employers adjust their required premium contributions so that lower-earning employees pay less for the same coverage, the required employee contributions to premiums on average were actually higher for employees in the lowest-wage firms ($5,500 compared to $4,200 for employees in high-wage firms).\(^{20}\)

HPC analysis of out-of-pocket costs from the All-Payer Claims Database found similar annual spending for residents in the lowest-income zip codes in the state (see Exhibit 2.8) as those in the highest-income areas.

---

\(^{16}\) Corresponding incomes for a family of two adults and one child are between $20,000 (poverty level) and $80,000 (four times the poverty level).

\(^{17}\) Massachusetts has higher average income than the nation, but ranks seventh highest among states in the degree of income inequality.

\(^{18}\) Approximately one million Massachusetts residents (15 percent of the state) have income levels between the poverty line and twice the poverty line, and another 1.6 million (24 percent of residents) have incomes between twice and four times the poverty line.

\(^{19}\) Average total premiums for employer-based family coverage in Massachusetts were $16,300 per year for employees in firms with the lowest average wages in the state and $19,300 for employees in firms with the highest wages.

\(^{20}\) Although some employers adjust their required premium contributions so that lower-earning employees pay less for the same coverage, the required employee contributions to premiums on average were actually higher for employees in the lowest-wage firms ($5,500 compared to $4,200 for employees in high-wage firms).
As a result, health care costs for a family of three living at 300 percent of the federal poverty level represent 30 percent of their total family income (see Exhibit 1.1 in Chapter 1: “Introduction”) and 25 percent for a family living at four times the poverty level.xiv

This burden of health care spending can have particularly serious consequences for low and middle income residents, leaving little room for other necessities and increasing financial pressure to make ends meet. Among residents between 138 and 300 percent of the federal poverty level in 2015, (between roughly $28,000 and $60,000 for a family of three), 15 percent reported that out-of-pocket health care spending was more than 5 percent of their income, 24 percent reported having difficulty paying medical bills, and 21 percent said someone in their family went without needed medical care due to cost in the past 12 months.20

QUALITY OF CARE

The Commonwealth seeks to contain health care spending while ensuring equal or better quality of care for all residents. The HPC reported previously that Massachusetts providers tend to perform well on technical measures such as mortality rates but not as well on reducing costly and avoidable care such as hospital readmissions and avoidable emergency department (ED) visits. New data collected and summarized by CHIA in its 2016 provider quality report and by CMS in the 2016 hospital quality ratings confirm and extend these earlier findings.

In November 2016, CHIA published its annual report evaluating health system performance on quality of care across three domains: safety, effectiveness and efficiency, and patient-centeredness.21 In the safety domain, which includes measures that are only calculated for hospitals, hospitals improved in an important composite measure of safety (Patient Safety Indicator 90) from 2014 and, in aggregate, performed better than the national average in 2015. On the other hand, hospitals demonstrate a need for improvement in some measures of health care-associated infections. For example, while Massachusetts performed better than the national average for methicillin-resistant Staphylococcus aureus (MRSA) and central line-associated bloodstream infections (CLABSI), Massachusetts performed worse than the national average on Clostridium difficile and catheter-associated urinary tract infections (CAUTI). In the efficient and effective care domain, which includes measures such as potentially preventable hospitalization, early elective deliveries and all-cause readmissions, Massachusetts providers performed worse, on average, than national benchmarks. Patients rated Massachusetts hospitals and primary care providers highly on how well their doctors communicated with them overall, but rated hospitals poorly on quietness in hospitals and rated primary care providers poorly on education about self-management in the primary care setting.

An analysis of CMS’ hospital quality rankings, which assign one to five stars for all hospitals in the U.S., found similar variation across Massachusetts (see Exhibit 2.9). Massachusetts hospitals performed well compared to the national average in the mortality and efficient use of medical imaging categories but poorly on measures of readmission and timeliness of care, the latter which includes measures such as ED wait times.xv

Exhibit 2.9: Massachusetts hospitals performance on each component of CMS' Hospital 5 Star Ratings, 2015

<table>
<thead>
<tr>
<th>Percent of hospitals</th>
<th>Performed better than national average</th>
<th>Performed the same as national average</th>
<th>Performed worse than national average</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety</td>
<td>33%</td>
<td>40%</td>
<td>27%</td>
</tr>
<tr>
<td>Readmissions</td>
<td>4%</td>
<td>40%</td>
<td>54%</td>
</tr>
<tr>
<td>Mortality</td>
<td>55%</td>
<td>45%</td>
<td>0%</td>
</tr>
<tr>
<td>Patient experience</td>
<td>33%</td>
<td>38%</td>
<td>29%</td>
</tr>
<tr>
<td>Effectiveness of care</td>
<td>29%</td>
<td>56%</td>
<td>15%</td>
</tr>
<tr>
<td>Timeliness of care</td>
<td>4%</td>
<td>35%</td>
<td>62%</td>
</tr>
<tr>
<td>Efficient use of medical imaging</td>
<td>25%</td>
<td>73%</td>
<td>2%</td>
</tr>
</tbody>
</table>

Notes: Green indicates areas of significantly better performance than the national average; yellow indicates worse performance. Fifty-seven Massachusetts hospitals were included in CMS’s first Hospital Compare release. However, not all hospitals were evaluated in each performance category (categories seen above). Hospitals were excluded from a performance category if they did not meet the minimum reporting threshold in that category of at least 3 measures. The number of hospitals in each category was: safety = 52, readmissions = 56, mortality = 56, patient experience= 55, effectiveness of care = 55, timeliness of care = 55, and efficient use of medical imaging = 52. Hospitals are represented as the combined product of their campuses, e.g. North Shore Medical Center includes both the Union and Salem campuses.

Source: Centers for Medicare and Medicaid Services, 2016

xv These measures include the average time patients wait in the ED before leaving, being seen by a health care professional, receiving pain medication for a broken bone, or being admitted to the hospital.
Nursing facility quality

The HPC also analyzed quality ratings for nursing facilities that are dually-certified by Medicare and Medicaid serving both short-term residents (skilled nursing facility beds) and long-term residents (long-term services and supports beds). While the Commonwealth continues to work toward enabling patients to receive high quality care across the continuum, including a range of post-acute care and long-term care options as needed (see Chapter 6: “Post-Acute Care”), some residents will continue to be most appropriately served in nursing facilities. For this population, ensuring access to high quality care remains critical.

As of January 2017, Massachusetts had 417 licensed nursing facilities, with about 48,000 beds. HPC analysis found substantial variation throughout the state in the quality of nursing facilities. The HPC also found that nursing facility quality varied by community income. In 2016, nursing facility beds located in the lowest income zip codes had an average quality rating of 3.01 on a scale of one to five stars, compared to an average rating of 3.44 in the highest income zip codes (see Exhibit 2.10). In these low-income areas, almost 16 percent of beds were in a facility that received one star and 15 percent received five stars; compared to 9 percent and 33 percent, respectively, in the highest income areas.

The quality of nursing facilities also varied by region. Based on HPC regions, the Berkshires and South Shore regions had the highest proportion of beds in four or five star facilities (see Exhibit 2.11). The Berkshires had the highest proportion, with 74 percent of regional beds located in four or five star facilities. In the Upper North Shore region, only 11 percent of nursing facility beds were located in four or five star facilities.

Exhibit 2.10: Distribution of beds, by nursing facility quality and median zip code income, 2016

Exhibit 2.11: Percentage of nursing facility beds in four or five star quality facilities, by HPC region, 2016

Notes: Quintiles are based only on median incomes of zip codes where nursing facilities are located. Quintile 1 = less than $48,700; quintile 2 = $48,700-$63,000; quintile 3 = $63,001-$77,420; quintile 4 = $77,421-$93,000; quintile 5 = more than $93,000.

Source: Centers for Medicare and Medicaid Services, Nursing Home Compare, December 2016

---

xvi From Massachusetts Department of Public Health, Division of Health Care Facility Licensure and Certification.

xvii The statewide facility average is weighted by number of beds per facility. The star rating data is from CMS Nursing Home Compare, which assigns ratings to nursing facilities certified by Medicare and Medicaid based on three criteria: state health inspection ratings, staffing, and quality measures. Composite scores are produced on a scale of one to five stars. The HPC used Nursing Home Compare data in conjunction with CMS Provider of Services data. 2016 data are used for cross-sectional analyses, and data from 2009-2013 are used for time trend analyses, as 2016 scores are not directly comparable to measures from previous years.
REFERENCES

13 Favreault M, Dey J. Long-term services and supports for older Americans: risks and financing research brief. Assistant Secretary for Planning and Evaluation. 2015.
Understanding the changing structure and composition of the health care provider market is critical to understanding the overall functioning of the health care system in delivering high quality and cost-effective care. Recognizing the importance of provider market structure—and specifically competition among health care providers—to health care cost containment, Chapter 224 of the Acts of 2012 gave the Health Policy Commission (HPC) a number of important tools to monitor the changing health care provider marketplace. These tools include the creation of the Registration of Provider Organizations (RPO) program (see Sidebar: “The Registration of Provider Organizations program”), the requirement that provider organizations file notices of material change (MCNs) with the HPC before engaging in significant market changes, and authority for the HPC to conduct cost and market impact reviews (CMIRs) of transactions anticipated to have a significant impact on health care spending or the competitive marketplace. Utilizing these tools and other data sources, this chapter summarizes the current state of and trends in the provider market in Massachusetts.

CURRENT STATE OF THE PROVIDER MARKET IN MASSACHUSETTS: Initial Data from the Registration of Provider Organizations Program

The Massachusetts provider market is characterized by having a relatively large number of both hospitals and physicians, with 57 general acute care hospitals and over 20,000 physicians practicing across the Commonwealth. Providers are particularly concentrated in the eastern part of the state; for example, primary care physicians’ primary sites of practice reported to the RPO program are more heavily concentrated in eastern Massachusetts (see Exhibit 3.1).

As noted in past reports, Massachusetts providers are predominantly part of one of several large provider organizations. Nearly all of such systems include both acute care hospitals and physicians, many are anchored by large teaching hospitals or academic medical centers (AMCs), and several also include other types of direct providers of patient care services (e.g., non-acute hospitals and home health providers). Through the RPO data, the HPC and the public now have access to far more robust and uniform data about the structure and functioning of these major provider organizations in Massachusetts.
Exhibit 3.2 provides a summary of some key features of these eight largest provider organizations in the Commonwealth, based on information collected through the RPO program in the first year of data collection. Together, these provider organizations account for 84.6 percent of all physicians (primary care physicians and specialists) in the RPO dataset.

As shown in Exhibit 3.2, these systems vary across a number of key features, including their direct employment of physicians, their geographic reach, and their organizational structure and corporate complexity. One particularly notable area of variation between these systems is their patterns of employing (versus creating contracting affiliations with) their physician networks (see Exhibit 3.3).

Exhibit 3.2: Summary data on the largest Massachusetts provider organizations, 2015

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Partners</th>
<th>Atrius</th>
<th>Steward</th>
<th>BIDCO</th>
<th>Wellforce</th>
<th>Lahey</th>
<th>UMass</th>
<th>Baystate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tax-exempt status</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Corporate affiliates</td>
<td>72</td>
<td>12</td>
<td>41</td>
<td>1</td>
<td>52</td>
<td>42</td>
<td>29</td>
<td>28</td>
</tr>
<tr>
<td>Contracting organizations/managed services</td>
<td>5</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>4</td>
<td>6</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Direct providers of patient care services</td>
<td>31</td>
<td>7</td>
<td>15</td>
<td>0</td>
<td>33</td>
<td>19</td>
<td>15</td>
<td>11</td>
</tr>
<tr>
<td>Acute hospital – main sites</td>
<td>8</td>
<td>0</td>
<td>8</td>
<td>0</td>
<td>2</td>
<td>4</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Non-acute hospital – main sites</td>
<td>4</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Contracting affiliates</td>
<td>12</td>
<td>0</td>
<td>160</td>
<td>15</td>
<td>15</td>
<td>1</td>
<td>0</td>
<td>185</td>
</tr>
<tr>
<td>Acute hospital – main sites</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>9</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

### Physicians

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Partners</th>
<th>Atrius</th>
<th>Steward</th>
<th>BIDCO</th>
<th>Wellforce</th>
<th>Lahey</th>
<th>UMass</th>
<th>Baystate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>6,721</td>
<td>859</td>
<td>2,525</td>
<td>2,353</td>
<td>2,123</td>
<td>1,018</td>
<td>1,438</td>
<td>1,487</td>
</tr>
<tr>
<td></td>
<td>(70.4% employed)</td>
<td>(80.1% employed)</td>
<td>(31.7% employed)</td>
<td>(0% employed)</td>
<td>(46.6% employed)</td>
<td>(69.4% employed)</td>
<td>(72.5% employed)</td>
<td>(46.4% employed)</td>
</tr>
<tr>
<td>PCPs</td>
<td>1,188</td>
<td>322</td>
<td>579</td>
<td>533</td>
<td>555</td>
<td>209</td>
<td>381</td>
<td>404</td>
</tr>
<tr>
<td></td>
<td>(53.5% employed)</td>
<td>(100% employed)</td>
<td>(38.2% employed)</td>
<td>(0% employed)</td>
<td>(32.6% employed)</td>
<td>(80.9% employed)</td>
<td>(63.5% employed)</td>
<td>(34.2% employed)</td>
</tr>
<tr>
<td>Specialists</td>
<td>5,724</td>
<td>537</td>
<td>2,044</td>
<td>1,898</td>
<td>1,644</td>
<td>838</td>
<td>1,096</td>
<td>1,101</td>
</tr>
<tr>
<td></td>
<td>(73.5% employed)</td>
<td>(68.2% employed)</td>
<td>(30.1% employed)</td>
<td>(0% employed)</td>
<td>(50.2% employed)</td>
<td>(37.7% employed)</td>
<td>(76.6% employed)</td>
<td>(50.8% employed)</td>
</tr>
<tr>
<td>Pediatricians</td>
<td>457</td>
<td>104</td>
<td>93</td>
<td>86</td>
<td>145</td>
<td>27</td>
<td>141</td>
<td>217</td>
</tr>
</tbody>
</table>

| Unique primary site of practice zip codes | 160 | 24 | 166 | 103 | 120 | 54 | 62 | 42 |

Source: HPC analysis of Registration of Provider Organizations data, 2015
Over time, the HPC expects that it and other government entities, researchers, and market participants will be able to use the RPO data to track changes to these patterns and other aspects of the provider market and to associate different organizational structures and affiliation practices with measures of provider system performance.

**Exhibit 3.3:** Physician employment status among Massachusetts’ largest provider systems, 2015

<table>
<thead>
<tr>
<th></th>
<th>Affiliated PCPs</th>
<th>Employed PCPs</th>
<th>Affiliated specialists</th>
<th>Employed specialists</th>
</tr>
</thead>
<tbody>
<tr>
<td>Partners</td>
<td>200</td>
<td>400</td>
<td>1,000</td>
<td>2,000</td>
</tr>
<tr>
<td>Atrius</td>
<td>1,000</td>
<td>2,000</td>
<td>5,000</td>
<td>6,000</td>
</tr>
<tr>
<td>Steward</td>
<td>600</td>
<td>1,200</td>
<td>3,000</td>
<td>4,000</td>
</tr>
<tr>
<td>BIDCO</td>
<td>400</td>
<td>800</td>
<td>2,000</td>
<td>4,000</td>
</tr>
<tr>
<td>Wellforce</td>
<td>200</td>
<td>400</td>
<td>1,000</td>
<td>2,000</td>
</tr>
<tr>
<td>Lahey</td>
<td>1,000</td>
<td>2,000</td>
<td>5,000</td>
<td>6,000</td>
</tr>
<tr>
<td>UMass</td>
<td>600</td>
<td>1,200</td>
<td>3,000</td>
<td>4,000</td>
</tr>
<tr>
<td>Baystate</td>
<td>400</td>
<td>800</td>
<td>2,000</td>
<td>4,000</td>
</tr>
</tbody>
</table>

**Notes:** Physician employment status is reported from the perspective of the registering Provider Organization. For example, Beth Israel Deaconess Care Organization (BIDCO) does not employ any physicians; however, these physicians may be employed by a member of BIDCO, such as Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, Inc. (HMFP) or Jordan Physician Associates.

**Source:** HPC analysis of Registration of Provider Organizations data, 2015

---

**The Registration of Provider Organizations program**

The RPO program is a first-in-the-nation initiative to collect and publicly report information about the corporate, contracting, and clinical relationships of Massachusetts’ largest health systems, which incorporates required reporting to both the HPC and the Center for Health Information and Analysis (CHIA).1,2

Under the applicable statutes, provider organizations are required to submit data to the RPO Program when they either receive substantial revenue from commercial payers or participate in payer contracts with downside risk. In the first year of data collection, which took place in fall of 2015, a total of 60 organizations submitted data, including 31 hospital systems, 23 physician groups, five behavioral health providers, and one laboratory provider.

The RPO dataset, which is designed to be uniform, provider-reported, linkable to other datasets, and publicly available, provides invaluable data for understanding the current structure and evolving trends in the Massachusetts health care provider market for policymakers, researchers, and market participants alike. Initial comparisons between the RPO dataset and other, largely commercially available, datasets indicate that the RPO data is a robust resource for information about large provider systems, general acute care hospitals, and physicians in the Commonwealth. Specifically, all general acute care hospitals (57) and four specialty hospitals are accounted for in the data, as well as 21,678 unique physicians, which is comparable the number of Massachusetts physicians counted in commercially available data sources.3

---

1 This figure represents approximately 85.5 percent of all licensed physicians in the Commonwealth. This aligns with expectations, as provider organizations were only required to report physicians on whose behalf they contract with payers. Some licensed physicians are not currently practicing or covered by current payer contracts, and thus may not be included in the RPO dataset.

2 The HPC found that physicians in the RPO dataset included 91.9 percent of the physicians in one major commercially available dataset, and 105.1 percent of the physicians in another commercially available physician dataset.
KEY PROVIDER MARKET TRENDS

Continued Market Consolidation

One of the key provider market trends that the HPC has highlighted in past Cost Trends Reports is the rapid pace of new provider alignments. The HPC tracks the frequency, type, and nature of these new provider system alignments in the Commonwealth and assesses their potential impact on health care spending, quality, and access through the filing of MCNs. The HPC also engages in a more comprehensive review of particular transactions anticipated to have a significant impact on health care costs or market functioning through its CMIRs. Through this work over the past year, the HPC found that the trend of provider market consolidation in Massachusetts is continuing.

From 2013 through December 2016, the HPC received notice of 72 proposed mergers, acquisitions, and affiliations. These notices reveal a rapidly changing health care marketplace, with transactions involving physician contracting or corporate affiliations being particularly common (see Exhibit 3.4).

The HPC has also observed that providers are participating in a wide range of different types of transactions, including corporate acquisitions, affiliations between providers for joint contracting, creation of clinical joint ventures, formation of new contracting entities like accountable care organizations (ACOs), and establishment of new preferred provider arrangements and other clinical affiliations (see Exhibit 3.5).

Exhibit 3.4: Frequency of providers involved in Material Change Notices consisting of corporate or contracting affiliations, 2013-2016

<table>
<thead>
<tr>
<th>Provider Type</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician Group</td>
<td>29</td>
</tr>
<tr>
<td>Acute Hospital</td>
<td>20</td>
</tr>
<tr>
<td>Other Provider</td>
<td>6</td>
</tr>
<tr>
<td>Payer</td>
<td>1</td>
</tr>
</tbody>
</table>

Source: HPC analysis of Notice of Material Change data, 2013-2016

Exhibit 3.5: Frequency of provider alignment types for which the HPC received Material Change Notices, 2013-2016

<table>
<thead>
<tr>
<th>Alignment Type</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corporate affiliation</td>
<td>33</td>
</tr>
<tr>
<td>Clinical affiliation</td>
<td>17</td>
</tr>
<tr>
<td>Contracting affiliation</td>
<td>9</td>
</tr>
<tr>
<td>Joint venture</td>
<td>8</td>
</tr>
<tr>
<td>Formation of contracting entity</td>
<td>5</td>
</tr>
</tbody>
</table>

Source: HPC analysis of Notice of Material Change data, 2013-2016

Through 2016, nearly half of the transactions (33 of 72) noticed to the HPC involved corporate affiliations, including mergers and acquisitions between acute care hospitals, physician groups, rehabilitation providers, and visiting nurse associations, as well as one transaction involving a provider organization and a payer. The HPC has also observed significant and increasing alignment of both hospitals and physicians through contracting and clinical affiliations, including through the formation and growth of new contracting entities like ACOs.

As a result of these and other changes to the health care system over the last several decades, the majority of care in the Commonwealth is now provided by a relatively small number of large provider systems. In 2015, the five largest health systems in the state accounted for 59.9 percent of hospital discharges for commercially insured patients, an increase from 54.6 percent in 2012. However, some of the consolidation of inpatient care into these largest systems appears to have stabilized, or even slightly decreased, from 2014 to 2015 (see Exhibit 3.6).

iii The HPC defines a clinical affiliation in its Final MCN and CMIR Regulation, 958 CMR 7.02, as any relationship between a Provider or Provider Organization and another organization for the purpose of increasing the level of collaboration in the provision of Health Care Services, including, but not limited to, sharing of physician resources in hospital or other ambulatory settings, co-branding, expedited transfers to advanced care settings, provision of inpatient consultation coverage or call coverage, enhanced electronic access and communication, co-located services, provision of capital for service site development, joint training programs, video technology to increase access to expert resources and sharing of hospitalists or intensivists.
The physician market has also seen a significant increase in consolidation in recent years. For example, the HPC found that the share of primary care physicians associated with the eight largest provider systems in Massachusetts grew from 62 percent to 76 percent from 2008 to 2014. Available data does not suggest that consolidation in the physician market is slowing. Through 2016, 40 percent of all transactions (29 of 72) reviewed by the HPC have involved physician group acquisitions or contracting affiliations, and almost all of these transactions have increased market concentration for physician services.

Although provider alignments may take a range of forms and may promote more patient-centered, accountable care, many such alignments involve acquisitions and contracting affiliations that can increase overall market concentration. Evidence suggests that increases in market concentration are not typically associated with increased quality of care, and there is strong consensus that hospital mergers lead to higher prices in the vast majority of cases. HPC analysis of the impact of some non-corporate affiliations, including contracting affiliations, has found that even alignments that do not involve corporate acquisition may increase the affiliating providers’ ability to leverage higher prices and other favorable contract terms. In addition, physician contracting and corporate alignments can result in immediate price increases when a physician group joins a provider network that has higher contracted rates, and early evidence on the impact of acquisitions of physician practices by hospitals suggests that such affiliations often lead to higher total spending as the affiliated physicians shift their referrals away from low cost, high quality hospitals and towards the acquiring hospital.

In examining the impact of provider market consolidation in the Commonwealth, the HPC also found that hospitals with higher market shares and those with certain large system affiliations tend to have higher inpatient prices that are not tied to increased quality (see Unwarranted Variation in Provider Prices below). As discussed in Chapter 5: “Hospital Utilization,” the HPC has also found that a large and increasing share of patients are being treated at AMCs or teaching hospitals for conditions that could be appropriately treated at lower cost providers, such as community hospitals. In many cases, these patients are referred to AMCs or teaching hospitals for routine care by their primary care physicians, a large and increasing majority of whom are affiliated with the dominant health systemsanchored by the AMCs or teaching hospitals to which they are referring. This movement of patients to higher-acuity settings is a consequence of provider consolidation and can significantly increase health care spending.

Despite these findings regarding the negative consequences of market consolidation to date, the HPC has seen some positive trends since the MCN process began in 2013. For example, an increasing number of notices have more robustly described efficiency goals, concrete action plans, and investment strategies to foster high quality, lower-cost, and coordinated care, and an increasing number of notices have included commitments to maintain or increase access to care for underserved populations. The HPC remains hopeful that proposed provider affiliations will increasingly include robust plans to improve quality and efficiency without increasing spending (e.g., through higher prices or inefficient referral patterns) that, over time, will show measurable results.

**Unwarranted Variation in Provider Prices**

As part of the 2015 Cost Trends Report, the HPC reported on the issue of variation in hospital and physician group prices in Massachusetts. The HPC found that, consistent with the work of CHIA and that of the Attorney General’s Office (AGO), extensive variation in provider prices has not diminished over time. The HPC also found that while some variation in pricing may support activities that are beneficial to the Commonwealth (e.g., provision of specialized services or stand-by capacity), much of the variation in inpatient hospital prices is likely unwarranted and reflects
the leverage of certain providers to negotiate higher prices with commercial insurers. We also found that unwarranted and extensive variation in prices, combined with the large share of patient volume at higher-priced providers, drives increased health care spending and creates inequities in the distribution of health care resources that threaten the viability of lower-priced, high-quality providers.12

In order to inform potential state action to address unwarranted price variation, the HPC conducted additional research and analysis and convened stakeholders throughout the spring of 2016 to discuss specific, data-driven policy options. Over three meetings, stakeholders discussed potential solutions organized around three main themes: demand-side incentives, supply-side incentives, and direct limits on variation.13

In June 2016, the Massachusetts legislature passed, and the Governor signed, Chapter 115 of the Acts of 2016. Chapter 115 allocated funds to support hospitals, including $45 million to be distributed over five years to hospitals with relative price at or below 120 percent of the statewide median through a Community Hospital Reinvestment Trust Fund distributed by the Secretary of the Executive Office of Health and Human Services. Chapter 115 also established a special commission to review variation in prices among providers, to be co-chaired by the House and Senate Chairs of the Joint Committee on Health Care Financing. The HPC and CHIA were charged to provide relevant data and analysis necessary for the commission’s work. The special commission began holding regular meetings in September 2016 and is required to submit any recommendations for legislative action by March 15, 2017.

In support of the special commission’s work, the HPC conducted new analyses. First, the HPC examined the relationship between hospitals’ commercial inpatient relative price for a given commercial payer and hospitals’ overall net inpatient revenue per discharge across all payers, including supplemental payments from the MassHealth program, adjusted for patient acuity. As shown in Exhibit 3.7 for one major payer, we found that the commercial price level and overall revenue per discharge across all payers are highly

**Exhibit 3.7:** Inpatient relative price for one major commercial payer compared to inpatient net patient service revenue per case-mix-adjusted discharge across all payers, 2014

<table>
<thead>
<tr>
<th>Hospitals with below-average relative price, but above-average revenue per discharge</th>
<th>Hospitals with above-average relative price, but above-average revenue per discharge</th>
</tr>
</thead>
<tbody>
<tr>
<td>Martha’s Vineyard</td>
<td>Fairview</td>
</tr>
<tr>
<td>MEEI</td>
<td>Dana Farber</td>
</tr>
<tr>
<td>Athol</td>
<td>Lahey</td>
</tr>
<tr>
<td>Cha</td>
<td>NWH</td>
</tr>
<tr>
<td>Baptist</td>
<td>NSH</td>
</tr>
<tr>
<td>Baptist</td>
<td>MGH</td>
</tr>
<tr>
<td>MetroWest</td>
<td>-Brigham</td>
</tr>
</tbody>
</table>

**Notes:** NPSR = net patient service revenue; CMAD = case mix adjusted discharge; THP = Tufts Health Plan. Source: HPC analysis of Center for Health Information and Analysis Relative Price Data, 2014 and Acute Hospital Data Appendix, 2014
correlated, with a few outliers. The notable outliers include several hospitals that are paid differently by Medicare and/or Medicaid (e.g., critical access hospitals and those that receive supplemental payments from the Medicaid program).

These findings suggest that in general, commercial relative price is strongly associated with the overall level of resources available to hospitals. It also highlights that for most hospitals, higher rates from commercial payers are not offsetting lower rates from public payers or vice versa. Rather, a hospital with higher commercial rates tends to also have higher overall revenue across all payers, and a hospital with lower commercial rates may be doubly disadvantaged financially by also having lower overall revenue across all payers.

The HPC also examined provider price variation in the MassHealth Managed Care Organization (MCO) market to supplement the well-documented issue of variation in commercial prices paid to providers. The most recent data demonstrates significant variation in inpatient prices paid by MCOs. As shown in Exhibit 3.8, as of 2014, the highest-priced hospitals received anywhere from three to nearly eight times the prices of the lowest-priced hospitals.

Recent policy changes aim to reduce this variation in the MassHealth MCO market. For example, under its current contracts with MCOs, MassHealth generally prohibits MCOs from contracting to pay acute care hospitals more than 105 percent of MassHealth fee-for-service rates. If an MCO does contract to pay a higher rate, the MCO must explain its reasons to MassHealth. In addition, as described in the Sidebar: “Update on out-of-network billing issues,” in 2017, MassHealth requires hospitals outside an MCO’s network to accept the hospital’s MassHealth fee-for-service rate for both emergency and non-emergency services, unless otherwise negotiated (a similar policy for emergency services has already been in place in 2016).

In the absence of limits on out-of-network charges such as these, some providers may have the leverage to demand higher rates from payers. If payers exclude that provider from their network, but members nonetheless seek care at the out-of-network provider, the out-of-network provider can demand reimbursement at the charge rates for their out-of-network patients, which are generally far higher than a negotiated rate would be. MassHealth’s policies may have the effect of reducing higher rates paid to some hospitals,
thereby reducing price variation. The HPC will continue to monitor price variation in MCO networks and work to understand any effects from these or other policy changes.

**Market Entry and Expansion of Urgent Care Centers**

While much of the HPC’s provider market work has focused on increasing the transparency of the market and mitigating the negative impacts of provider consolidation, the HPC also engages in activities to support a more competitive health care marketplace, such as monitoring innovation and the entry of new market competitors. One important new trend is that the HPC is monitoring the entrance of urgent care centers and retail clinics into the health care market.

Since 2008, the number of urgent care centers and retail clinics in Massachusetts has increased dramatically, though growth of retail clinics appears to have leveled off in recent years. As shown in **Exhibit 3.9**, since 2008, the number of retail clinics grew from 11 locations to 56, while the number of urgent care centers grew from six locations to 90. The majority (88 percent) of urgent care centers are independently owned, with 8 percent owned by physician groups and 3 percent owned by hospitals. Of these independently owned urgent care centers, 43 percent are owned

---

**Update on out-of-network billing issues**

Out-of-network billing continues to be a policy area of interest for the HPC. As outlined in the 2015 Cost Trends Report and the HPC’s Policy Brief on Out-of-Network Billing, out-of-network billing issues can have significant consequences for consumers and the functioning of the health care market overall. There are two key situations in which a patient may receive out-of-network care when they did not or could not intentionally choose the provider: (1) emergency care; and (2) when a patient seeks care at an in-network facility or from an in-network provider, but during the course of treatment, the patient is unexpectedly treated by an out-of-network provider (e.g., anesthesiologist). Such circumstances can result in the patient receiving a balance bill or a “surprise bill,” which can be for a substantial amount. In addition to the potential impact on consumers, the absence of balance billing prohibitions and limits on what out-of-network providers may charge for emergency care may also affect provider-insurer negotiations and potentially impact price variation and overall spending.

Massachusetts policymakers are engaged in this topic. As outlined in the reports cited above, the HPC has made recommendations to the Legislature to augment existing protections around out-of-network billing, which include requiring insurers to hold their members harmless in cases of emergency out-of-network services and prohibiting balance billing, increasing consumer awareness of existing surprise billing protections, and establishing a maximum reasonable price for out-of-network services.

Efforts to address out-of-network billing issues continue to gain momentum around the nation. In 2016, new laws in Florida and California establish additional out-of-network billing protections with bipartisan support. California’s comprehensive approach extends balance billing protections to non-emergency care, establishes a default payment rate for out-of-network providers, and institutes a binding dispute resolution process. Several other states are engaged in more preliminary efforts to address out-of-network billing issues (e.g., Washington, Pennsylvania).

New research further supports action on this issue. National data estimates that of the 99 percent of emergency department (ED) visits that occurred at in-network hospitals, 22 percent involve out-of-network physicians. Another national study on the likelihood of surprise bills in different scenarios suggests that 14 percent of outpatient visits to the ED in 2014 may have led to a surprise bill.

The HPC conducted stakeholder listening sessions on out-of-network billing issues in 2016 at which stakeholders generally agreed that patients should be protected from emergency and surprise out-of-network bills, payers provided new data regarding the impact of out-of-network payments on total spending, and stakeholders recognized the need to balance interests in determining provider payment levels. The HPC will continue to engage with stakeholders about these issues and will continue to support efforts to enhance out-of-network billing protections in the Commonwealth.

---

<sup>iv</sup> Balance billing refers to when a patient is billed for the difference between the insurer’s payment and the provider’s charges. Surprise billing refers to when a patient receives an unexpected bill from an out-of-network provider after seeking and receiving care at an in-network facility.

<sup>v</sup> For example, one payer said that out-of-network payments cost $134 million in 2014.
by three groups: CareWell (20 percent), Doctors Express (15 percent) and Health Express (8 percent). All retail clinics in the Commonwealth are CVS MinuteClinics.

New market entrants such as urgent care centers and retail clinics provide low-complexity services that have traditionally been offered by emergency departments, primary care physician offices, and hospital outpatient departments. These new market entrants may increase access to care, particularly after normal office hours and for patients without established primary care relationships. Urgent care centers and retail clinics are also typically lower-cost than hospitals, although some of these facilities are affiliated with hospital systems and may refer patients to higher-priced affiliated hospitals rather than to local community hospitals in the event that patients need follow-up care.

The entry of these new providers into the market has also created competitive pressure on established health care providers. While this competition may ultimately encourage traditional providers to lower prices and improve the quality of certain medical services, there is not yet definitive evidence as to whether these competitive changes are occurring. The impact of these new entrants on the provider market – particularly on community hospitals for whom low-acuity commercially-insured patients have traditionally been an important source of revenue – should continue to be studied. The HPC expects to continue to monitor the growth and impact of urgent care centers and retail clinics and conduct a more in-depth review of their impact on cost, quality and access.

REFERENCES
8. Health Policy Commission. Review of Beth Israel Deaconess Care Organization’s Proposed Contracting Affiliation with New England Baptist Hospital and New England Baptist Clinical Integration Organization (HPC-CMIR-2015-1) and Beth Israel Deaconess Care Organization’s Proposed Contracting Affiliation and Beth Israel Deaconess Medical Center’s and Harvard Medical Faculty Physician’s Proposed Clinical Affiliation with MetroWest Medical Center (HPC-CMIR-2015-2 AND HPC-CMIR-2016-11), Pursuant to M.G.L. Chapter 6D Section 13, Final Report. 2016 Sep; 62-71.


17 California Health and Safety Code Section 1371.9 (in-network cost-sharing limit), Section 1371.31 (out-of-network provider payment determination), and Section 1371.30 (dispute resolution process).


19 Garmon C, Chartock B. One in Five Inpatient Emergency Department Cases May Lead to Surprise Bills. Health Affairs. 2017; 36(1).
PRESCRIPTION DRUG SPENDING

Section II: Trends in Spending and the Delivery System

For the second year in a row, prescription drug spending exceeded historical growth rates in Massachusetts and the U.S., ensuring that drug spending will remain an area of focus for health care cost containment at both the state and federal level in the immediate future.

This chapter focuses on trends in prescription drug spending, including estimates of growth net of rebates, drivers of drug spending growth, trends in consumer out-of-pocket spending, outlook for future spending trends, and discussion of policy efforts to contain drug spending.

TRENDS IN SPENDING GROWTH

Prescription drug spending in Massachusetts grew 10.2 percent in 2015, following 13.5 percent growth in 2014, to $8.1 billion or 14.1 percent of total health care expenditures (THCE). This growth accounted for one third of the per capita growth in THCE in 2015.1

In the commercial market, Massachusetts’ total medical expenditures (TME) for prescription drugs grew 8.8 percent per capita in 2015. While this growth represents a decrease from the growth rate in 2014 (12.5 percent), prescription drug spending in 2015 exceeded growth in all other categories of service (see Exhibit 4.1). Notably, the THCE and TME drug figures capture spending only for prescription drugs – those obtained through a pharmacy – and do not capture spending for drugs covered under the medical benefit, emphasizing the need for greater tracking of drug spending in this area (see Sidebar: “Medical benefit drug spending”).

Exhibit 4.1: Growth in commercial spending categories and proportion of total medical expenses, 2013-2015

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Professional physician</td>
<td>1.9%</td>
</tr>
<tr>
<td>Hospital outpatient</td>
<td>1.7%</td>
</tr>
<tr>
<td>Prescription drugs (pharmacy)</td>
<td>12.5%</td>
</tr>
<tr>
<td>Hospital inpatient</td>
<td>1.3%</td>
</tr>
<tr>
<td>Other</td>
<td>-2.5%</td>
</tr>
</tbody>
</table>

Notes: TME = total medical expenses. Prescription drug figures exclude impact of rebates.
Source: HPC analysis of Center for Health Information and Analysis 2016 Annual Report TME Databook

Medical benefit drug spending

Prescription drug spending figures from the Center of Health Information and Analysis (CHIA) do not include spending for drugs covered under the medical benefit. Medical drugs, such as chemotherapeutic agents and flu vaccine, are administered by providers, and paid for separately under a medical benefit rather than a prescription drug benefit. Medical benefit drug spending accounted for 4.0 percent of all commercial health care spending in the Massachusetts All-Payer Claims Database (APCD) in 2014. In contrast, prescription pharmacy drugs accounted for about 17 percent of all commercial health care spending. Therefore, including both prescription and medical drugs, drug spending now accounts for more than 20 percent of commercial spending in Massachusetts.

Between 2011 and 2014, medical benefit drug spending in commercial claims grew an average 5.7 percent annually. In addition to those covered by the pharmacy benefit, spending on medical benefit drugs should continue to be monitored.
Role of rebates

The drug spending estimates above do not reflect rebates and other discounts that occur after the initial acquisition price. The prices paid by the insurer for prescription drugs are almost always determined by negotiations between a pharmacy benefit management company (PBM) and drug manufacturers (see Exhibit 4.2 for an illustration of the flow of payments and prescription medicines).1 PBMs manage drug benefits for many health plans and act on behalf of insurers and pharmacies to negotiate prices, discounts and rebates with manufacturers. Following the purchase of drugs, manufacturers pay rebates to PBMs to distribute to insurers, which PBMs may pass on in part or in full to insurers. Furthermore, insurers can also negotiate directly with manufacturers for additional rebates or other concessions.

Exhibit 4.2: Flow of payments and prescription medications

Source: Adapted from Shepherd J. Is more information always better? Mandatory disclosure regulations in the prescription drug market. Cornell Law Review Online. 2013; 99(1)

Accounting for rebates is important as it can affect both the estimated level and the growth trend for drug spending (the latter, if rebates comprise a growing or falling percentage of the gross amount paid by payers). Available evidence indicates, however, that even including discounts, prescription drug spending growth remains high (see Exhibit 4.3). In its recent report, the Attorney General’s Office found that accounting for rebates decreased the growth of commercial drug spending per capita in Massachusetts from 8.2 percent to 6.1 percent, a difference of 26 percent.2 IMS Health found a similar difference (30 percent) in national drug spending growth after accounting for rebates.3


<table>
<thead>
<tr>
<th>2014-2015 growth</th>
<th>Pre-rebate</th>
<th>Net-rebate</th>
<th>Percent difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>MA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHIA: Total prescription drug growth</td>
<td>10.2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHIA: Commercial per capita</td>
<td>8.8%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AGO: Commercial* per capita</td>
<td>8.2%</td>
<td>6.1%</td>
<td>26%</td>
</tr>
<tr>
<td>IMS: Total prescription drug growth</td>
<td>12.2%</td>
<td>8.5%</td>
<td>30%</td>
</tr>
<tr>
<td>CMS: Total prescription drug growth</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CMS: Commercial per capita</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: *AGO data based on five commercial health plans.
Sources: Center for Health Information and Analysis 2016 Annual Report; Attorney General’s Office, 2016; IMS Institute for Healthcare Informatics, 2016; Centers for Medicare and Medicaid Services, 2016

DRIVERS OF SPENDING GROWTH

Many of the factors that drove high national drug spending growth in 2014 persisted in 2015: the entry of new high-cost drugs, price growth for existing drugs, and a low level of patent expirations (see Exhibit 4.4). Across the U.S., spending on new branded drugs (brands launched within the past 24 months) in 2014 and 2015 more than tripled relative to the levels in 2013.3 As in 2014, viral Hepatitis C (HCV) drugs that launched in late 2013 and 2014, such as Gilead Science’s Sovaldi, continued to comprise a substantial share of new brand spending ($7.0 billion of $24.2 billion or 29 percent) in 2015. Introduction of new diabetes management drugs, such as SGLT2 inhibitors, also contributed

---

1 For more information on how prices are determined for drugs covered by the medical benefit, see the HPC’s 2015 Cost Trends Report.

2 The Attorney General’s Office calculated commercial drug spending growth for five commercial health plans, which account for 75 percent of Massachusetts commercial market membership. See the Attorney General’s Office Examination of Health Care Cost Trends and Cost Drivers Pursuant to G.L. c. 12C, s. 17 for more detail.
to new brand spending growth in 2015 ($4.6 billion). In addition, increased volume (utilization) of existing drugs contributed slightly to the growth in national drug spending in 2015 for the first time since 2007. Growth of spending on branded drugs that have been on the market for over 24 months continued to contribute to drug spending growth in 2015, although rebates and discounts on these drugs moderated the effect. Savings from expiration of patents for branded drugs, which dropped to historically low levels in 2014, grew only slightly in 2015.

**DRUG SPENDING AND COST SHARING IN MASSACHUSETTS**

To further explore trends in total spending and out-of-pocket spending on prescription drugs in the Commonwealth, the HPC analyzed data from the APCD between 2012 and 2014. This analysis showed that average annual spending on prescription drugs for those with commercial prescription drug coverage in Massachusetts increased on average about 9 percent per year from 2012 to 2014, from $876 per member in 2012 to $1,044 in 2014, regardless of whether the member used that coverage.iii,iv For those who used their prescription drug coverage at least once in the calendar year, average spending also increased about 9 percent per year, from $1,177 in 2012 to $1,402 in 2014 (see bottom table in Exhibit 4.5).

Average spending for both generics and branded drugs increased between 2012 and 2014 (see Exhibit 4.5). While panelists at the 2015 and 2016 Cost Trends Hearings noted substantial increases in prices for certain generic drugs, average spending per claim for generic drugs has risen slowly, increasing just over $1 per claim in two years (a 2 percent average increase per year) to $31 per claim in 2014. In contrast, spending per branded drug claim grew an average 18 percent per year, increasing $126 over the two years to $447 per claim on a pre-rebate basis in 2014. Generic drugs grew from 82 percent of claims in 2012 to 84 percent in 2014, yet have accounted for an increasingly smaller share of prescription drug spending over this time: from 30 percent of spending in 2012 to 27 percent in 2014.v Therefore, the increase in the proportion of generic prescriptions has not offset the increased spending from branded drugs. Under-scoring these findings, panelists at the 2016 Cost Trends Hearing raised concerns about reaching a “saturation point” for savings that can be gained through generic substitution of branded drugs.

---

iii Average spending is defined as the allowed amount, or the amount recorded in the claims paid by the insurer and the patient.

iv Among commercial members, 80 percent have the pharmacy benefit included in their coverage. Approximately 70 percent of these members use their pharmacy benefit at least once within a calendar year (referred to here as “users” of prescription drug coverage). The remaining 30 percent of members defined as non-users do not have any pharmacy claims in the APCD within the year. These numbers include non-users of the pharmacy benefit.

v This may be driven by Mass. General Laws c. 112, s. 12D, which mandates that pharmacists substitute brand name drugs with generic drugs, unless otherwise indicated by the prescriber.
Out-of-pocket spending for prescription drugs averaged $198 per member per year (PMPY) in 2014, comprised of an average $117 PMPY for generic drugs and $81 PMPY for branded drugs. Despite the lower out-of-pocket cost per claim for generic drugs, spending over the course of the year was higher for generic drugs, as commercial members in the Commonwealth fill 5.4 times more generic prescriptions than branded prescriptions.

Whereas total drug spending increased between 2012 and 2014, average patient cost sharing for prescription drugs decreased. Out-of-pocket spending per year decreased 9 percent from 2012 to 2014, from $219 PMPY to $198 PMPY. These trends in the Commonwealth mirror the U.S. trend, for which total out-of-pocket spending on prescription drugs has reached the lowest cost sharing amount since 2004. Despite this trend toward lower out-of-pocket spending, a small share of Commonwealth residents continues to have high cost sharing; for claims with over $50 in patient cost sharing, average cost sharing increased $10 in two years, from $98 in 2012 to $108 in 2014 (see Exhibit 4.6).

Exhibit 4.5: Average spending and cost sharing for branded and generic drugs, per claim and per member year, 2012-2014

<table>
<thead>
<tr>
<th></th>
<th>Generic drugs</th>
<th>Branded drugs</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Average spending per claim</td>
<td>Average cost sharing per claim</td>
<td>Average spending per claim</td>
</tr>
<tr>
<td>2012</td>
<td>$30</td>
<td>$11</td>
<td>$321</td>
</tr>
<tr>
<td>2013</td>
<td>$30</td>
<td>$10</td>
<td>$358</td>
</tr>
<tr>
<td>2014</td>
<td>$31</td>
<td>$10</td>
<td>$447</td>
</tr>
</tbody>
</table>

Notes: PMPY = per member per year. Data include privately insured individuals covered by Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, and Tufts Health Plan who use the prescription drug benefit at least once in the calendar year. Figures exclude impact of rebates.

Source: HPC analysis of Massachusetts All-Payer Claims Database, 2012-2014

Exhibit 4.6: Distribution of cost sharing, per claim, 2012-2014

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>$0-$10</td>
<td>54.5%</td>
<td>54.4%</td>
<td>54.5%</td>
</tr>
<tr>
<td>$10-$20</td>
<td>24.7%</td>
<td>24.7%</td>
<td>24.7%</td>
</tr>
<tr>
<td>$20-$30</td>
<td>10.5%</td>
<td>10.5%</td>
<td>10.5%</td>
</tr>
<tr>
<td>$30-$40</td>
<td>8.8%</td>
<td>8.8%</td>
<td>8.8%</td>
</tr>
<tr>
<td>$40-$50</td>
<td>4.4%</td>
<td>4.4%</td>
<td>4.4%</td>
</tr>
<tr>
<td>$50+</td>
<td>2.0%</td>
<td>2.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

Average cost sharing for the highest spending bucket: $98 in 2012, $108 in 2014

Notes: Data include privately insured individuals covered by Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, and Tufts Health Plan who use the prescription drug benefit at least once in the calendar year. Figures exclude impact of rebates.

Source: HPC analysis of Massachusetts All-Payer Claims Database, 2012-2014
Two factors appear to be driving the decline in out-of-pocket spending in the U.S.: generic substitution following patent expirations and the Affordable Care Act’s (ACA) mandatory coverage of preventative services without cost sharing. Expiration of patents and generic products entering the market allow patients to substitute generic drugs for branded drugs. Since payers tend to place generic drugs on lower cost sharing tiers than branded drugs, this substitution can result in lower cost sharing for patients.

The preventive service mandate of the ACA includes a number of preventative drugs, including contraceptive medications and smoking cessation medications.\textsuperscript{vi} With respect to coverage of some preventative drugs under the ACA, the HPC found that the number of drug claims in Massachusetts with $0 in cost sharing increased from 2.2 percent of claims in 2012 to 8.7 percent of claims in 2014 (see \textit{Exhibit 4.6}). Given the inclusion of contraception under the ACA mandate, the HPC analyzed cost sharing trends by gender and found that the share of drug claims with $0 cost sharing for women grew from 3.2 percent of claims in 2012 to 13.4 percent in 2014, compared to a smaller difference for men: 0.9 percent of claims in 2012 to 2.4 percent of claims in 2014 (see \textit{Exhibit 4.7}). These ACA protections have contributed to reducing the out-of-pocket burden for both men and women in the Commonwealth, with average cost sharing per claim dropping 16 percent for women and 6 percent for men from 2012 to 2014. On an annual basis, out-of-pocket spending on prescription drugs dropped 7.0 percent for women PMPY and 2.1 percent for men PMPY. National data from the Kaiser Family Foundation (KFF) support HPC’s finding in Massachusetts; KFF found that the share of reproductive age women with out-of-pocket spending on oral contraceptive pills declined from 20.9 percent in 2012 to 3.6 percent in 2014. That decline accounted for nearly two-thirds (63 percent) of the total decrease in out-of-pocket spending on retail drugs during this time period.

\textbf{EpiPens}

While Sovaldi and other HCV drugs garnered attention last year for their high launch prices, in recent months other drugs have attracted scrutiny for continued increases in price beyond market entry level, such as Mylan’s EpiPen epinephrine injector. The HPC analyzed commercial spend-

\begin{center}
\textbf{Exhibit 4.7:} Spending and cost sharing by gender, per claim and per member per year, 2012-2014
\end{center}

<table>
<thead>
<tr>
<th></th>
<th>Women</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Average spending per claim</td>
<td>Average cost sharing per claim</td>
<td>Percent of claims with $0 cost sharing</td>
<td>Average spending (PMPY)</td>
<td>Average cost sharing (PMPY)</td>
</tr>
<tr>
<td>2012</td>
<td>$77</td>
<td>$15</td>
<td>3.2%</td>
<td>$1,132</td>
<td>$221</td>
</tr>
<tr>
<td>2013</td>
<td>$79</td>
<td>$13</td>
<td>10.7%</td>
<td>$1,169</td>
<td>$198</td>
</tr>
<tr>
<td>2014</td>
<td>$88</td>
<td>$13</td>
<td>13.4%</td>
<td>$1,333</td>
<td>$191</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Men</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Average spending per claim</td>
<td>Average cost sharing per claim</td>
<td>Percent of claims with $0 cost sharing</td>
<td>Average spending (PMPY)</td>
<td>Average cost sharing (PMPY)</td>
</tr>
<tr>
<td>2012</td>
<td>$92</td>
<td>$16</td>
<td>0.9%</td>
<td>$1,233</td>
<td>$216</td>
</tr>
<tr>
<td>2013</td>
<td>$94</td>
<td>$16</td>
<td>1.6%</td>
<td>$1,251</td>
<td>$208</td>
</tr>
<tr>
<td>2014</td>
<td>$108</td>
<td>$15</td>
<td>2.4%</td>
<td>$1,486</td>
<td>$207</td>
</tr>
</tbody>
</table>

Notes: PMPY = per member per year. Data include privately insured individuals covered by Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, and Tufts Health Plan who use the prescription drug benefit at least once in the calendar year. Figures exclude impact of rebates. Source: HPC analysis of Massachusetts All-Payer Claims Database, 2012-2014

\textsuperscript{vi} Insurers must cover at least one version of each FDA-approved contraceptive method without cost sharing.
ing and cost sharing for EpiPens between 2012 and 2014. Commercial spending on EpiPens in the Commonwealth jumped over $100 per claim in two years, from $244 per claim (which includes two injectors) in 2012 to $362 per claim in 2014, an average 22 percent increase per year (see Exhibit 4.8). These values are consistent with prices reported nationally, which reached over $600 in 2016. Average cost sharing, however, rose just over $2.50 in two years to $36.60 in 2014. These findings suggest that insurers are generally not shifting the cost increases to higher patient cost sharing for this drug, but ultimately, the drug price increase will result in higher premiums for all patients. Furthermore, a small portion of the Massachusetts commercial population pays much or all of Mylan’s EpiPen cost out-of-pocket. About three percent of EpiPen consumers in the APCD paid more than $100 out-of-pocket for an EpiPen in 2014, and more than one percent paid over $300. In 2014, some claims reached over $800 in out-of-pocket costs.

Exhibit 4.8: Average spending and cost sharing, per claim, on Mylan’s EpiPen epinephrine injector in Massachusetts, 2012-2014

Average total spending per claim

- 2012: $243.7
- 2013: $209.3
- 2014: $362.0

Average cost sharing per claim

- 2012: $34.1
- 2013: $36.5
- 2014: $36.6

Notes: An EpiPen claim includes two injectors. Data include commercially insured individuals covered by Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, and Tufts Health Plan who use the prescription drug benefit at least once in the calendar year. Total spending figure excludes impact of rebates. Source: HPC analysis of Massachusetts All-Payer Claims Database, 2012-2014

EXPECTATIONS FOR FUTURE SPENDING

Estimates suggest that high cost growth will continue, in the absence of policy changes; data from the first three quarters of 2016 show national drug spending grew 3.5 percent from the previous year. CMS’s National Health Expenditure (NHE) data continue to predict high single digit annual spending growth over the next decade (see 2015 Cost Trends Report for more detail on trends likely to influence future spending).

DEVELOPING POLICY ISSUES

Sustained growth in drug spending has led states, along with payers and other stakeholders, to consider a number of policy options and initiatives. Although most drug expenditure patterns are driven by federal law, interventions are available to states. Recent activity at the state level is highlighted below.

Strategies for cost containment

The HPC collected information on payers, hospitals and providers’ efforts to address prescription drug spending in written testimony for the 2016 Annual Cost Trends Hearing. Payers in the Commonwealth are already implementing many strategies, including: strengthening utilization management and pre-authorization tools; adjusting cost sharing tiers and/or placement of certain drugs in specialty tiers; providing education and information to prescribers on drug and treatment alternatives, monitoring prescribing variation and conducting outreach; implementing medication adherence strategies and programs, and establishing alternative payment contracts that include accountability for pharmaceutical spending; and pursuing exclusive contracts with pharmaceutical manufacturers. Fewer payers are currently implementing value-based price benchmarks in their negotiations with drug manufacturers or shifting billing for specialty drugs from the medical benefit to the pharmacy benefit. Providers in Massachusetts are making similar efforts to manage pharmaceutical spending and utilization responsibly, using many of the strategies listed above as well.

Risk-based contracts

Risk-based contracting was highlighted in the 2015 Cost Trends Report as an opportunity for insurers to consider value in use of certain pharmaceuticals, such as negotiating price-volume or performance-based models with manufacturers. During the 2016 Cost Trends Hearing, Harvard Pilgrim Health Care (HPHC) discussed its risk-based contract with Amgen for Repatha, a PCSK9 drug for cholesterol management. Under this arrangement, in exchange for exclusivity for Repatha in its formulary, HPHC will receive additional rebates if the drug fails to meet certain performance targets, or if spending on the drug exceeds a certain threshold, especially for use of the drug outside of the target patient population. HPHC discussed being in the process of developing more risk-based contracts.

vii The most commonly adopted included providing education and information to prescribers on drug and treatment alternatives and implementing medication adherence/compliance strategies, as well as alternative payment contracts and implementing internal “best practices.”
One barrier to greater use of risk-based contracting is that rebates in the commercial sector can affect the price for which manufacturers provide drugs for Medicaid programs, under the Medicaid best-price regulations. These regulations specify that manufacturers must provide Medicaid with the largest rebate for branded drugs.viii Therefore, if a risk-based contract results in the largest rebate, the manufacturer must provide this same rebate to all state Medicaid programs. Opportunities to preserve this important protection for Medicaid while allowing for more innovation in value-based contracts among commercial and government payers should be examined at the state and federal level. Furthermore, risk-based contracting is aided by the use of value-based price benchmarks, which continue to be developed by groups such as the Institute for Clinical and Economic Review (ICER) and others.

**State-level legislation**

Many states have responded to drug spending growth with proposed legislation to address various aspects of drug distribution and pricing. In summer 2016, Vermont became the first state to pass drug price transparency legislation.¹⁰ Among other measures to improve transparency in the pharmaceutical industry, this law requires Vermont to identify prescription drugs that have become substantially more expensive for the state to purchase. Pharmaceutical manufacturers must then justify such price increases. In the 2015 to 2016 legislative season, a number of other states also considered drug price transparency legislation.¹¹ A national measure to establish drug pricing transparency, The Fair Drug Pricing Act, was also introduced in Congress in September 2016 with bipartisan support.¹²

In recent years, many states have passed legislation regulating aspects of the PBM industry (e.g., registration/licensure, transparency around maximum allowable cost).¹³ States that took such action in 2016 include Delaware, Kansas, Kentucky, Maine, Mississippi, Missouri, New Hampshire, Rhode Island, South Carolina, Tennessee, Washington, and Wyoming.¹⁴ Mississippi extended the regulatory authority of its State Board of Pharmacy to PBMs.¹⁵ Several states, such as Delaware and Kentucky, established maximum allowable cost definitions or requirements.¹vi Such state laws seek to promote more accountability and provide greater oversight over PBMs, but the effectiveness of such efforts remains uncertain. It will be important for the Commonwealth to work with stakeholders to determine the most effective methods of pharmaceutical cost containment for the state.

In 2016, the National Academy for State Health Policy (NASHP) convened a working group of state government officials from across the U.S., including the HPC, to explore state-based strategies to address pharmacy costs. Informed by this working group, NASHP published a recent report outlining potential policy options. Strategies for states to consider include various methods of increasing drug price transparency, utilizing consumer protection laws and protecting patients from misleading marketing, promoting purchasing flexibility in Medicaid through regulatory changes, the state acting as a pharmacy benefit manager (negotiating as a unified state purchaser), and implementing return-on-investment pricing structures.¹⁷ Some approaches involve direct regulation of the pharmaceutical industry; others involve redesigning how the state acts in the market as a purchaser of drugs. While not all policy options are optimal for each state, the report presents a range of options for states to consider. The HPC will continue its involvement in collaborative discussions with a range of stakeholders, including other state leaders, to explore innovative state-based approaches to enhance the transparency and accountability of pharmaceutical spending in the Commonwealth.

---

viii For branded drugs, manufacturers must provide the greater of 23.1 percent of the Average Manufacturer Price (AMP) per unit or the difference between the AMP and the best price per unit and adjusted by the Consumer Price Index-Urban (CPI-U) based on launch data and current quarter AMP.
ix In general, maximum allowable cost is the upper limit that a payer or PBM will reimburse a pharmacy for multi-source drugs. Maximum allowable cost is determined by the PBM.

---

x Massachusetts requires registration of PBMs as third party administrators (TPAs). The state, however, may not capture PBMs that are not TPAs, such as for fully insured plans. See Code of Mass. Regulations 211 s. 148.02.
xi See Maine Revised Statutes Title 24-A s. 4317(12); Rhode Island Public Law 166; Wyoming Insurance Code Title 26 c. 4, 52; National Conference of State Legislators, Prescription Drug State Database.

---

xiii See Delaware Laws 80 c. 245; Kentucky Acts of 2016 c. 79 (revises Kentucky’s earlier maximum allowable cost law).
## REFERENCES


10. Vermont Act No. 165 of 2016 (S216).


The future outlook for health care spending growth in Massachusetts is highly uncertain, in large part due to the likelihood of significant changes to state and federal health policy. However, the spending, utilization, and overall market trends outlined in this section, and other recent data suggest higher spending growth is likely in subsequent years. For example, health plan testimony indicates continued prescription drug spending growth into 2016. Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, and Tufts Health Plan, the three largest commercial insurers in the Commonwealth, estimated commercial prescription drug spending growth per member per year (PMPY) in 2016 to be 15.0 percent, 7.2 percent, and 13.1 percent, respectively.

Overall U.S. health spending has been projected by CMS to grow at a rate of 5.8 percent per year from 2015 to 2025, and recent developments signal that Massachusetts may be catching up to the U.S. on this measure. The Massachusetts Division of Insurance has reported rate increases for premiums in the small group and individual markets of between 5.4 and 8.3 percent from the end of 2015 through the first quarter of 2017, after 12 quarters of growth below 4 percent (see Figure below), suggesting higher growth in 2016 and 2017.

Finally, although uptake of alternative payment methods (APMs) stalled in 2015 (see Chapter 8: “Alternative Payment Methods”), participation is projected to increase in 2016 and 2017 with the expansion of a preferred provider organization (PPO) based APMs in several large provider groups’ commercial contracts and the launch of MassHealth’s new accountable care organization (ACO) program. If successful, these mechanisms could act to mitigate spending growth in future years.

Note: Increases for Q1 of each year reflect carriers in the individual and small group market combined. Increases for all other quarters reflect small group market renewals only.

Source: Massachusetts Division of Insurance, 2011-2017

Announced rate increases for the Massachusetts merged market, 2011-2017

i Note that these rates are prospective and do not directly correspond to actual realized spending growth reported earlier in this Report. For example, if consumers switch to less expensive plans in response to a rate increase, realized spending growth would be lower.
HOSPITAL UTILIZATION

Section III: Care Delivery Performance: Opportunities to Improve Quality and Efficiency

In previous Cost Trends Reports, the Health Policy Commission (HPC) has shown that hospital use in Massachusetts is higher than the national average, and the HPC identified several strategies to curb hospital-based spending growth, including reducing unnecessary hospital use and shifting appropriate inpatient care to community hospitals. According to the Commonwealth Fund’s Scorecard on State Health System Performance, in 2015 Massachusetts was ranked 31st in the nation with regard to avoidable hospital use and costs, suggesting this is an area for continued improvement for the state.

This chapter briefly reviews recent trends in hospital use before examining several avoidable hospital utilization measures, particularly avoidable emergency department (ED) use and readmissions, in depth. It concludes with an examination of the Commonwealth’s progress on directing appropriate inpatient care to community hospitals.

**TRENDS IN HOSPITAL USE, MASSACHUSETTS AND THE U.S., 2010-2014**

Given that hospital care accounts for a substantial share of total health care spending in Massachusetts (see Chapter 2: “Overview of Trends in Spending and Care Delivery”), reducing unnecessary hospital utilization is critical to both controlling statewide spending and growth. It is therefore encouraging that hospital utilization declined in the Commonwealth from 2010 to 2014; inpatient discharges declined by 11 percent and both hospital outpatient and ED visits declined by 2 percent.

Despite these declines, however, Massachusetts continues to use hospitals at higher rates than national averages. In 2014, inpatient, hospital outpatient, and ED utilization rates per capita in Massachusetts were 8 percent, 50 percent, and 10 percent higher than the national averages, respectively (see Exhibit 5.1). These differences have decreased slightly since 2010 when Massachusetts utilization was 11 percent, 58 percent, and 17 percent higher than the national average, respectively.

**Exhibit 5.1: Hospital use in Massachusetts and the U.S., 2010-2014**

<table>
<thead>
<tr>
<th>Inpatient discharges per 1,000 persons</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
</tr>
<tr>
<td>MA</td>
</tr>
<tr>
<td>U.S.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hospital outpatient visits per 1,000 persons</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
</tr>
<tr>
<td>MA</td>
</tr>
<tr>
<td>U.S.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ED visits per 1,000 persons</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
</tr>
<tr>
<td>MA</td>
</tr>
<tr>
<td>U.S.</td>
</tr>
</tbody>
</table>

Notes: ED = emergency department. Some non-Massachusetts residents are captured in the Massachusetts discharges. In 2015, non-Massachusetts residents accounted for 5 percent of all inpatient discharges and 4 percent of all ED visits in Massachusetts. Source: Kaiser Family Foundation analysis of American Hospital Association data, 2010-2014
A number of factors likely contribute to the significantly higher per capita volume of hospital-based outpatient care in Massachusetts. One key driver is the number of physicians corporately affiliated with hospitals or contracting with payers as part of a hospital-based network. Joint contracting relationships between physicians and hospitals can encourage in-system referral patterns that bypass non-hospital settings in favor of care at in-system hospital outpatient settings. Hospital acquisitions of physician practices can further inflate the volume of hospital-based outpatient care as hospital ownership of a physician practice may allow the hospital to license the practice as a hospital outpatient department and bill for the practice’s services as outpatient hospital visits rather than physician office visits, which results in higher spending for the same services (for more detail, see the Health Policy Commission’s 2015 Cost Trends Report).

This chapter continues with an in-depth examination of ED visits and inpatient discharges and highlights opportunities to reduce inappropriate utilization and increase efficiency in the delivery system.

ED VISITS IN MASSACHUSETTS, 2015

ED visits in Massachusetts continued to decline in 2015, falling from 366.2 per 1,000 population in 2014 to 364 per 1,000 population. To better understand this trend, the HPC used the NYU Billings algorithm to classify ED visits into three visit categories: emergency, avoidable, and behavioral health (BH)-related.¹

Emergency ED visits includes two types of visits: visits that required immediate ED care (e.g., injuries) and visits that required immediate ED care, but which could have been prevented with better primary care (e.g., visits for emergency’s related to a chronic condition such as diabetes and asthma). Avoidable ED visits also includes two types of visits: emergency, primary care treatable visits (e.g., visits that required medical care within 12 hours, but where care could have been provided by a primary care provider, such as ear or urinary tract infections) and non-emergent visits (e.g., visits for which the complaint did not require immediate medical care within 12 hours, such as a bad sore throat with no fever). Finally, BH-related visits includes both substance use disorders and mental health conditions.

As seen in Exhibit 5.2, the reduction in ED visits from 2014 to 2015 was entirely due to a 2.1 percent decline in emergency ED visits, which have been steadily decreasing since 2011. Though avoidable ED visits steadily declined from 2011 to 2014, in 2015 these visits increased slightly (0.3 percent). Meanwhile, behavioral health-related ED visits have steadily increased since 2011 growing 13 percent. The next sections discuss avoidable and BH-related ED visits in greater detail.

Exhibit 5.2: ED visits per 1,000 population, by type, 2011-2015

<table>
<thead>
<tr>
<th>Type of visit</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emergency</td>
<td>377.8</td>
<td>381.2</td>
<td>375.9</td>
<td>366.2</td>
<td>364.0</td>
</tr>
<tr>
<td>Avoidable</td>
<td>166.5</td>
<td>167.4</td>
<td>163.7</td>
<td>159.4</td>
<td>156.1</td>
</tr>
<tr>
<td>BH-related</td>
<td>162.2</td>
<td>162.1</td>
<td>159.5</td>
<td>153.8</td>
<td>154.2</td>
</tr>
</tbody>
</table>

Notes: ED = emergency department; BH = behavioral health. The total ED rate (in orange above the bars) includes all categories of ED visits, including unclassified ED visits which are not shown here. Unclassified visits increased 5.7 percent during this time period. ED categories are based on NYU Billings algorithm categorization of a patient’s primary diagnosis and are mutually exclusive. BH ED visits include any discharge with a primary mental health, substance use disorder, or alcohol-related diagnosis code. Emergency visits include the Billings categories of requires ED care and is not potentially preventable and emergent, ED care preventable; avoidable visits include the Billings categories of non-emergent and emergent, primary care treatable. Some non-Massachusetts residents are included in the number of ED visits. In 2015, non-Massachusetts residents accounted for 4 percent of all ED visits in Massachusetts.

Sources: NYU Center for Health and Public Service Research, HPC analysis of Center for Health Information and Analysis Emergency Department Database, 2011-2015

AVOIDABLE ED UTILIZATION

Inappropriate and unnecessary use of the ED is problematic from both a cost and quality vantage point. In 2015, of the nearly 2.5 million ED visits in Massachusetts, 42 percent were considered avoidable (22 percent were non-urgent visits and 20 percent were emergent, primary care treatable

¹ The Billings algorithm provides probabilities that an ED visit with a given primary diagnosis is non-emergent, emergent but primary care treatable, requires ED care but is potentially avoidable, or requires ED care and is not potentially preventable. Emergency visits include the Billings categories of requires ED care and is not potentially preventable and emergent, ED care preventable; avoidable visits include the Billings categories of non-emergent and emergent, primary care treatable. All categorizations are based on a patient’s primary diagnosis code and are mutually exclusive.
The use of EDs to treat conditions that are non-emergent or amenable to primary care can be an indicator of barriers to primary care access, and the high volume of preventable or avoidable ED visits provides insight into the quality and accessibility of the health care system in the surrounding community. Strategies to curb this type of ED overuse include redesigning primary care practices to improve access (particularly after typical business hours), providing alternative sites for urgent primary care (e.g., retail clinics and urgent care centers), improving care management for chronic disease patients, and aligning patient and provider incentives regarding use of the ED.

**BEHAVIORAL HEALTH-RELATED ED UTILIZATION**

As discussed previously, despite reductions in general ED utilization, BH-related ED utilization increased steadily in recent years. In 2015, patients with a primary BH diagnosis comprised 7 percent of all ED visits. This measure is conservative as it does not include visits where a BH condition was a secondary diagnosis or where a medical problem may have had a BH condition as its root cause (such as an injury from a motor vehicle accident where the driver was intoxicated). When secondary diagnoses are included, BH conditions in 2015 accounted for 14 percent of all Massachusetts ED visits.

BH patients provide unique challenges for EDs, and prompt treatment and discharge of such patients can be particularly difficult. As seen in Exhibit 5.3, BH patients in Massachusetts have significantly longer lengths of stay in the ED than non-BH patients. In 2015, the median length of stay for patients with a primary BH diagnosis (5.4 hours) was twice as long as for patients without a BH diagnosis (2.6 hours).

Despite accounting for a small portion of all ED visits, BH patients comprised 70.5 percent of all ED boarders, defined as patients with a length of stay in the ED of more than 12 hours from time of registration to time of discharge. In 2015 patients with a primary BH diagnosis were 16.3 times more likely to board than non-BH patient—over a fifth of all BH ED patients (22.8 percent) boarded compared to only 1.4 percent of ED patients without a primary BH diagnosis (see Exhibit 5.4). ED boarding negatively affects the quality of care, and BH-related boarding is potentially harmful to both patients and staff as external stimuli from busy EDs often increases patient anxiety, agitation, and aggression. ED boarding is also associated with leaving the ED before receiving treatment (elopement), which increases BH patients’ risk of self-harm and suicide. Finally, ED boarding is costly, contributes to overcrowding, and consumes ED resources, delaying treatment for other patients. It is concerning then that, unlike non-BH patients, the share of BH patients that boarded has steadily grown over time, increasing 5.4 percentage points from 2011 to 2015.

**Exhibit 5.3: Median length of stay in the ED, 2015**

<table>
<thead>
<tr>
<th>Hours spent in the ED</th>
<th>All ED</th>
<th>No BH diagnosis</th>
<th>Non-primary BH diagnosis</th>
<th>Primary BH diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>2.7</td>
<td>2.6</td>
<td>3.4</td>
<td>5.4</td>
</tr>
</tbody>
</table>

Note: ED = Emergency department, BH = behavioral health. BH ED visits identified using NYU Billings algorithm and includes any discharge with a primary “mental health, substance abuse, or alcohol”-related diagnosis code. Hours spent in the ED calculated from time of registration to time of discharge. Sources: NYU Center for Health and Public Service Research, HPC analysis of Center for Health Information and Analysis Emergency Department Database, 2015

**Exhibit 5.4: Percent of patients with an ED length of stay of 12 hours or more, 2011-2015**

<table>
<thead>
<tr>
<th>Year</th>
<th>BH patients</th>
<th>Non-BH patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>17.4%</td>
<td>1.3%</td>
</tr>
<tr>
<td>2012</td>
<td>19.1%</td>
<td>1.3%</td>
</tr>
<tr>
<td>2013</td>
<td>21.1%</td>
<td>1.2%</td>
</tr>
<tr>
<td>2014</td>
<td>22.2%</td>
<td>1.2%</td>
</tr>
<tr>
<td>2015</td>
<td>22.8%</td>
<td>1.4%</td>
</tr>
</tbody>
</table>

Notes: ED = emergency department; BH = behavioral health. The categories of BH and non-BH are based on a patient’s primary diagnosis. BH ED visits identified using NYU Billings algorithm and includes any discharge with a primary “mental health, substance abuse, or alcohol”-related diagnosis code. Hours spent in the ED calculated from time of registration to time of discharge. Source: HPC analysis of Center for Health Information and Analysis Emergency Department Database, 2011-2015
The steady increase in BH-related ED utilization and ED boarding is likely driven by several factors. One factor is the growing opioid epidemic in Massachusetts, which continues to impact hospitals and particularly EDs. Since 2011, opioid-related ED visits in Massachusetts have more than doubled, growing from 17,897 visits in 2011 to 33,444 visits in 2015 (an 87 percent increase). In 2014, Massachusetts had the highest rate of opioid-related ED visits across the U.S. with 441.6 per 100,000 population, a rate that was 1.5 times higher than the next highest state, Rhode Island (288.6), and 14 times higher than the state with the lowest rate, Iowa (31.1) (see Exhibit 5.5). As of 2015, HPC analysis found that a fifth of all BH-related ED visits in Massachusetts had a primary or secondary opioid-related diagnosis.

Strategies to reduce BH ED visits and BH ED boarding often focus on systemic changes such as improving access to inpatient beds and outpatient behavioral health services. Innovative hospital-level interventions are being tested nationwide. For example, many hospitals have sought to reduce ED boarding by improving access to psychiatrists in the ED through telepsychiatry, which allows for psychiatric assessment and care through videoconferencing. Telepsychiatry can shorten ED lengths of stay by providing consultations for BH patients in the ED when staff psychiatrists are otherwise unavailable (often during nights and weekends).

Some hospitals are leveraging emergency responders to reduce BH-related ED utilization. For instance, Grady Hospital in Atlanta, Georgia, employs a round-the-clock crisis hotline and mobile crisis team. The Grady EMS Upstream Crisis Intervention Unit closely analyzes mental health-related 911 calls and provides mental health professional evaluations and on-scene outpatient referrals to providers and services other than the ED.

In Massachusetts, several hospitals, supported by awards through the HPC Community Hospital Acceleration, Revitalization, and Transformation Investment Program (CHART) awards (for more on CHART, see Sidebar: “Reducing readmissions: CHART interventions”) have implemented initiatives that aim to reduce unnecessary BH-related ED utilization and boarding. For example, Beth Israel Deaconess-Milton (BID-Milton) is partnering with South Shore Mental Health to target BH patients for rapid triage, timely crisis evaluation, intensive stabilization and care management, and peer support and navigation services. HealthAlliance Hospital is working to reduce BH-related ED visits and boarding by redesigning its medical clearance protocol to increase efficiency and creating a designated BH area of the ED to provide patients with assessment, treatment, and/or referral in a reduced-stimuli environment. Mercy Medical Center is staffing its ED with BH-trained nurses at all times and partnering with outpatient community health workers who assist patients in home and community settings with intensive follow up services and referrals, thereby reducing the risk of return to the ED. Finally, Hallmark Health System flags BH-related patients in the ED, enabling a multidisciplinary care team to support patients across the continuum of care, from providing ED clinicians with information of patient circumstances that may not surface during medical workups, to providing intensive post-discharge support, care, and linkages to community resources.

Exhibit 5.5: Rate of opioid-related ED visits per 100,000 population, by state, 2014

Note: ED = emergency department. Opioid-related ED visits includes patients with either a primary or secondary diagnosis of: opioid type dependence (ICD-9 304.00-304.02); combinations of opioid type drug with any other drug dependence (ICD-9 304.70-304.72); opioid abuse (ICD-9 305.50-305.52); poisoning by opioid alkaloids (ICD-9 965.00-965.02; 965.09); poisoning by opiate antagonists (ICD-9 970.1); accidental poisoning by heroin, methadone, other opiates and related narcotics causing adverse effects in therapeutic use (ICD-9 E950.0-E950.2); heroin, methadone, other opiates and related narcotics causing adverse effects in therapeutic use (ICD-9 E935.0-E935.1); Data was only available for the 30 states included in the analysis.

Source: Agency for Healthcare Research and Quality (AHRQ), Center for Delivery, Organization, and Markets, Healthcare Cost and Utilization Project (HCUP), HCUP Fast Stats, Opioid-Related Hospital Use, 2016.
In 2016, Health and Human Services (EHS) Undersecretary Alice Moore convened a working group on ED boarding to bring together providers, payers, government, and patients to address the growing issue of BH-related ED boarding in Massachusetts. The goals of the work group are to align on definitions, identify need for and ways to capture additional data on boarding, and reduce the number of individuals with BH needs who board in the ED. Efforts to reduce boarding identified by the working group to date include improving ability of providers to provide timely reports on status of patients in EDs, increasing efficiency of ED workflow patterns and inpatient discharge planning, as well as increasing capacity to treat patients who currently are hardest to place (e.g., patients with autism, intellectual disability, developmental delays, or comorbid aggression, SUD, and/or medical complexity). The working group will finalize its work, including securing commitments from payers and providers, and present final recommendations to the Secretary of EHS, in mid-2017.

INPATIENT CARE IN MASSACHUSETTS, 2015

After declining in recent years, inpatient discharges in Massachusetts increased 1.4 percent in 2015, from 785,485 in 2014 to 796,834. This increase was entirely due to growth in discharges for patients ages 65 and older, a 1.8 percent per Medicare beneficiary growth (see Exhibit 5.6). From 2014 to 2015, there was a 4.5 percent increase in the number of discharges among patients ages 65 to 84 and a 5.5 percent increase among patients ages 85 and older. Meanwhile, inpatient discharges for patients ages 18 and under continued to decline in 2015 and discharges for patients ages 18 to 64 remained the same. The increase in Massachusetts inpatient discharges mirrors national trends; initial findings released by the Medicare Payment Advisory Commission (MedPAC) show that after eight years of decline, Medicare inpatient discharges increased 0.4 percent per beneficiary nationally in 2015. It is unclear if the 2015 increase in inpatient discharges in Massachusetts and the U.S. is the beginning of a new growth trend or a one-time deviation from continued declines. The HPC will continue to monitor inpatient discharges to better understand this trend.

In addition to total inpatient utilization trends, the HPC also analyzed various measures of avoidable inpatient care. The following sections focus on two of these measures: preventable inpatient admissions and readmissions.

PREVENTABLE INPATIENT ADMISSIONS

The Agency for Healthcare Research and Quality (AHRQ) defines preventable inpatient admissions as visits for which better outpatient care could have potentially prevented the need for hospitalization or for which early intervention could have prevented complications or more severe disease. In Massachusetts, the rate of preventable inpatient admissions has steadily improved, falling 22 percent between 2011 and 2015, from 7.8 admissions per 1,000 population to 6.1 per 1,000. While this decline is consistent with the declining trend in hospital utilization overall, the preventable inpatient admission rate fell three times faster than the overall hospital utilization rate.

READMISSIONS

Unplanned readmissions following an inpatient discharge are often caused by deterioration in a patient’s health due to inadequate management of their condition, misunderstanding of how to manage it, and/or a lack of access to appropriate services or medications. These readmissions are costly, negatively affect patient experience of care, and may be an indicator of health care system fragmentation, as they could, in some cases, be avoided with more timely and coordinated follow up care.
In the 2015 Cost Trends Report, the HPC recommended the Commonwealth set a target of a 20 percent reduction in all-cause, all-payer 30-day hospital readmissions relative to the 2013 level. Achieving this goal would mean the Commonwealth attains an all-payer, all-cause readmission rate below 13 percent by 2019. However, rather than decreasing in 2015, the statewide all-payer all-cause readmission rate grew 3 percent from the previous year. While the statewide all-payer all-cause readmission rate initially declined slightly from 16.1 percent in 2011 to 15.2 percent in 2013, it remained relatively unchanged in 2014 at 15.3 percent, and increased to 15.8 percent in 2015, as shown by the yellow line in Exhibit 5.7. The Center for Health Information and Analysis (CHIA) found that 60 percent of the 2014 all-payer all-cause readmissions in Massachusetts were patients with BH conditions.iii Patients with heart failure and a BH comorbidity, for instance, had a 56 percent higher readmission rate than patients with heart failure and no BH comorbidity. These data suggest that hospitals aiming to reduce readmissions should consider targeting BH patients for additional discharge services and supports.

Exhibit 5.7: Thirty-day readmission rates, Massachusetts and the U.S., 2011-2015

<table>
<thead>
<tr>
<th>Year</th>
<th>MA Rank</th>
<th>MA Medicare</th>
<th>U.S. Medicare</th>
<th>MA - All-payer</th>
<th>HPC’s 2019 target all-payer readmission rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>40</td>
<td>18%</td>
<td>16%</td>
<td>12%</td>
<td>HPC’s 2019 target all-payer readmission rate</td>
</tr>
<tr>
<td>2012</td>
<td>41</td>
<td>18%</td>
<td>16%</td>
<td>12%</td>
<td>HPC’s 2019 target all-payer readmission rate</td>
</tr>
<tr>
<td>2013</td>
<td>39</td>
<td>16%</td>
<td>14%</td>
<td>10%</td>
<td>HPC’s 2019 target all-payer readmission rate</td>
</tr>
<tr>
<td>2014</td>
<td>43</td>
<td>16%</td>
<td>14%</td>
<td>10%</td>
<td>HPC’s 2019 target all-payer readmission rate</td>
</tr>
<tr>
<td>2015</td>
<td></td>
<td>14%</td>
<td>12%</td>
<td>9%</td>
<td>HPC’s 2019 target all-payer readmission rate</td>
</tr>
<tr>
<td>2016</td>
<td></td>
<td>12%</td>
<td>10%</td>
<td>8%</td>
<td>HPC’s 2019 target all-payer readmission rate</td>
</tr>
</tbody>
</table>

Sources: Centers for Medicare and Medicaid Services (Medicare, 2011-2014); Center for Health Information and Analysis (all-payer, MA Medicare 2015)

CHIA also found that in 2014, Massachusetts residents covered by either Medicaid or Medicare had higher readmission rates than commercially insured patients (17.0 and 17.4 percent compared to 10.3 percent, respectively). As with the all-payer all-cause readmission rate, the Commonwealth initially made progress in lowering its Medicare readmission rate, decreasing from 18.9 percent in 2010 to 17.4 percent in 2013, yet this encouraging trend reversed in 2014 when the Medicare readmission rate increased to 17.7 percent, and then again in 2015 when it grew to 18.2 percent (orange line in Exhibit 5.7). Unlike Massachusetts, the U.S. Medicare readmission rate continued to decline in 2014 (blue line in Exhibit 5.7). As a result, though Massachusetts had made progress in closing the gap with the national average, in 2014 Massachusetts returned to its 2010 ranking of 43rd in the nation.iv

Massachusetts’ high Medicare readmission rate is an area of concern. Since the Affordable Care Act’s (ACA) readmissions penalties began in 2012, 79 percent of eligible Massachusetts hospitals have been penalized every year. In the most recent fiscal year, 86 percent (49 hospitals) of all eligible hospitals in the state received readmission penalties, compared to 78 percent nationally, making the Commonwealth the fourth highest penalized state in the U.S.iv Some researchers speculate that Massachusetts’ high readmission rates are due in part to an oversupply of hospital beds, which may shape practice patterns towards providing more institutional care.iii HPC will continue to undertake research and analysis and engage with stakeholders to better understand the Commonwealth’s high readmission rates.

The Commonwealth’s stalled progress on reducing readmissions suggests that there are opportunities for providers to improve care, reduce unnecessary readmissions, and potentially reduce spending. Reducing readmissions requires interventions that focus on improving both the quality of inpatient care and the transition to ambulatory care by ensuring continuity and coordination between providers and access to follow-up services (see Sidebar: “Reducing readmissions: CHART interventions” for noteworthy examples). Research on the root causes of readmissions also suggests that a variety of non-clinical factors contribute to readmission events, including social determinants of health.iv Hospitals and health systems seeking to offset these factors may provide a variety of enhanced non-clinical services to patients post-discharge, including transportation to follow up care, initial and recurrent 30-day refills on medication, follow-up phone calls, and telemedicine consults.iii Furthermore, non-hospital entities in the market increasingly have similar incentives to reduce readmissions. For example, starting in October 2017, skilled nursing facilities will be subject to all-cause, all-condition readmission penalties imposed by Centers for Medicare and Medicaid Services (CMS).

iii CHIA’s report focused on patients with a primary and/or secondary BH-related diagnosis i.e. included patients with a primary BH condition or a BH comorbidity.
iv Massachusetts’ 2015 Medicare readmissions rank was not available at the time of publication.
Reducing readmissions: CHART interventions

The HPC’s Community Hospital Acceleration, Revitalization, and Transformation Investment Program (CHART) is a $120 million reinvestment program funded by an assessment on large health systems and commercial insurers that makes phased investments in community hospitals. Beginning in September 2015, 20 Massachusetts community hospitals received grants under CHART Phase 2. Approximately half of Phase 2 programs specifically aim to reduce readmissions for target populations using innovative approaches.

One noteworthy example is Signature Healthcare Brockton Hospital. Through CHART, Signature Healthcare Brockton Hospital is investing $3.76 million over two years to reduce 30-day readmissions by 20 percent for its target population. Patients with a history of high utilization are served by the multi-disciplinary Complex Care Team (CCT). The CCT provides cross-setting care (across the ED, hospital, skilled nursing facility, and at home) including care planning, case management, palliative care, and medication reconciliation. Patients over the age of 65 with 10 or more medications, or patients with congestive heart failure (CHF) or chronic obstructive pulmonary disease (COPD) diagnoses, are supported by pharmacists in Signature’s medication therapy management program. Pharmacists conduct an initial assessment of medication regimens to ensure safety and cost effectiveness, provide patient and family education, and engage in medication optimization with the overall goal of adherence to treatment. Additionally, patients with CHF or COPD diagnoses are voluntarily enrolled in Signature’s Homeward Bound telemedicine program following an inpatient discharge. Homeward Bound links patients to telehealth nurses and nursing students. Patients use biometric equipment connected to iPads to electronically send weight and blood pressure data directly to Signature’s electronic health record (EHR) on a daily basis. Nursing students (accompanied by an instructor) conduct home visits, as needed, on weekdays and weekends. Approximately one year in to its CHART Phase 2 program, Signature Healthcare Brockton Hospital has meaningfully decreased its readmission rate.

Other notable CHART supported interventions:

• Berkshire Medical Center administers intake questionnaires to identify key social determinants of health to improve whole patient understanding and better address social issues that lead to recurrent acute care utilization. Berkshire Medical Center is also increasing access to outpatient programs for those with chronic conditions and/or BH diagnoses using the former North Adams Regional Hospital site.

• Winchester Hospital and Milford Regional Medical Center both provide patients with large-format business cards featuring a photo and direct contact information of the care provider/coordinator that will follow up with them post-discharge to ensure a smooth transition home.

• Beth Israel Deaconess Hospital – Plymouth automatically provides a palliative care consult, as appropriate, for dually-eligible patients in its CHART program with the goal of improving pain management and thus reducing readmissions.

COMMUNITY HOSPITALS

Another strategy to reduce spending on hospital care is to shift clinically appropriate inpatient care to lower cost settings, namely from academic medical centers (AMCs) and teaching hospitals to community hospitals. Some complex care may not be suitable for treatment in community hospitals, which may lack the specialized technology or staffing to care for certain high acuity cases, such as organ transplantation. Other cases, which are less complex or which can be treated using well-established treatment protocols, can be treated safely in community hospitals, such as routine labor and deliveries. This section focuses on these less complex cases, referred to as community appropriate discharges.

Previous HPC research has shown that many community hospitals in Massachusetts provide care at lower costs to consumers and insurers than AMCs and teaching hospitals, even accounting for differences in complexity of services. For example, HPC analysis found that community hospitals have lower median spending for routine labor and deliveries ($2,100 lower for caesarian sections and $2,200 lower...
for vaginal deliveries). The appropriate use of community hospitals not only lowers costs but also provides patients with convenient local access. For this reason, the HPC considers community hospitals an integral component of creating an efficient, high-quality health care system accessible to all residents.

Despite the availability of high quality community hospitals throughout the Commonwealth, however, research has shown that many patients tend to go to AMCs and teaching hospitals for community appropriate discharges. Further, while many provider organizations have expressed commitment to shifting appropriate cases to community hospitals, the share of community appropriate discharges provided by community hospitals in Massachusetts declined 2 percentage points over time, from 55.3 percent in 2011 to 53.3 percent in 2015 (see Exhibit 5.8). Teaching hospitals absorbed these community appropriate discharges; in 2011, 16.7 percent of all community appropriate discharges occurred at teaching hospitals, but by 2015 the share rose to 18.6 percent.

Exhibit 5.8: Share of community appropriate discharges, by hospital type, 2011-2015

<table>
<thead>
<tr>
<th>Year</th>
<th>Community</th>
<th>Teaching</th>
<th>Academic medical center</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>28.1%</td>
<td>16.7%</td>
<td>55.3%</td>
</tr>
<tr>
<td>2012</td>
<td>27.7%</td>
<td>17.5%</td>
<td>54.9%</td>
</tr>
<tr>
<td>2013</td>
<td>27.6%</td>
<td>17.7%</td>
<td>54.7%</td>
</tr>
<tr>
<td>2014</td>
<td>28.1%</td>
<td>18.3%</td>
<td>53.6%</td>
</tr>
<tr>
<td>2015</td>
<td>28.2%</td>
<td>18.6%</td>
<td>53.3%</td>
</tr>
</tbody>
</table>

Note: Discharges which could be appropriately treated in community hospitals were determined based on expert clinician assessment of the acuity of care provided, as reflected by the cases’ diagnosis-related groups (DRGs).

Source: HPC analysis of Center for Health Information and Analysis Hospital Inpatient Discharge Database, 2011-2015

Trends for the Lahey Health System suggest that the shift of community appropriate discharges away from community hospitals is not universal. Lahey Health System acquired Winchester Hospital (Winchester), a community hospital, in 2014. Representatives of Lahey Health System provided testimony during the 2015 and 2016 Annual Cost Trends Hearings highlighting the system’s efforts to direct more inpatient care to Winchester and other appropriate community settings rather than to AMCs or teaching hospitals.

As seen in Exhibit 5.9, following Lahey Health System’s acquisition of Winchester, care shifted between Lahey Hospital & Medical Center (Lahey HMC), the system’s anchor teaching hospital, and Winchester. Prior to the 2014 acquisition, the number of community appropriate discharges at Winchester fell each year. After the merger, however, this trend reversed, and Winchester treated more than 300 more community appropriate discharges in 2015 than in 2014. Meanwhile, despite the overall increase in community appropriate discharges at teaching hospitals across the state, the number of community appropriate discharges at Lahey HMC declined after the merger.

Exhibit 5.9: Discharges at Lahey and Winchester hospitals, by type of discharge, 2012-2015

<table>
<thead>
<tr>
<th>Year</th>
<th>Winchester (community appropriate)</th>
<th>Lahey HMC (community appropriate)</th>
<th>Lahey HMC (higher acuity)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>6,000</td>
<td>12,000</td>
<td>10,000</td>
</tr>
<tr>
<td>2013</td>
<td>8,000</td>
<td>14,000</td>
<td>12,000</td>
</tr>
<tr>
<td>2014</td>
<td>10,000</td>
<td>16,000</td>
<td>14,000</td>
</tr>
<tr>
<td>2015</td>
<td>12,000</td>
<td>18,000</td>
<td>16,000</td>
</tr>
</tbody>
</table>

Note: Discharges considered “community appropriate” were those that could be appropriately treated in community hospitals, determined based on expert clinician assessment of the acuity of care provided as reflected by the cases’ diagnosis-related groups (DRGs). All other discharges are classified as “higher acuity” for the purposes of this analysis.

Source: HPC analysis of Center for Health Information and Analysis Hospital Inpatient Discharge Database, 2011-2015

The data from the first year following the Winchester acquisition show small but promising signs that Lahey HMC may be redirecting more community appropriate inpatient care to Winchester. The HPC will continue to assess changes in community appropriate discharges within Lahey Health System and within other provider systems following new provider affiliations.
In summary, Massachusetts residents continue to use more hospital-based care than the national average. While the Commonwealth has made some progress in curbing overall hospital utilization, progress on reducing hospital use and readmissions has stalled in recent years, and BH-related ED use continues to grow. Returning appropriate care to community hospitals remains a focus for the Commonwealth.

REFERENCES


Post-acute care (PAC) services include short-term nursing or rehabilitative care following a hospital discharge. PAC recipients may receive nursing or rehabilitative services at home (home health) or in an institutional setting such as a skilled nursing facility (SNF), inpatient rehabilitation facility (IRF), or long-term care hospital (LTCH). Besides these PAC settings, patients may visit a provider’s office for follow-up care or receive physical therapy outside the home. Different PAC settings have different capabilities, but there is overlap in many of the kinds of patients treated by the various PAC service types (see 2014 Cost Trends Report for overview of settings). The average cost of care differs substantially by setting, and all institutional PAC settings are markedly more costly, on average, than home health. Choosing the appropriate setting of PAC is important in ensuring optimal care and has significant effects on the cost of an episode of care for many patients. The choice of PAC setting also has implications for patient experience and overall quality. Previous HPC research found that Massachusetts has much higher use of both home health and institutional PAC than the U.S. average. This chapter will update trends in utilization and spending for PAC in Massachusetts.

Medicare is the largest payer of PAC services nationally, covering nearly three quarters of all PAC spending. In 2014, PAC spending for Original Medicare beneficiaries age 65 and older totaled $54.2 billion nationally, accounting for 16.7 percent of Original Medicare spending. In Massachusetts, PAC spending accounted for a somewhat higher share of total Medicare spending for beneficiaries age 65 and older at 18.7 percent, totaling $1.7 billion of $9.0 billion Medicare dollars spent in the Commonwealth. Particularly given the lack of clinical consensus on best practices for PAC discharge for many types of cases, PAC use varies substantially across the U.S. Controlling for population factors, a 2013 Institute of Medicine report found that differences in PAC spending accounted for 73 percent of all regional differences in Medicare spending.

Consistent with findings in past reports, the HPC found that PAC use in Massachusetts is higher than the U.S. average for all payer types, not just Medicare. Overall, 40 percent of patients in Massachusetts used some form of PAC following an inpatient stay, compared to only 29 percent of patients nationwide in 2013 (the most recent year for which the HPC has national comparator data) (see Exhibit 6.1). (Patients in the “No PAC” category may receive follow-up care in a provider’s office or visit a physical therapist outside the home.) Much of the difference in overall PAC use between Massachusetts and the U.S. is driven by the Commonwealth’s more intensive use of home health; 18.6 percent of all patients discharged in Massachusetts were discharged with home health services compared to 12.2 percent nationwide, over 50 percent higher. Furthermore, in Massachusetts, 21.8 percent of all patients were discharged to an institutional setting (SNF, IRF, or LTCH), compared with 17.1 percent of patients in the U.S. overall in 2013.

### Exhibit 6.1: PAC discharges, all DRGs, all payers, 2013

<table>
<thead>
<tr>
<th>Discharge destination</th>
<th>PAC: institutional</th>
<th>PAC: home health</th>
<th>No PAC</th>
</tr>
</thead>
<tbody>
<tr>
<td>MA Commercial</td>
<td>14.4</td>
<td>8.5</td>
<td>8.1</td>
</tr>
<tr>
<td>U.S. Medicare</td>
<td>37.8</td>
<td>6.5</td>
<td>5.1</td>
</tr>
<tr>
<td>U.S. Medicaid</td>
<td>19.2</td>
<td>31.3</td>
<td>19.2</td>
</tr>
<tr>
<td>MA Medicaid</td>
<td>79.3</td>
<td>9.3</td>
<td>5.3</td>
</tr>
<tr>
<td>U.S. Total</td>
<td>18.6</td>
<td>21.8</td>
<td>17.1</td>
</tr>
</tbody>
</table>

Source: HPC analysis of HCUP data, 2013

---

i Calculated from 2014 CMS Public Use Files for spending on Medicare Parts A and B for beneficiaries age 65 and older.

ii The institutional PAC facilities are distinct and where possible we considered each separately. However, limitations in the site coding of some of the datasets complicate efforts to distinguish between the different institutional sites of care. For this reason, we group SNFs, IRFs, and LTCHs together into one “institutional” category for many of our analyses.
Discharge patterns in both Massachusetts and the U.S. were fairly consistent from 2012 to 2013.4 The HPC found that patterns of care changed little in Massachusetts over time. When adjusted for changes in patient acuity over time, the probability of discharge to PAC increased slightly between 2010 and 2015; while the rate of discharge to an institutional setting declined by less than one percentage point, the rate of discharge to home health increased by 2.4 percentage points (see Exhibit 6.2).iii,5

Massachusetts’ average spending on PAC per Medicare beneficiary is higher than the U.S. average across all PAC service types, reflecting the state’s higher rates of use of home health and institutional PAC than the national average (Exhibit 6.3). PAC spending per beneficiary in Massachusetts is 28.7 percent higher than the U.S. average, and 13.5 percent higher when excluding the price adjustments Medicare makes to account for regional differences in wages and supplemental program spending.iv,vi

Exhibit 6.2: Adjusted percentage of discharges to post-acute care, all DRGs, 2010-2015

<table>
<thead>
<tr>
<th>Year</th>
<th>No PAC</th>
<th>PAC: institutional</th>
<th>PAC: home health</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>58.7%</td>
<td>21.2%</td>
<td>20.1%</td>
</tr>
<tr>
<td>2011</td>
<td>58.1%</td>
<td>21.4%</td>
<td>20.5%</td>
</tr>
<tr>
<td>2012</td>
<td>58.7%</td>
<td>21.6%</td>
<td>19.7%</td>
</tr>
<tr>
<td>2013</td>
<td>58.1%</td>
<td>22.1%</td>
<td>19.8%</td>
</tr>
<tr>
<td>2014</td>
<td>57.4%</td>
<td>22.9%</td>
<td>19.7%</td>
</tr>
<tr>
<td>2015</td>
<td>57.0%</td>
<td>23.6%</td>
<td>19.4%</td>
</tr>
</tbody>
</table>

Notes: Rates adjusted for changes in DRG mix over time. Several hospitals were excluded (UMass, Clinton, Cape Cod, Falmouth, Marlborough) due to coding irregularities in the database. Sources: HPC analysis of Center for Health Information and Analysis Hospital Inpatient Discharge Database, 2010-2015

Exhibit 6.3: Original Medicare adjusted spending per beneficiary on PAC by setting, 2014

<table>
<thead>
<tr>
<th>Setting</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Home health</td>
<td>$157</td>
<td>$127</td>
<td>$214</td>
<td>$205</td>
<td>$999</td>
<td>$889</td>
</tr>
<tr>
<td>LTCH</td>
<td>$999</td>
<td>$999</td>
<td>$999</td>
<td>$999</td>
<td>$999</td>
<td>$999</td>
</tr>
<tr>
<td>IRF</td>
<td>$889</td>
<td>$889</td>
<td>$889</td>
<td>$889</td>
<td>$889</td>
<td>$889</td>
</tr>
<tr>
<td>SNF</td>
<td>$616</td>
<td>$616</td>
<td>$616</td>
<td>$616</td>
<td>$616</td>
<td>$616</td>
</tr>
</tbody>
</table>

Source: HPC analysis of Geographic Variation Public Use File from CMS, 2014

Joint replacements

While some conditions, such as a traumatic brain injury or severe stroke, almost always require intensive institutional PAC, other conditions typically rely on greater clinical discretion to determine the appropriate care following discharge. Therefore, differences in practice patterns may be seen more clearly by examining trends following procedures around which less consensus exists regarding appropriate post-operative care, particularly with respect to the duration and intensity of rehabilitation, and thus discharge destination. In past reports, HPC research has focused on joint replacements without major complications or comorbidities. PAC practice patterns following joint replacements represent a particularly important service area to track, given that the procedure is high volume, frequently requires some PAC, and may have greater opportunities for care improvement and relative standardization of PAC protocols, given that the procedure is typically elective and non-emergent.

Rates of PAC use for joint replacements continue to be much higher in Massachusetts than in the U.S. overall for all payers, suggesting that practice patterns in Massachusetts favor more intensive PAC use where there is less consensus among providers regarding appropriate post-operative care.

Notes:

iii HPC accounted for patient acuity by adjusting for changes in DRG mix over time.

iv While average PAC spending per Medicare beneficiary is higher in Massachusetts than in the U.S. overall, Massachusetts spends less per Medicare beneficiary that uses these services. This lower spending per user in Massachusetts likely reflects that lower acuity patients with shorter stays are included in the average, given the higher use rate in the population. Per Medicare beneficiary using these services, Massachusetts spent approximately $4,700 per home health user and $13,800 per SNF user, compared to national averages of $5,400 and $16,100, respectively.
For example, among Original Medicare patients, rates of discharge to institutional care following joint replacement were much higher in Massachusetts than the U.S. average; 63.8 percent of Original Medicare patients in Massachusetts were discharged to institutional settings following joint replacement compared to 46.1 percent in the U.S. in 2013 (see Exhibit 6.4). While rates of discharge to institutional care following joint replacement have fallen in Massachusetts, a wide gap remains between Massachusetts and the U.S. Furthermore, higher rates of PAC in Massachusetts do not appear to result in higher quality outcomes, with no difference in readmission or complication rates following joint replacements between Massachusetts and the national average. Due to the wide variation in costs and practice patterns surrounding the procedure, joint replacement has emerged as a national focus of cost-savings efforts. The Centers for Medicare and Medicaid Services (CMS) has been a leader in promoting bundled payments for joint replacement, in which hospitals are responsible for all costs of care in excess of a previously arranged episodic payment (see Chapter 8: “Alternative Payment Methods” for further information on CMS’ Comprehensive Care for Joint Replacement payment model). Early evidence from one hospital system suggests that bundled payments have reduced the cost of joint replacement by 21 percent, almost half of which was attributable to reduced PAC spending.

Exhibit 6.4: PAC discharge destination following joint replacement among Original Medicare patients, 2013

Large employers have also begun to initiate episodic bundling agreements with preferred providers. General Electric Co. (GE), having recently relocated its headquarters to Boston, has designated New England Baptist Hospital as a preferred provider of joint replacements for GE employees. New England Baptist, an orthopedic specialty hospital, has been found to provide high-value care on the basis of cost and quality and also has one of the lowest rates of discharges to institutional care following joint replacements among Massachusetts hospitals. GE will provide a bundled payment to New England Baptist for each joint replacement episode and will waive out-of-pocket costs and travel expenses for employees that elect to use New England Baptist for joint replacement.

In addition to higher costs associated with institutional care, the high use of institutional PAC in Massachusetts is particularly concerning, given the importance of days at home as a patient quality outcome. Previous HPC reports have called for greater adoption of planning tools to standardize the discharge process and enable systematic consideration of key factors and have also called for consensus guidelines for patient discharge planning. At the federal level, the 2014 Improving Medicare Post-Acute Care Transformation (IMPACT) Act requires standardized data collection and sharing on Medicare patient outcomes across all post-acute care settings by 2019. IMPACT will require PAC providers to document patient outcomes over a number of quality and resource use metrics including functional status, cognitive changes, hospital readmissions, and discharge to the community, among others. Payers and providers in Massachusetts can use this outcomes data to inform high-quality and high-value discharge strategies.

More broadly, providers across primary care, inpatient care, PAC, and specialty care should focus on how to improve the number of patient days at home in the Commonwealth. This focus could drive change in Massachusetts’ high reliance on institutional PAC and have important impacts on overall health care quality and spending.

REFERENCES

Section III: Care Delivery Performance: Opportunities to Improve Quality and Efficiency


VARIATION IN SPENDING BY PRIMARY CARE PROVIDER GROUP

Section III: Care Delivery Performance: Opportunities to Improve Quality and Efficiency

Variation in provider prices, spending, and clinical practice patterns is well documented in Massachusetts. The Health Policy Commission (HPC) has previously highlighted variation in episode spending for specific diagnoses and procedures across hospital, post-acute, and specialty care (for example, in the areas of hip or knee replacements and maternal care). In this chapter, the HPC examined variation in primary care provider group spending.

Primary care providers (PCPs) who manage a patient’s care across the continuum of care have considerable influence over where a patient decides to seek secondary care, including specialist visits, diagnostic testing, and hospitalization. This chapter presents data on variation in patient spending by PCP group using health status-adjusted total medical expenses (HSA TME) as reported by the Center for Health Information and Analysis (CHIA). HSA TME includes all categories of medical expenses (including patient copays and deductibles) and all non-claims payments to providers, including payments based on spending and quality performance, and is adjusted to account for the acuity of the patient population (i.e., health status-adjusted). HSA TME by PCP group encompasses spending only for members of health maintenance organization (HMO) or point of service (POS) plans who have an assigned PCP in that PCP group. This measure includes a patient’s spending at any provider or site of care, including hospitals or specialists which may not be affiliated with the PCP group, capturing variation due to differences in utilization and prices.

PCP groups in Massachusetts are increasingly participating in alternative payment methods (APMs), which hold providers accountable for TME as well as clinical quality, including patient outcomes (for more see Chapter 8: “Alternative Payment Methods”). For this reason, the HPC also explored the relationship between the percent of a provider’s population that is covered by an APM (APM uptake) and TME among the patients of the Commonwealth’s ten largest PCP groups. Though the HPC did not conduct causal analyses, high-level patterns provide directional evidence about the effectiveness of APMs.

The final section of this chapter explores spending variation for patients attributed to these PCP groups in one particular subcategory of spending: services that are not evidence-based or recommended by physician specialty societies for certain populations. Based on a framework from the Choosing Wisely campaign the HPC examined rates of “non-recommended care” by provider group to determine if certain organizations used these services and procedures at lower rates.

VARIATION IN HSA TME

The measure of TME in this chapter combines spending for patients attributed to PCP groups who are covered under any of Massachusetts’ three largest commercial payers: Blue Cross Blue Shield of Massachusetts (BCBS), Harvard Pilgrim Health Care (HPHC), and Tufts Health Plan (THP) for the years 2012 to 2015 (see Technical Appendix for

---

i TME excludes prescription drug rebates and thus reflects the gross amounts paid to pharmacies for prescription drugs, rather than the net amounts paid. Most payers use similar risk-adjustment software that is driven by provider-recorded diagnoses.

ii Some payers already do this assignment based on claims (for example, the Medicare program does for ACOs) for enrollees in preferred provider organizations (PPOs), and future data reporting by CHIA will likely report TME for PPO members.

iii The ten largest PCP groups defined by member months. The HPC aggregated local provider groups to the ‘parent’ level – that is, groups working under the same managing corporate or contracting umbrella as defined by CHIA. Some groups have had significant changes in membership or populations over this period, which can affect their TME or number of members under APMs.

iv In 2012, the American Board of Internal Medicine (ABIM) launched the Choosing Wisely campaign with the goal of avoiding wasteful or unnecessary medical tests, treatments and procedures. Medical societies developed lists of tests, treatments or services that each specialty commonly overuses and submitted them to ABIM. As of February 2013, there were 135 recommendations targeting a range of procedures to either question or avoid without special consideration.
The HPC calculated HSA TME for patients of the ten largest PCP groups in the Commonwealth to ensure large enough patient populations to make comparisons meaningful. As seen in Exhibit 7.1, HSA TME for these PCP groups has been converging somewhat over time, with the exception of Partners Community Physicians Organization (Partners). Of the ten largest PCP groups, Partners had the highest HSA TME in 2015 at $497 per member per month (PMPM), which was $36 PMPM (7.2 percent) higher than the next highest provider group (New England Quality Care Alliance, or NEQCA) and $39 PMPM above the average HSA TME. Baycare Health Partners (Baycare) had the lowest HSA TME ($422 PMPM) in 2015, 15 percent below that of Partners. Further, Atrius Health (Atrius) and Mount Auburn Cambridge Independent Physician Association (MACIPA) moved from being high-cost provider groups in 2012 to average or below in 2015.

As illustrated in Exhibit 7.1, growth in HSA TME over time for most groups was generally low, between 2.3 percent growth for Boston Medical Center Management Services (BMC) and a 2.3 percent reduction for MACIPA. Comparing HSA TME and TME unadjusted for health status changes (see Exhibit 7.2) over time shows that these reported growth rates were low partly because payers and providers reported large increases in patient acuity each year from 2012 to 2015. For example, between 2012 and 2015, unadjusted TME grew 3.5 percent per year, on average, for all provider groups in Exhibit 7.1, but these groups also reported that patient acuity increased by 3.1 percent per year, resulting in HSA TME growth of merely 0.4 percent. Whether the reported increase in patient acuity is due to worsening member health or, for example, changes in coding practices will be the subject of continued investigation. 

Providers and payers often face incentives to report higher patient acuity. For example, the Affordable Care Act’s (ACA) risk adjustment methodology redistributes funds from plans with lower-risk enrollees to plans with higher-risk enrollees in the individual and small group markets. Additionally, provider groups in Massachusetts may be subject to Performance Improvement Plans under Chapter 224, the criteria of which are largely based on health status-adjusted changes in TME.
Chapter 7: Variation in Spending by Primary Care Provider Group

VARIATION IN APM UPTAKE AND HSA TME

Across the ten largest PCP groups, APM uptake (the percent of a provider group’s HMO and POS members covered by APMs) increased 14.7 percentage points from 2013 to 2015, from an average of 69.3 to an average of 84.0 percent. However, APM uptake varied significantly by provider group in 2015, with a low of 55.5 percent (Boston Medical Center) and a high of 95.9 percent (Atrius). Because many APMs are designed to reward providers for lower total TME in subsequent contract years, the HPC analyzed the relationship between APM uptake and TME growth rate in the following year.

Exhibit 7.3 suggests that provider groups with high APM uptake in one year did indeed tend to have low TME growth rates in the following year. This tendency appeared stronger in 2014-2015 (correlation of -.7) compared to 2013-2014 (correlation of -.3), which is consistent with the possibility that APMs may grow in effectiveness over time as providers gain more experience with them.

To further the analysis, the HPC divided provider groups into two categories: those with high APM uptake in 2013 (more than 74 percent of their HMO or POS members were in APMs) and those with low APM uptake in 2013. The HPC found that provider groups with high APM uptake had average HSA TME growth of 0.9 percent per year between 2013 and 2015, while provider groups with low APM uptake had average HSA TME growth of 2.6 percent across the three years (see Exhibit 7.3).

VARIATION IN NON-RECOMMENDED CARE

Non-recommended care, defined as services that medical communities agree provide few benefits to patients, is one example of unnecessary medical spending. Such care can lead to additional procedures and downstream costs, further contributing to wasteful medical spending. For this reason, several initiatives have been launched to reduce non-recommended care, such as the American Board of Internal Medicine Foundation’s Choosing Wisely campaign. Rates of non-recommended care measures have also been used as quality measures to set shared savings or deficit amounts in APMs.

Using 16 measures from the Choosing Wisely campaign, for which researchers had developed algorithms to identify in claims data, HPC analyzed commercially-insured patients insured with either BCBS, HPHC, or THP in the Massachusetts All-Payer Claims Database. Identifying instances of non-recommended care in claims data has a

---

vi This is a correlational analysis unable to prove causality.

vii This effect was found in BCBS’ Alternative Quality Contract in Massachusetts. See Song Z, et al. Changes in health care spending and quality 4 years into global payment. New England Journal of Medicine. 2014: 371.18; 1704-1714. Nevertheless, conclusions are highly tentative as CHIA’s spending data reported for 2015 is preliminary (some of the finalized numbers include additional settlement payments between payers and providers related to APMs) and because of the limited statistical power of this analysis.

viii For example, one of the measures, imaging for back pain, is also a Healthcare Effectiveness Data and Information Set (HEDIS) measure and has been monitored and reported on by CHIA in its Annual Report on the Performance of the Massachusetts Health Care System.
number of limitations, including that some patients may have unique needs, history or predisposition not captured in claims records. Nevertheless, rates of many of these measures are now routinely reported in the Medicare program (and in commercial populations) as important indicators of program efficiency; recent research has found, for example, that Medicare beneficiaries in Pioneer ACOs had lower rates of non-recommended care than other beneficiaries.

The non-recommended care measures the HPC examined can be grouped into three main categories: screening measures, imaging, and general procedures and surgeries. For a list of specific measures, see Technical Appendix. Overall, Massachusetts had a rate of non-recommended care of two instances per 100 patients in 2013 and 2014 (which translates to 192,176 instances of low-value care performed in 2013 and 185,543 in 2014), with considerable variation across measures. In 2013, imaging and lab tests represented some of the highest rates of non-recommended care use, for example imaging for plantar fasciitis (38.3 per 100 eligible patients) and back imaging for non-specific lower back pain (24.4 per 100 eligible patients). Conversely, surgeries and invasive procedures had lower rates of non-recommended care, such as inferior vena cava (IVC) filters (0.01 per 100 eligible patients) and renal artery stenting (0.03 per 100 eligible patients).

The HPC also analyzed rates of non-recommended care by geographic region, income, gender, payer and PCP group, the latter using the HPC’s Registry of Provider Organizations (RPO) data to attribute care to specific PCP groups (see Chapter 3: “The Massachusetts Provider Market” for more detail on the RPO). While rates of non-recommended care did not appear to vary consistently by payer or commu-

---

Exhibit 7.4: Indexed rates of non-recommended care, by provider group, 2013

<table>
<thead>
<tr>
<th>Provider Group</th>
<th>Index Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMC</td>
<td>0.5</td>
</tr>
<tr>
<td>MACIPA</td>
<td>1.0</td>
</tr>
<tr>
<td>Atrius</td>
<td>1.5</td>
</tr>
<tr>
<td>BIDCO</td>
<td>2.0</td>
</tr>
<tr>
<td>UMass Memorial</td>
<td>0.0</td>
</tr>
<tr>
<td>Baystate</td>
<td>0.5</td>
</tr>
<tr>
<td>Steward</td>
<td>1.0</td>
</tr>
<tr>
<td>Partners</td>
<td>1.5</td>
</tr>
<tr>
<td>Lahey</td>
<td>2.0</td>
</tr>
</tbody>
</table>

Notes: PCP = primary care provider. Analysis includes the same PCP groups used in Exhibit 7.1, with the exception of New England Quality Care Alliance (NEQCA). Data include only privately insured individuals covered by Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, and Tufts Health Plan. Rates of each measure of non-recommended care by provider group are shown relative to the statewide average (indexed to 1.0 for each measure). Each dot represents one measure. A smaller subset of measures is used in this analysis (compared to the regional and payer-level analyses) due to small cell sizes in some cases. If a majority of provider groups did not meet the reporting threshold of >10 instances for a given measure, the measure was excluded from the analysis. Additionally, some measures were reported for some PCP groups, but not others.

Sources: HPC analysis of Massachusetts All-Payer Claims Database, 2013 and Registry of Provider Organizations, 2016

---

x These rates were also higher than rates for similar commercial populations in a recent analysis undertaken in Oregon. However, the populations and data specifications were not perfectly comparable. See Charlesworth CJ, et al. Comparison of Low-Value Care in Medicaid vs Commercially Insured Populations. JAMA Internal Medicine. 2016; 998-1004.

xi Claims were attributed to PCP groups using the referring provider noted on the claim, the provider rendering the service if no referring physician was indicated, and the billing provider if neither were indicated. Physicians were matched to their larger provider organizations using the RPO dataset. See Technical Appendix for additional details.
Community income, HPC did observe persistent variation by PCP group and by geographic region. As seen in Exhibit 7.4, several PCP groups had consistently low rates of non-recommended care across measures. For example, BMC and MACIPA were below the state average for all of the measures, and Atrius performed below the state-wide rate for most measures. Most groups had either similarly low or similarly high rates across all measures in both 2013 and 2014.\textsuperscript{xii}

A recent analysis of rates of non-recommended care within the Medicare program similarly found that provider groups tended to be consistent across measures and over time.\textsuperscript{3} Examples of best practices shared by PCP groups with lower rates include leveraging their electronic medical record (EMR) systems to provide alerts to physicians who may be about to perform a non-recommended service (which is also recently noted in the literature as an important strategy),\textsuperscript{6} incorporating these and other measures into monthly quality report cards, using clinically-respected physician champions to disseminate best practices on measures within their expertise, and in one case, leveraging grant funding from MassHealth’s Delivery System Transformation Initiatives (DSTI) to improve adherence to the Choosing Wisely recommendations.

Finally, rates of non-recommended care also varied by HPC region (see Exhibit 7.5). Rates were similar for the two measures displayed in Exhibit 7.5 and were higher in the Upper North Shore, Central Massachusetts, Fall River, and New Bedford, while lower in the Metro Boston and Berkshires regions. Further analyses on this topic are necessary to examine whether variation in rates results from differences in provider practice patterns or patient characteristics.

\textbf{Exhibit 7.5: Rates of non-recommended care for two selected measures, by HPC region, 2013-2014}

<table>
<thead>
<tr>
<th>Measure</th>
<th>Per 100 eligible patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Back imaging for non-specific back pain</td>
<td></td>
</tr>
<tr>
<td>Imaging for diagnosis of plantar fasciitis</td>
<td></td>
</tr>
</tbody>
</table>

Notes: Data include privately insured individuals covered by Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, and Tufts Health Plan. Source: HPC analysis of Massachusetts All-Payer Claims Database, 2013 and 2014 data combined

\textsuperscript{xii} 2014 results are preliminary, but suggest that rates for provider systems were similar to those in 2013. Rates of lower-back pain imaging in 2014 were compared to HEDIS rates for the same measure calculated by Massachusetts Health Quality Partners and reported in CHIA’s 2015 Report on Provider Quality. Rates were similar across PCP groups between both analyses.

\textbf{REFERENCES}

ROLE OF ALTERNATIVE PAYMENT METHODS

Chapter 224 calls for a transition to alternative payment methods (APMs) as a key strategy to promote high-quality, efficient care and reduce health care costs. Traditional fee-for-service (FFS) payments reward providers for maximizing services rendered. In contrast, APMs, such as bundled payments or global-budget contracts, seek to reward providers for keeping patients healthy, reducing unnecessary utilization, and producing high quality treatment outcomes. At the same time, evidence from a variety of sources highlights the need for improvement in extending the reach of APMs and in designing APMs in a manner that consistently and equitably reinforces quality and efficiency. While APMs hold promise, nearly half of the provider systems testifying as part of the 2016 Annual Cost Trends Hearings reported barriers to increasing APM adoption, such as lack of infrastructure, provider reluctance, and inadequate size to take on financial risk. This chapter reviews the progress of APMs in Massachusetts and elsewhere and comments on opportunities to advance their use.

TARGETS FOR APMS IN MASSACHUSETTS

Chapter 224 requires commercial health plans to reduce the use of FFS payments to the maximum extent feasible and requires all health plans (both commercial and public) to report their use of APMs. The Massachusetts Health Connector, the Group Insurance Commission (GIC), and MassHealth are also required to implement APMs to the maximum extent possible.

In the 2015 Cost Trend Report, the HPC noted that the expansion of APM coverage had stalled in the commercial sector and called for payers and providers to continue to focus on increasing the adoption and effectiveness of APMs, identifying two specific goals:

- **APMs for HMO patients.** All commercial payers should increase the use of global APMs to pay for at least 80 percent of their health maintenance organization (HMO)-covered lives in 2017.
- **APMs for PPO patients.** Market participants should begin introducing APMs for preferred provider organization (PPO) products with the goal of reaching at least 33 percent of their PPO lives in 2017.

In addition, the HPC encouraged payers and providers to develop and adopt arrangements to include behavioral health spending in APM budgets, to agree on and institute a common methodology for risk adjustment, and to develop a coordinated quality strategy that is aligned across public agencies and market participants.

LEVELS AND TRENDS OF APMS IN MASSACHUSETTS

**APM coverage in 2015**

In Massachusetts, the overall rate of residents covered by APMs in 2015 declined to 36 percent from 38 percent in 2014 (see Exhibit 8.1). Virtually all of the commercial and Medicare Advantage members covered under APMs were covered by global budget contracts (as opposed to other types of APMs). The rate of all commercial members covered by APMs decreased to 35 percent in 2015 from 37 percent in 2014, after increasing between 2013 and 2014. Across commercial plans, APM coverage within HMOs fell to 58 percent.

---

i Section 280(c): Private health plans shall to the maximum extent feasible reduce the use of fee-for-service payment mechanisms in order to promote high-quality, efficient care delivery.
in 2015, two percentage points below the HPC’s target of 60 percent by 2016. The decrease in APM coverage within HMOs was driven largely by a decrease in the percentage of HMO members covered by APMs in Blue Cross Blue Shield of Massachusetts (BCBS) (91 percent in 2014 to 86 percent in 2015) and Tufts Health Plan (THP) (60 percent in 2014 to 47 percent in 2015). As a result, it appears unlikely the market overall will accomplish the HPC’s target of 80 percent APM coverage of commercial HMOs by 2017 without substantial effort on the part of payers and providers. The commercial PPO market’s APM coverage rate of 1 percent in 2015 reflects the many challenges associated with introducing APMs for PPO products. Payers, however, report recent progress in this area, as discussed below.

Despite its drop from 2014, BCBS has 86 percent of HMO members seeking care from a provider under an APM. As of 2015, CHIA reports that three of the six largest Massachusetts-based commercial payers – BCBS, Harvard Pilgrim Health Care (HPHC) and Health New England (HNE) – met the HPC’s target of covering 60 percent of HMO members in global-budget payment models.iii Among the six largest Massachusetts-based commercial payers, APM adoption across all members ranged from 28.7 percent (Fallon Health) to 69.8 percent (HNE) in 2015 – though these rates are strongly affected by the percentage of each payer’s business that is made up of HMO products versus PPO products.

Across public payers, APM coverage among MassHealth managed care organization (MCO) and primary care clinician (PCC) plans remained relatively stable in 2015 at 32 and 23 percent, respectively. MassHealth launched an APM program to support accountable care organizations (ACOs) starting in 2016 with six pilot ACOs and rolling out more broadly at the end of 2017, as described in the section below. APM coverage among Original Medicare and Medicare Advantage plans decreased slightly in 2015, with 38 and 58 percent of their members covered by APMs, respectively. Rates of APM coverage in Original Medicare in Massachusetts are still substantially higher than in the U.S. overall. In Original Medicare nationwide, ACO participation increased to 20 percent in 2015 from 16 percent in 2014.iv

### Exhibit 8.1: Proportion of member months under alternative payment methods (APMs) by insurance category, 2013-2015

<table>
<thead>
<tr>
<th>Category</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>All commercial</td>
<td>33%</td>
<td>35%</td>
<td>38%</td>
</tr>
<tr>
<td>Commercial HMO</td>
<td>57%</td>
<td>58%</td>
<td>58%</td>
</tr>
<tr>
<td>Commercial PPO</td>
<td>1%</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr>
<td>Original Medicare</td>
<td>14%</td>
<td>22%</td>
<td>23%</td>
</tr>
<tr>
<td>MassHealth PCC</td>
<td>40%</td>
<td>43%</td>
<td>43%</td>
</tr>
<tr>
<td>MassHealth MCO</td>
<td>40%</td>
<td>31%</td>
<td>32%</td>
</tr>
<tr>
<td>Medicare Advantage</td>
<td>63%</td>
<td>62%</td>
<td>58%</td>
</tr>
<tr>
<td>Total</td>
<td>64%</td>
<td>62%</td>
<td>58%</td>
</tr>
</tbody>
</table>

Note: *2015 results for Original Medicare include an estimate for certain populations. See Technical Appendix. Sources: Centers for Medicare & Medicaid Services, 2014-2016; Center for Health Information and Analysis, 2016

### Footnotes

iii The six largest MA-based commercial payers include Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, Tufts Health Plan, Fallon Health, Neighborhood Health Plan, and Health New England.

iv This trend reflects a decrease in participation in the Pioneer ACO program and an increase in MSSP participation in the U.S. overall. In Massachusetts, two Pioneer ACOs terminated their involvement in the Pioneer program in 2015: Steward Healthcare and Mount Auburn Cambridge Independent Practice Association dropped out of the Pioneer ACO program in 2015. Steward Healthcare joined the Next Generation ACO model in 2016.
DEVELOPMENTS IN EXPANDING APMS

Commercial payers
In the last two years, health plans have begun to expand APMS to their PPO products. One significant challenge in expanding APMS to PPO products is attributing or linking a member to a given primary care provider (PCP) since members are not required to select a PCP. Using the Massachusetts Consensus Guidelines for Commercial Non-HMO Patient Attribution Methodology developed in 2015, payers are reporting increased adoption of APMS in PPO products. BCBS reports that it has 26 percent of its PPO members in global budget contracts in 2016. Furthermore, as of October 2016, THP reports having 11 percent of its PPO business under a risk contract and HPHC reports 2 percent.

Health plans are also beginning to implement pilots with bundled payments, which cover defined episodes of care. For example, HPHC expects to pilot an orthopedic bundle with one key provider in 2017 and plans to expand the number of bundled procedures and pilot providers. THP also reported having bundled payment pilots underway with certain specialty hospitals.

MassHealth
In an effort to promote more coordinated and efficient care for members, MassHealth has worked toward introducing more APMS over the past three years (see Sidebar: “MassHealth plans to transform care delivery”). In 2014, MassHealth launched the Primary Care Payment Reform Initiative (PCPRI), a comprehensive primary care payment system that combines a shared savings/risk arrangement with quality incentives. In December 2016, MassHealth launched a new global budget ACO pilot program with six ACOs: Community Care Cooperative, Partners HealthCare ACO, Children’s Hospital Intgrated Care Organization, Steward Integrated Care Network, UMass Memorial Health Care Inc., and Boston ACO (associated with Boston Medical Center). In December 2017, MassHealth will launch the full ACO program, which is based on a global budget shared savings financial model akin to Medicare’s ACO payment model and BCBS’s Alternative Quality Contract, but with higher care delivery and integration standards in line with HPC’s ACO certification standards. Investments in the infrastructure and capabilities necessary for this restructuring effort and payments to providers under this new model will be supported by MassHealth’s extension to its 1115 waiver, which authorized $52.4 billion in spending over five years. A critical component of the new waiver is the Delivery System Reform Incentive Program (DSRIP), which allows MassHealth to invest directly in shared resources (such as analytics) as well as direct investment in provider-specific care delivery transformation. The HPC anticipates that MassHealth’s adoption of APMS will serve as a catalyst for even wider APM adoption among providers in the Commonwealth.

MassHealth plans to transform care delivery
MassHealth’s ACO program is a major component of statewide delivery system reform. Currently, MassHealth accounts for over a third of the Commonwealth’s budget and serves approximately 1.8 million members. Given its size, MassHealth’s adoption of global budget APMS is likely to accelerate the delivery system’s transition to more coordinated and efficient care.

A key feature of the program is its focus on integrating members’ physical and behavioral health (BH) care, and strengthening linkages to long-term services and supports (LTSS) and social service providers. MassHealth will build community capacity for BH and LTSS providers through its Community Partners (CP) program in order to improve outcomes and coordination of care for members with complex health and social service needs. Moreover, ACOs that establish formal partnerships with BH and LTSS CPs will be eligible to receive federal funds for health-related non-reimbursed flexible services, such as air conditioners for children with asthma, through the Delivery System Reform Incentive Program (DSRIP).

Additionally, as part of its reform efforts, MassHealth will make statewide investments to improve emergency department boarding, accommodations for persons with disabilities, and health care workforce development.

Medicare
In early 2015, the U.S. Department of Health and Human Services (HHS) set the goal of linking 30 percent of FFS Medicare payments to value through APMS by the end of 2016 and tying 50 percent of payments to these models by the end of 2018. Centers for Medicare & Medicaid Services’ (CMS) APMS include ACO and bundled payment programs and advanced primary care medical homes, among others (see Sidebar: “CMS Medicare ACO and bundled payment programs”).
Chapter 8: Alternative Payment Methods

Accountable Care Organizations (ACOs)
The CMS ACO models remain voluntary for provider organizations to participate in and provider organizations may discontinue participation at any time.

• **Pioneer ACO.** Medicare’s first ACO demonstration program launched in 2011 for a five-year term, offering downside risk opportunities to large provider organizations. In 2016, the final year of the program, there were three Pioneer ACOs in Massachusetts (Atrius Health, Beth Israel Deaconess Care Organization, and Partners HealthCare).

• **Medicare Shared Savings Program (MSSP).** Medicare’s lower-risk ACO program, which launched in 2013, initially offered provider organizations three tracks with increasing levels of upside risk and included a downside option when the program was revised in 2015. There are eleven Massachusetts-based MSSP provider organizations with another five located in neighboring states with operations in Massachusetts.

• **Next Generation ACO.** CMS introduced this program in 2015, offering provider organizations higher levels of downside risk, as well as new beneficiary engagement tools such as a financial reward for staying within the ACO network. Steward Health System and Pioneer Valley Accountable Care (Baystate Health System) joined this program in 2016. Steward and Pioneer Valley had previously participated in Pioneer ACO and MSSP, respectively.

Bundled payment initiatives

• The Bundled Payments for Care Improvement Initiative (BCPI) is a voluntary program that began in 2013. Participating providers choose to receive a bundled payment for one or more episodes of care, ranging from diabetes to joint replacement, and also choose the extent of the bundle (inpatient only, inpatient plus post-acute care [PAC], PAC only, inpatient plus professional). Massachusetts providers participating in BCPI include Hebrew Senior Life, Steward Health System, and UMass Memorial Health Care. Early results of the BPCI program’s impact on cost and quality are mixed, but orthopedic bundle results were more positive.

• The Comprehensive Care for Joint Replacement payment model requires hospitals in 67 geographic regions to accept bundled payments for inpatient hip and knee replacements for five years starting January, 2016. However, none of the mandatory service areas for this bundle are in Massachusetts.

• CMS introduced a mandatory bundle for cardiac episodes, specifically bypass surgeries and heart attacks. The five-year demonstration will go into effect in July, 2017, with 98 geographic regions, including one in Massachusetts.

Under the Medicare Access & CHIP Reauthorization Act (MACRA) of 2015 and CMS’s implementing regulations, Medicare physician payments will now be linked more closely to quality performance. Replacing the patchwork system of Medicare quality reporting programs (i.e., PQRS, Meaningful Use, and Value-Based Modifier), the regulations provide two paths for payment. The first is the Merit-Based Incentive Payment System (MIPS), through which providers earn a performance-based payment adjustment of their FFS revenue based on their performance on a number of self-selected quality measures in 4 categories: quality, improvement activities, advancing care information, and cost/resource use. The second is the Advanced Alternative Payment Models (Advanced APMs) path, through which providers that participate in the Next Generation ACO, Shared Savings programs, or CPC+ are eligible for the quality bonus, further incentivizing health systems to enter into ACO programs. MACRA goes into effect in 2019 and will be based on performance in the 2017 calendar year.

**PRIORITY AREAS FOR FURTHER DEVELOPMENT: REFINING APMS**

While payers and providers have made considerable progress in implementing APMs across the Commonwealth, this progress has resulted in a variety of contractual arrangements using disparate approaches to ACO definition, risk adjustment, attribution, and measuring and rewarding the quality of care, as well as expectations for care delivery. Opportunities exist to improve each of these components to realize the quality improvement and cost containment goals of APMs.

**Care delivery standards for ACOs**
As payers enter into APMs with providers, they need to make decisions about the financial and clinical readiness of provider systems to be accountable for patient outcomes and costs across the care continuum. Chapter 224 requires the HPC to set care delivery standards for ACOs and in 2017, the HPC will launch the ACO certification program. The certification program puts forth a set of standards for how ACOs organize and govern themselves, provide inte-
grated care for their populations across the continuum, and perform under quality-based risk contracts. The program is designed to promote transparency about ACOs to promote learning of best practices. MassHealth requires ACOs participating in its global budget model to be certified by the HPC. Other payers looking to enter into or expand APM arrangements with provider organizations may also use the HPC certification program as a validated approach to assess organizational capabilities that will help lead to success under risk contracts.

Quality measurement evolution
Written testimony from both payers and providers demonstrates a consensus that alignment and improvement in quality measurement is critical. Massachusetts providers reported that they are tracking over 300 quality measures, some of which vary across risk contracts. Many of these measures focus on processes of care, such as cancer screenings or chronic disease management tests, and not health outcomes or metrics that may be more meaningful to patients such as functional status after a surgery. Payers use different measure specifications, reporting methods and timelines, and benchmarking approaches to these measures. Several provider organizations reported that the lack of alignment in quality measurement contributes to physician burnout alongside other administrative issues such as new coding requirements and electronic medical record implementations. The variety of quality measures used in each APM may undermine the collective ability to improve patient care and outcomes.

A majority of quality measures in APMs today focus on processes of care because these measures are more easily calculated from administrative data such as claims, while outcome measures require clinical data or patient reported data that must be reported by providers to payers in order to calculate performance. There is a growing interest in using outcome measures to evaluate population health and health system performance, yet these measures often require clinical chart reviews and are burdensome to collect and measure. Presently, provider systems have to report clinical data for the outcomes measures in their risk contracts individually to each payer. The reporting mechanisms vary widely in sophistication from secure file transfer to easier-to-use websites to linkages with electronic medical record systems. At the 2016 Annual Cost Trends Hearing and in testimony, providers and payers called for a centralized method for reporting clinical outcome measures that would offer both providers and payers timely access to this data. Providing more timely and actionable data, particularly on an aligned set of patient outcomes, for which data are derived from, clinical data sources, would greatly improve provider systems’ ability to drive quality improvement.

Improving risk adjustment
The majority of payers have achieved alignment around risk adjustment methodologies, as most are using industry-standard approaches that adjust risk based on patient claims using algorithms such as the DxCG predictive modeling software. Current risk adjustment methods, however, do not typically account for sociodemographic risk factors and other social determinants of health. Furthermore, methods are presently based on patients’ age, sex, and clinical history, and may not work as well for certain subpopulations, such as children. Accounting for all potential risk factors is important as research has found that socio demographic factors can have a substantial impact on health, spending and health outcomes; not accounting for these can penalize a provider organization that takes on financial risk for disadvantaged populations. MassHealth has proposed a new risk adjustment methodology for their ACO payment model that will account for members’ social risk factors.

Integration of behavioral health and long-term services and supports in APMs
Another area for improvement of APMs is the integration of behavioral health (BH). With the exception of BCBS and THP, many commercial payers exclude BH from risk contracts and subcontract with managed BH organizations to process BH claims. This exclusion results in structures and incentives that may weaken efforts to foster provider accountability for total cost of care and to properly integrate BH and medical care. At the same time, many providers may find it difficult to assume financial accountability for BH care, given the gaps in the delivery system and the shortcomings of the available data. Efforts to develop APMs that include BH are integral to delivery system integration efforts for patients with BH needs.

Relatedly, promoting linkages between medical teams, BH providers, long-term services and supports (LTSS) providers and social services is fundamental to successfully improve population health. MassHealth seeks to drive progress in this area through the Community Partners (CP) program, which will certify BH and LTSS providers and require MassHealth ACOs to partner with CPs, as described above. One of the main barriers to integrating care across these entities is the lack of infrastructure to coordinate care and facilitate

---

vi Federal privacy regulation imposes some limits on the use and distribution of behavioral health data to providers, most notably data on substance use disorder diagnosis and treatment.
data sharing between organizations/providers. MassHealth’s DS RIP program will make targeted investments to better develop this infrastructure to share data.

**Improving financial methodologies to address price variation**

Finally, financial benchmarking methodologies generally employ historic spending rates to set the budget and targets for risk contracts, perpetuating unwarranted variation in payment rates (see sidebar in Chapter 3: “The Massachusetts Provider Market: Status and Trends”) and, under most global budget arrangements, most payers reimburse providers on a FFS basis with a settlement after the performance year ends.17 Provider groups that enjoy larger budgets can invest in building capabilities required to be successful in global contracts. Revisiting how global budgets are determined is critical to expand APMs and enable provider organizations to succeed in these contracts, while ensuring sufficient incentives to encourage efficient care delivery.

**REFERENCES**

In the 2015 Cost Trends Report, the Health Policy Commission (HPC) examined developments toward a value-based health care market with improved market competition, innovative insurance products, and supportive tools. The Board’s recommendations included encouraging employers to offer plan choice and reward employees for choosing high-value plans, encouraging payers to expand use of tiered and limited products as well as expand the utility of price and quality websites, and encouraging all purchasers of care to consider tools such as cash-back incentives and reference pricing to foster high-value provider choices. This chapter updates progress in Massachusetts in the use of these tools, products, and market changes.

**USE OF DEMAND-SIDE TOOLS AND PRODUCTS IN 2016**

Chapter 224 of the Acts of 2012 required Massachusetts health insurers to develop websites with accessible price information about proposed treatments and services by October, 2014. While all of the major payers had established such sites, with the exception of Aetna, the health plan websites had not been extensively used by enrollees by early 2015. In 2016, however, Harvard Pilgrim Health Care (HPHC) reported a notable increase in use (from 19,500 views in the first two quarters of 2015 to 24,200 in the first two quarters of 2016) and Blue Cross and Blue Shield of Massachusetts (BCBS) reported an increase from 645 views in the first two quarters of 2015 to almost 15,000 in the first two quarters of 2016.1 Of note, BCBS launched an online cost estimation tool at the end of 2015, which likely accounts for the substantial increase in inquiries.

The use of cash-back incentives, whereby members receive direct cash rebates when they use high-value providers, has been limited. Notably, UniCare adopted this strategy for its members covered under the Group Insurance Commission (GIC) in 2016. The program’s vendor has claimed reductions in total health care spending (and market shifts toward lower cost providers in some cases) when implemented for state employees in New Hampshire, although a rigorous evaluation of the program’s impact has not been performed.2

Uptake of tiered network products (which assign higher cost-sharing to higher-cost providers) in Massachusetts remained steady at 15.9 percent in 2015 (versus 16.0 percent in 2014), while the proportion of the state’s commercial members in limited network products (which exclude coverage to non-network providers) inched upward from 3.0 percent in 2014 to 3.2 percent in 2015. Nationally, limited network products have been a popular choice in the Affordable Care Act (ACA) exchanges, which place intense pressure on plans to offer low premiums due to the lower incomes of enrollees and fixed-dollar tax credits.1,2 The share of Massachusetts Health Connector enrollees in limited network plans was 4 percent in 2015, which is below national figures.1

**MARKET STRUCTURE: THE SMALL AND MID-SIZED GROUP MARKET**

In 2015, the HPC also recommended improvements to the structure of the employer-based health insurance market to impact the competitiveness of the health care system. In particular, improvements can be made in markets serving small employers.3 This section describes health insurance costs and offerings by market segment, focusing on the small employer (fewer than 50 employees) market, which accounts for 11 percent of all commercial health insurance enrollees in Massachusetts, and 28 percent of the fully-insured market. Almost all small firms are fully-insured, meaning they purchase health insurance for a fixed premium and the

---

1 Limited network products made up 7 percent of the Massachusetts individual market in 2013 but just 4 percent in 2015 (compared to 3 percent outside of the individual market). The drop is largely attributable to the inclusion of a large number of members from former Commonwealth Care plans (such as the Tufts Public Health Plan) in 2015 in the individual market totals. The Tufts plan, like many others available through the Massachusetts Health Connector, is a low-premium plan and excludes most providers in the Partners HealthCare System, but is not considered a limited network plan.
insurer bears the risk of health costs exceeding premiums paid. A majority of larger groups self-insure, meaning they bear this risk themselves while using insurers as third party administrators to manage benefits, establish networks and pay providers. Some analyses in this section also include somewhat larger firms (for example employers with between 50 and 100 employees), which can face similar challenges as smaller groups but are often treated differently in state and federal regulations.iii

**Health insurance costs by firm size in Massachusetts**

To better understand how the market serves employees of small firms, the HPC first analyzed how much small-firm employees pay for health insurance compared to other segments of the fully-insured commercial market.ii Health insurance premium dollars pay for both medical benefits and administrative expenses (e.g., claims processing, marketing, profits, fees paid to brokers). Premiums differ because of differences in administrative expenses, underlying health needs of the insured population, prices paid to providers for services, level of coverage (e.g., the amount of deductibles and copays), and plan design (e.g., how members are encouraged to use cost-effective care).

Employees of small firms paid, on average, similar amounts for health insurance coverage in 2013 as the market-wide average in that year ($430 per member per month (PMPM)) (see Exhibit 9.1). Small-firm premiums remained near the market-wide average in 2015, several percent below premiums for employees of larger firms. In the fully insured market, average premiums for GIC members and those in the individual market are significantly lower than those for small-firm employees.iv A substantially higher percentage of small-firm employees (47 percent) are enrolled in high-deductible plans compared to the market-wide average (21 percent), which could depress premiums even accounting for the plan generosity adjustments made in Exhibit 9.1.iv Nevertheless, it does not appear that smaller firm employees pay significantly more for coverage than employees of larger firms.

---

**Exhibit 9.1: Adjusted premiums by market segment, fully-insured market, 2013-2015**

<table>
<thead>
<tr>
<th>Firm size</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Large</td>
<td>-30%</td>
<td>-25%</td>
<td>-20%</td>
</tr>
<tr>
<td>Jumbo</td>
<td>-20%</td>
<td>-15%</td>
<td>-10%</td>
</tr>
<tr>
<td>GIC</td>
<td>-15%</td>
<td>-10%</td>
<td>-5%</td>
</tr>
<tr>
<td>Mid-size</td>
<td>-10%</td>
<td>-5%</td>
<td>0%</td>
</tr>
<tr>
<td>Small</td>
<td>-5%</td>
<td>0%</td>
<td>5%</td>
</tr>
<tr>
<td>Individual</td>
<td>5%</td>
<td>10%</td>
<td>15%</td>
</tr>
</tbody>
</table>

**Notes:** Premiums shown are relative to scaled small group premiums in 2013 ($425 per member per month). Premium amounts have been adjusted to account for age, gender, and actuarial value (generosity) and do not necessarily represent actual amounts paid.

**Sources:** Center for Health Information and Analysis and Oliver Wyman Consulting, 2016

---

ii For example, groups with fewer than 50 employees are exempt from penalties for not offering coverage under the ACA and are part of the ‘merged market,’ in which their employees are part of the same large insurance pool as individual purchasers. Premiums for individuals and employees in this market cannot be adjusted for health status and can only vary by the allowable federal factors (geography, family structure, actuarial value, tobacco use, age) and additional state factors (industry, participation rate in health insurance within the firm, wellness program participation, a group size factor, and use of an intermediary for purchase). Groups with more than 50 employees may be ‘experience rated,’ in which insurers can adjust premiums based on health or claims history of the group. While experience rating is less consequential in very large groups, where healthy and sick employees tend to balance out, they can cause large swings in premiums in smaller groups due to very high-cost individuals. Employees in companies with fewer than 50 employees may also seek coverage through the Massachusetts Health Connector. Starting in 2017, under the ACA, groups between 50 and 100 employees are generally eligible for Exchange coverage, a state option that Massachusetts has opted not to pursue at this time.

iii For employer-sponsored insurance, employers usually pay the majority of the premium to the insurer while the employee pays the remainder. In most of the discussion in this chapter, we consider the combined employee plus employer spending as the premium, the full cost of health insurance. Note that the premium data upon which this exhibit is based is retrospective and based on actual amounts paid – and are therefore not directly comparable to the premium increases announced by carriers in the merged market for future quarters as reported by the Massachusetts Division of Insurance. See “Future Outlook” earlier in this report.

iv Most GIC coverage is fully-insured and therefore not included in Exhibit 9.1.
However, administrative costs are higher in smaller firms than in larger firms. Approximately 7.8 percent of premium spending by smaller firms and their employees in Massachusetts in 2014 went toward administrative costs, compared to 5.8 percent for larger firms (see Exhibit 9.2). With regard to broker commissions and fees (which are a subset of administrative expenses), the Kaiser Family Foundation found that small firms in Massachusetts paid on average $13.91 PMPM for brokers compared to $10.39 PMPM among large firms in 2013 and that the gap between small and larger firms has grown since 2010 in the Commonwealth.\(^v\)

Small firms also experience large swings in premiums from year to year, which can make it difficult for firms to maintain their balance sheet, make wage adjustments, and even continue to offer coverage. In 2014, 10.5 percent of small firms reported a jump in single-coverage premiums of more than 15 percent from the previous year compared to 5.9 percent of firms with more than 50 employees.\(^v\) Also, small firms tend to require larger premium contributions for employees to cover dependents than larger firms (both in Massachusetts and in the U.S. overall), possibly because with less ability to absorb dependent health care costs, they seek to encourage employees to seek dependent coverage elsewhere (for example, through a spouse's employer). In 2014, 72 percent of small firms in Massachusetts required employees to contribute more than a quarter of the full premium for family coverage while just half of large firms required a contribution that large.\(^v\)

The ability to offer plan choices to employees is important for fostering a competitive market and for employee satisfaction. For example, when employers or insurance markets couple plan choice with fixed contributions, employees have strong incentives to select lower cost plans.\(^viii\)\(^vii\) Having a choice of plan allows employees to make different tradeoffs according to what is most valuable to them (e.g. broad or limited choice of providers, lower premiums or lower deductibles). The HPC found in a 2015 survey of 188 small to mid-size firms that benefits managers of firms that offer only a single broad network plan reported that some of their employees would have selected a limited or tiered network product if they were offered one at a 15 percent premium discount.\(^ix\)

### Exhibit 9.2: Broker fees, per member per month, by group size

*Average broker fee per member, 2010-2013*

<table>
<thead>
<tr>
<th>Year</th>
<th>Small group</th>
<th>Individual</th>
<th>Large group</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>$12.65</td>
<td>$11.95</td>
<td>$10.39</td>
</tr>
<tr>
<td>2011</td>
<td>$13.91</td>
<td>$13.29</td>
<td>$11.83</td>
</tr>
<tr>
<td>2012</td>
<td>$15.27</td>
<td>$14.65</td>
<td>$12.19</td>
</tr>
<tr>
<td>2013</td>
<td>$16.63</td>
<td>$16.01</td>
<td>$13.91</td>
</tr>
</tbody>
</table>

### Broker fees and administrative expenses as a percentage of premiums, 2014

<table>
<thead>
<tr>
<th>Category</th>
<th>Small group</th>
<th>Large group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agent &amp; broker fees and commissions</td>
<td>2.9%</td>
<td>2.2%</td>
</tr>
<tr>
<td>Other general and administrative expenses</td>
<td>4.9%</td>
<td>3.6%</td>
</tr>
</tbody>
</table>

Sources: Kaiser Family Foundation: State Health Facts; U.S. Centers for Medicare and Medicaid Services: Office for Consumer Information and Insurance Oversight, Medical Loss Ratio reports.

---

\(^v\) However, the gap in commissions and fees was wider between smaller and larger firms in the rest of the U.S. In the rest of the U.S., small firm commissions were $19.10 PMPM in 2013, on average, and those for large firms were $8.10.

\(^vi\) Figures were similar for family coverage. At the same time, a higher proportion of smaller firms also experienced large premium decreases.

\(^vii\) For single coverage, the order is reversed; more than half of smaller firms require less than 25 percent premium contribution for single coverage, and more than half of large firms require premium contributions greater than 25 percent of the premium.

\(^viii\) For example, Fallon promotes this strategy among its employers, coupling broad network product offerings with narrow network products at a 20 percent premium discount and encouraging employers to use defined contribution strategies so employees retain the full savings. See pre-filed testimony, 2016.

\(^ix\) Firms were asked to estimate the percentage of employees that would choose either a broad network plan, a narrow network plan (at a 15 percent lower premium) or a high deductible plan (at a 15 percent lower premium). The subset of respondents that only offered a single broad network plan reported that, on average, 8 percent of their employees would have selected a tiered or narrow network plan at this level of discount.
Among employees of small firms (fewer than 50 employees) that offer health insurance, only 31 percent were offered more than one plan to choose from, while almost half of employees who were only offered one plan were offered a high deductible plan. In contrast, a majority (60 percent) of employees of mid-sized firms (50-100 employees) were offered a choice of plans, and nearly three quarters of employees of larger firms were offered at least two plans (see Exhibit 9.3).

Exhibit 9.3: Plan offerings by firm size in Massachusetts, 2014

Furthermore, few firms of any size that offered multiple plans used fixed-contribution methods (where the employer pays the same amount regardless of the plan selected by the employee). As a result, most employers contributed more of the premium when employees chose more expensive plans, reducing the incentive for employees to choose a high-value plan.

Small firms face challenges in offering multiple plan options to employees. In the HPC survey of 188 predominately small and mid-sized employers, HPC staff asked benefits managers why they did not offer plan choices to their employees. Of those that offered only one plan, nearly a quarter of respondents said that offering multiple plans would be too administratively complicated, while 57 percent said that they had too few employees to offer multiple plans. Among those that did offer plan choices, when asked why they did not use fixed dollar contributions, 58 percent stated there was no particular reason. When asked why they did not offer tiered or limited network plans, 30 percent noted that they offered only one plan and felt it should be broad, 22 percent were unaware of tiered and limited options, and 18 percent felt that they were too complicated. In a follow-up focus group with 10 of the small firm benefits managers, many expressed frustration with the complexity of offering and managing health benefits and helping employees understand their benefits.

EXCHANGES

Health insurance exchanges are designed to overcome many of the challenges of the small group market. Massachusetts has two examples of robust public exchanges: the GIC, which uses an exchange for more than 400,000 state and local employees and retirees, and the Massachusetts Health Connector. Representing most of the individual market, the Health Connector is a particularly effective public exchange, with a notably low premium trend as shown in Exhibit 9.1. Established in 2006 by Chapter 58 of the Acts of 2006, the Health Connector has been in operation for longer than other state exchanges created under the ACA, and uses a number of strategies to foster high-quality, low-cost plans, most notably in its ConnectorCare program for lower-income individuals and families earning up to 300 percent of the Federal Poverty Level. In addition to offering a wide array of comparable choices to potential ConnectorCare enrollees, the Health Connector offers seven carriers through its ConnectorCare program (no more than five in any given region) to compete in each region for its significant volume of more than 180,000 enrollees. Until 2017, Massachusetts had made additional contributions to minimize premium differences for enrollees of the most expensive plans, but the Health Connector changed its subsidy structure for 2017 plans so that the highest level of subsidization is only available for the most competitively-priced plans.\(^x\)

\(^x\) This change appears to have led to significant movement away from Neighborhood Health Plan, which, as one of the more expensive plans offered, had benefited from this additional subsidy. It was also the only Health Connector plan that offered coverage of all providers in the Partners HealthCare System. See Board of Director’s Meeting Dec 8, 2016, “Open Enrollment 2017 Status,” Massachusetts Health Connector.
In part because of the health plan competition, premiums on the Health Connector are relatively low by national standards. Monthly non-group premiums for a 40-year old non-smoking male (a single plan) for the Silver metallic tier (approximately 70 percent actuarial value) were $250 per month in 2016, below a national median of $278 (see Exhibit 9.4). Comparatively, single premiums for small firm employees in Massachusetts were significantly above the U.S. median ($485) at $520 per month in 2015.

In Massachusetts, as in other states, the Connector also offers small firms the ability to enroll their employees in dozens of ACA-compliant plans either with or without assistance from brokers. Few small firms have taken advantage of the opportunity at the Connector to date. Roughly 6,000 workers and dependents were enrolled as of 2016. There may be several reasons for this limited enrollment. First, some small employers find it convenient to use a single vendor for health insurance and other benefits such as long-term and disability insurance and retirement benefits, though these are not available with the Massachusetts Health Connector. There may also be a lack of awareness of the Connector’s offerings. For example, the Health Connector offers a 15 percent premium discount for firms that enroll employees in the Health Connector’s wellness program, but in the HPC survey of employers noted above, only 28 percent were aware of this benefit. More broadly, only 30 percent of eligible employers considered using the Health Connector to offer insurance. Among those who considered the Connector but opted not to use it, 25 percent did not believe they were eligible, 26 percent cited administrative difficulty, and 16 percent pointed to website malfunctions and technical problems.

Some of these issues may be resolved by a forthcoming redesign of the Health Connector’s small group website. Other recent developments at the state and federal level may also expand the Health Connector’s employer market and allow more Massachusetts employees to purchase insurance through the exchange. The Health Connector is currently considering strategies to implement the “employee choice” model allowed under the ACA as part of a refreshed group market platform. In contrast to the standard model wherein a small employer selects one plan or one carrier for all employees, the employee choice approach allows employees to select from a wide variety of plans for which the employer makes a benchmark contribution. This approach: (a) allows employees of small businesses to pick the best plan to meet their individual needs; (b) allows the employer to predict their own costs year-over-year with greater predictability; and (c) enhances competitive dynamics between carriers in the small group market by promoting the same shop-
ping behavior exhibited by individual Exchange shoppers. Essentially, this option allows smaller firms to mimic the pro-competitive features of the individual and larger group markets.

In addition, the recently-passed federal 21st Century Cures Act could also attract more small businesses to the Connector in 2017. The Cures Act will give employees of small businesses access to the full functionality of the Health Connector, while allowing employers to continue to make a pre-tax contribution to their employees’ non-group premiums (not currently allowed) without facing penalties for not offering coverage.6

For larger firms (ineligible to use the Health Connector), private exchanges offer many of the same benefits as public exchanges, while charging a fee for the services they provide. Private exchanges are growing in popularity nationally. While only 2 percent of employees in firms of more than fifty employees received coverage through a private exchange in 2016, 18 percent of employers reported that they were considering offering benefits through a private exchange.7 These exchanges often offer additional benefits beyond what may be available on public exchanges such as health and wellness benefits and other forms of insurance coverage.8 Data on private exchanges in Massachusetts will be available in 2017 with the release of CHIA’s Massachusetts Employer Survey.

REFERENCES

In light of the findings presented in this Report, as well as our other analytic and policy work throughout the year, the HPC has developed recommendations for market participants, policy makers, and government agencies. These recommendations reflect both prior and new areas of focus. The HPC has also updated its set of measures to track health system performance (see Exhibit 10.1 on page 78).

**RECOMMENDATIONS**

In order to constrain health care spending growth and create an affordable, accessible, and high quality system of care for all residents of the Commonwealth, we recommend that the Commonwealth take action across the following four primary areas:

1. **Fostering a value-based market** in which payers and providers openly compete, and in which providers are supported and equitably rewarded for providing high-quality and affordable services;

2. **Promoting an efficient, high-quality, health care delivery system** that improves health by delivering coordinated, patient-centered health care that accounts for patients’ behavioral, social and medical needs;

3. **Advancing aligned and effective financial incentives** for providers to deliver high-quality, cost effective care and for consumers and employers to make high-value choices for their care and coverage; and

4. **Enhancing transparency through publicly available data and information** on health care system performance in order for providers, payers, patients, employers, and policymakers, including state agencies and the Legislature, to successfully implement reforms and evaluate performance over time.

**FOSTERING A VALUE-BASED MARKET**

A transparent and competitive health care market that supports and equitably rewards high-value providers, and which enables consumers and employers to afford high quality care, is essential to creating a financially sustainable health care system. To advance the goal of a more value-based market in 2017, the HPC recommends:

1. **The Commonwealth should examine how health care costs differentially impact individuals, families, and businesses in Massachusetts, and should further consider opportunities to promote equity, affordability, and sustainability.** The state should continue to track and analyze differences in health care spending, health insurance costs, and member cost-sharing across a range of dimensions, including by certain socio-demographic characteristics (e.g., household income), employer characteristics (e.g., employer size, employee wages), and health status characteristics (e.g., behavioral health co-morbidity) in order to identify inappropriate disparities. Policies should be developed to address those disproportionately burdened by the high cost of health care in Massachusetts. For example, the cost of any given insurance product represents a larger share of total income for lower earning employees compared to higher earning employees. Employers should explore options to promote affordability for their lower-earning employees, including through salary-based employee premium contributions.

2. **The Commonwealth should take action to reduce increases in drug spending including enhancing the transparency of drug prices and spending, and payers and providers should consider further opportunities to maximize value.** Given the current national regulatory framework, many aspects of drug spending are outside the direct control of the state, payers, and providers in Massachusetts; significant reforms may require Federal action. However, some levers for action are available at...
the state level. Specifically, to address spending growth associated with pharmaceuticals:

a **Require increased transparency:** Building on action in other states and prior efforts in Massachusetts, the Legislature should require increased transparency in drug pricing and manufacturer rebates and use this information to enhance accountability for manufacturers in cases where drug pricing is deemed excessive and unjustified. Increased transparency should apply to manufacturers and pharmacy benefit managers.

b **Expand witness list for Cost Trends Hearing:** The Legislature should add pharmaceutical and medical device manufacturers to the list of mandatory market participant witnesses at the HPC’s annual Cost Trends Hearing.

c **Advocate for negotiating drug prices and federal regulatory review:** State and federal lawmakers should advocate for legislation to allow Medicare to negotiate prescription drug prices, and for Federal review of regulations to encourage competition and value-based contracting.

d **Use value-based benchmarks:** Payers should pursue the use of value-based benchmarks when negotiating prices, and consider opportunities for the use of risk-based contracting with manufacturers and other value-based strategies.

e **Treatment protocols and guidelines:** Payers and providers should work together to develop and use treatment protocols and guidelines that make appropriate use of lower-cost drugs when available and to achieve consensus on appropriate use when new high cost drugs enter the market.

f **Provide education and monitor prescribing patterns:** Providers should disseminate information to prescribers on drug and treatment alternatives, invest in system technology to alert prescribers to alternatives and support adoption of treatment protocols, and support other educational activities. Providers should also monitor prescribing patterns, particularly for identification of outlier behavior, to help ensure that prescribing is consistent with value-based and evidence-based guidelines.

3 The Commonwealth should enhance out-of-network protections to implement safeguards for consumers, enhance the viability of limited and tiered network products, and address unwarranted provider price variation. Consumers and insurers may face high charges from out-of-network hospitals and physicians in certain circumstances where consumers do not have the ability or information to select an in-network provider, including in emergency situations and when services are received at in-network facilities but provided by out-of-network providers without the consumer’s informed agreement. These high out-of-network charges can create financial burdens for consumers and, when such costs are borne by insurers, they impair tiered and limited network products and increase overall spending. Drawing on models from other states (such as Connecticut, California and New York), the Legislature should require providers to inform consumers whether they are in- or out-of-network before services are delivered. The Legislature should also require that insurers hold their members harmless in cases of out-of-network emergency services and enhance consumer awareness of existing “surprise billing” protections. Finally, the Legislature should establish a maximum reasonable price for such services to enhance the viability of limited and tiered network products, facilitate value-driven payer and provider rate negotiations, and ensure that out-of-network protections for consumers do not increase overall spending.

4 The Commonwealth should take action to reduce unwarranted variation in provider prices. Extensive variation in prices paid to health care providers for the same sets of services is a persistent issue in the Commonwealth, driving increased health care spending and perpetuating inequities in the distribution of health care resources. However, unwarranted variation in provider prices is not likely to decrease absent direct policy action. The HPC will continue to monitor the extent of provider price variation in the commercial market and looks forward to working with the Special Commission on Provider Price Variation, policymakers and other stakeholders to advance specific, data-driven policies to address this pressing issue in the coming year.
The Commonwealth should take action to equalize payments for the same services for similar patients between hospital outpatient departments and physician offices. In some cases, the same service can be provided both at hospital outpatient sites and at physician offices, but hospital outpatient department rates and cost-sharing can be substantially higher than those of physician offices for the same service due to the addition of hospital “facility fees.” This ability to receive higher reimbursement at hospital outpatient sites encourages hospitals to acquire and license physician practices as hospital outpatient sites and to provide services in hospital outpatient departments unnecessarily. Policymakers and payers should act to limit both newly licensed and existing sites that can bill as hospital outpatient departments and implement site neutral payments for select services for similar patients, both to reduce inappropriate health care spending and to reduce confusion for patients who can face increased cost sharing at hospital outpatient sites.

The Commonwealth, payers, and providers should work to redirect community-appropriate care to high value, community settings. Specifically:

- Identify appropriate patients: Provider organizations should develop systems to identify patients who could safely receive care in community hospitals, and develop or enhance case management and patient education programs to direct community appropriate care to high-value community providers. This could include the development of referral and transfer protocols so that patients are served more often at community hospitals when clinically appropriate, instead of academic medical centers (AMCs) or teaching hospitals.

- Develop information resources: Payers and providers should work together to improve information resources necessary to better track and manage patients across settings of care, including across provider organizations, especially to support referrals of community-appropriate care to community hospitals.

- Incentivize high-value choices: Payers should encourage the use of community hospitals for community-appropriate care, through consumer-focused incentives, such as specific tiering for low-acuity procedures, as well as provider-focused incentives, such as rewarding providers for appropriate referral for community-appropriate care.

PROMOTING AN EFFICIENT, HIGH-QUALITY, HEALTH CARE DELIVERY SYSTEM

Over its history and in the current report, the HPC’s research has highlighted Massachusetts’ high levels of spending and above average use of institutional care relative to the nation. Within the state, the HPC has also identified variation in provider practice patterns as well as health care spending in different communities.

To advance the goal of a community-based, accountable, and integrated care delivery system, the HPC recommends:

- The Commonwealth should continue to focus on strengthening partnerships between the health care delivery system and community-based organizations in order to reduce the unnecessary hospital use and other institutional care. As part of this focus, the HPC sets the following targets:
  - Reduce all-cause 30-day hospital readmissions: The Commonwealth should achieve a 20 percent reduction in all-cause, all-payer 30-day hospital readmissions relative to the 2013 level, attaining an all-payer readmission rate below 13 percent by 2019.
  - Increase the integration of behavioral health in primary care: The Commonwealth should aim to increase the number of patients cared for in an integrated setting. To ensure better access to integrated primary care, 25 more practices should achieve HPC PCMH PRIME certification in 2017, bringing the total number of certified practices to 53.
  - Reduce the rate of discharge to institutional care following hospitalization: The Commonwealth should achieve a 5 percentage point reduction in the rate of discharge to institutional post-acute care to meet the national average (22% in MA, 17% national) by 2020.
  - Reduce the rate of behavioral health (BH) related ED utilization: The Commonwealth should reverse the upward trend of BH-related ED visits, consistent with success realized in reducing all other types of ED utilization.
8 The Commonwealth, payers, and providers should continue to improve tracking and treatment of substance use disorder (SUD). Because of the growing burden of opioid use disorder in the Commonwealth (opioid related ED visits increased by 87 percent between 2011 and 2015), the state should continue to track the impact of SUD on the health care system and also test, evaluate, and scale innovative care models for treatment. Investments in care delivery models that enable rapid engagement in care (e.g., in emergency settings) and integration efforts that increase availability of pharmacological treatment of opioid use disorder in primary care will help the Commonwealth achieve the goal of making timely SUD treatment available and improve patient care.

9 The Commonwealth, payers, and providers should work to focus on the highest possible adherence to evidence-based care, including reducing provision of non-recommended care. Provider groups should track and put systems in place to reduce provision of non-recommended care such as alerts embedded into electronic health records. The HPC will continue to expand evaluation of provider system-level trends and practice pattern variation, including referrals to institutional care and rates of non-recommended and recommended care.

ADVANCING ALIGNED AND EFFECTIVE FINANCIAL INCENTIVES

Alternative payment methods
Effective APMs offer incentives that support value-based, accountable, patient-centered care. To advance the goal of more value-based care and expanded adoption of effective APMs in 2017, the HPC recommends:

10 Payers and providers should continue to focus on increasing the adoption of alternative payment methods (APMs). Market participants should set the following targets:

a APMs for HMO patients. All commercial payers should increase the use of APMs with the goal of having 80 percent of the state HMO population in APMs by 2017.

b APMs for PPO patients. Commercial payers should also seek to increase the use of APMs for members enrolled in PPO plans, with the initial goal of having one third of the state PPO population in APMs by 2017.

c APMs for MassHealth members. Consistent with the target set in the state’s Medicaid 1115 waiver, at least 30 percent of eligible MassHealth members should be enrolled in an APM model by the end of 2018. A majority of provider systems in the Commonwealth should apply for participation in MassHealth’s accountable care organization (ACO) program in 2017.

d Bundled payments. As a complement to global payment and a core strategy to reduce post-acute care utilization, payers and providers should continue to implement bundled payments for common and costly episodes of care such joint replacement, cardiac care, cancer treatment, and maternity stays.

11 Payers should align and improve features of APMs in order to increase their effectiveness in promoting high quality, efficient care.

a Quality measurement. The Commonwealth should convene stakeholders to develop consensus recommendations on alignment and improvement of quality measures for use in global-budget APMs. The recommendations should lead to an agenda for moving toward patient-reported outcome measures and an aligned set of measures to reduce provider burden.

b Disparities in spending levels. As part of a strategy to reduce spending, payers should develop plans to lessen the unwarranted disparity in global budgets paid to different providers by establishing stricter targets for spending growth for highly paid providers or by moving away from historical spending as the basis of global budgets.

c Inclusion of behavioral health. Payers should include behavioral health services in their global budget models or work with carve-outs to better align incentives toward accountability for overall patient care.

d Certification standards. As the HPC launches the ACO certification program in early 2017, payers and purchasers (including the Group Insurance Commission) should require provider organizations in risk-based contracts to meet HPC certification standards to ensure a consistent set of care delivery capabilities for ACOs across the Commonwealth. Statewide standards for ACOs as well as regular transparent monitoring of performance will focus providers’ transformation efforts for all patients and improve the likelihood of success of these care models.
**Demand-side incentives**

Effective demand-side incentives that provide consumers and purchasers with relevant information and meaningful options and that reward them for making high-value coverage and care choices are critical to creating a more affordable health care system. To advance these goals, the HPC recommends:

12 Payers and employers should continue to enhance strategies that empower consumers to make high-value choices, including increasing the transparency of comparative prices and quality. Specifically:

- **Employers should incentivize employees to choose high-value plans:** Employers should further encourage selection of high-value plans by contributing the same premium amount regardless of the plan chosen or by offering greater premium sharing for higher value plans. Additionally, employers should consider purchasing health insurance through the Massachusetts Health Connector, which provides employees the opportunity to shop among a range of product options at very competitive market rates. The Health Connector should continue efforts to increase ease of use for employers and implement “employee choice”.

- **Encourage value-based provider choices:** Employers should also explore options to encourage employees to make value-based provider choices, including using provider cost and quality information, rewarding employees directly for choosing high-value providers, or by contracting directly with particular high-value providers.

- **Improve design of tiered and limited plans:** Payers should continue to improve value-oriented products such as tiered and limited plan designs that create incentives, such as financial rewards, for choosing high-value services and providers through strategies including:
  
  - Using transparent, aligned methods to evaluate quality and cost in order to tier providers.
  
  - Increasing the cost-sharing differentials between preferred and non-preferred tiers to better reflect value-based differences among providers.

iii Improving educational and outreach efforts to help health insurance brokers, employers, and employees better understand the range of products available and their benefits and tradeoffs.

iv Exploring limited network products that are associated with one or more high performing ACOs.

d Increase availability of price and quality information to enhance the selection of value-based providers: Payers should increase the availability of information on price and quality at the point of referral to allow patients and providers to make better-informed decisions about treatment options.

**ENHANCING DATA AND MEASUREMENT FOR TRANSPARENCY AND ACCOUNTABILITY**

Transparency and data availability are critical to realizing quality improvement and cost containment goals for the Commonwealth’s health system. Data are essential to all aspects of system transformation, including setting priorities, harnessing the power of consumer choice, strengthening care delivery, designing and succeeding in new payment models, and monitoring progress.

To advance the goal of greater transparency and data availability in 2017, the HPC recommends:

13 Recognizing CHIA’s substantial progress on the recommendations from the 2015 Cost Trends Report, CHIA should continue to improve and document its data resources and develop key spending measures. Specifically:

- **Data on drug rebates.** CHIA should continue efforts to collect and report aggregate drug rebate amounts and reflect this information in estimates of total health care expenditures.

- **The All-Payer Claims Data Base (APCD).** The APCD is a critical tool for evaluating and monitoring system performance and represents a significant investment on the part of the state’s payers. To enhance the return on this asset, CHIA should:
  
  - Implement a master provider crosswalk to link providers to organizations in connection with the Massachusetts Registration of Provider Organization Program.
ii Continue to improve and validate methods to attribute patients to primary care providers within the APCD both for HMO and PPO populations.

iii Seek to minimize loss of employer-based claims due to the Gobeille decision and to evaluate the impact of expected loss on the representativeness of the data that remain.

c **Total Medical Expenditures for PPO populations.** CHIA should continue to work on ensuring that payers report total medical expenditure measures for PPO populations.

d **Provider-level measures of spending growth.** In 2017, CHIA and the HPC should seek to finalize their development and implementation of measures of spending for hospitals, specialist physician groups and other provider types as necessary and feasible.

e **Ambulatory quality measures.** CHIA should continue efforts to collect and report on measures of healthcare quality for services provided in the community including measures of patient experience and outcomes.

**CONCLUSION**

In the coming year, the HPC will pursue the activities noted above and work collaboratively with the Baker-Polito Administration, the Legislature, Massachusetts health care industry, employers, consumers, and other stakeholders to advance the goals of a more affordable, effective, accountable, and transparent health care system in Massachusetts.
### Exhibit 10.1: Dashboard of HPC system performance metrics

<table>
<thead>
<tr>
<th>Key area</th>
<th>Measure</th>
<th>MA time trend</th>
<th>Comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>U.S.</td>
</tr>
<tr>
<td></td>
<td><strong>Benchmark and spending</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Efficient, high-quality care delivery</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4a. Readmission rate (All payer)*</td>
<td>15.3% (2014)</td>
<td>15.8% (2015)</td>
</tr>
<tr>
<td></td>
<td>5a. BH-related ED utilization (per 1,000 persons)</td>
<td>25.6 (2014)</td>
<td>26.0 (2015)</td>
</tr>
<tr>
<td></td>
<td>8. Number of PCPs practicing in certified PCMHs</td>
<td>2,024 25.3% of all PCPs (2015)</td>
<td>2,347 28.6% of all PCPs (2016) ▲</td>
</tr>
<tr>
<td></td>
<td>10. Of decedents who used hospice, percent who used hospice for 7 days or less</td>
<td>N/A</td>
<td>30.9% (2012) (Medicare 65+)</td>
</tr>
</tbody>
</table>

| Better performance | Similar performance | Worse performance | Projected worse performance |
# Chapter 10: Policy Recommendations

## Key area Measures

<table>
<thead>
<tr>
<th>Measure</th>
<th>MA time trend</th>
<th>Comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>APMs</strong></td>
<td><strong>U.S.</strong></td>
<td><strong>Target</strong></td>
</tr>
<tr>
<td>12. Percentage of commercial HMO patients in APMs</td>
<td>64% (2014)*</td>
<td>58% (2015)</td>
</tr>
<tr>
<td>13. Percentage of commercial PPO patients in APMs</td>
<td>2% (2014)</td>
<td>1% (2015)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Measure</th>
<th>MA time trend</th>
<th>Comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Value-based markets</strong></td>
<td><strong>U.S.</strong></td>
<td><strong>Target</strong></td>
</tr>
<tr>
<td>15. Enrollment in tiered and limited network products</td>
<td>19.1% (2014)</td>
<td>19.1% (2015)</td>
</tr>
<tr>
<td>16. Percentage of discharges in top 5 networks</td>
<td>60.9% (2014)</td>
<td>59.9% (2015)</td>
</tr>
<tr>
<td>17. Percentage of community appropriate discharges from community hospitals</td>
<td>53.6% (2014)</td>
<td>53.3% (2015)</td>
</tr>
</tbody>
</table>

---

Notes: THCE = total health care expenditures; ED = emergency department; PAC = post-acute care; PCP = primary care physicians; PCMH = patient-centered medical home; HMO = health maintenance organization; PPO = preferred provider organization; APM = alternative payment method. For additional notes, see Technical Appendix.

Sources:
- Measure 1-MA: Centers for Health Information and Analysis 2016 Annual Report
- Measure 2-MA: Center for Health Information and Analysis 2016 Annual Report Private Commercial Enrollment Databook
- Measure 2-U.S.: Centers for Medicare and Medicaid National Health Expenditure Data, 2016
- Measure 4: Centers for Medicare and Medicaid Services Geographic Variation Data Files, 2016
- Measure 4a: Center for Health Information and Analysis Hospital-Wide Adult All-Payer Readmissions in Massachusetts: SFY 2011-2015 (Report)
- Measures 5, 5a-MA: HPC analysis of Center for Health Information and Analysis Emergency Department Data Base, 2011-2015
- Measure 5-U.S.: Kaiser Family Foundation State Health Facts, 2016
- Measure 6-MA: HPC analysis of Center for Health Information and Analysis Hospital Discharge Database, 2014–2015
- Measure 6a-US: HPC analysis of Healthcare Cost and Utilization Project (HCUP) Emergency Department Database, 2013
- Measure 10-MA: HPC analysis of Massachusetts All-Payer Claims Database, 2012
- Measure 10-US: National Hospice and Palliative Care Organization, Facts and Figures Hospice Care in America, 2013
- Measures 12, 13, and 14: HPC analysis of Center for Health Information and Analysis 2016 Annual Report Alternative Payment Methods Databook
- Measure 15: HPC analysis of Center for Health Information and Analysis 2016 Annual Report Private Commercial Enrollment Databook
- Measure 16: HPC analysis of Center for Health Information and Analysis Hospital Discharge Database, 2012-2015
- Measure 17: HPC analysis of Center for Health Information and Analysis Hospital Inpatient Discharge Database, 2014-2015
## LIST OF TECHNICAL APPENDICES

| A: | Acute Care Hospitals in Massachusetts by Type of Hospital |
| B1: | Overview of Trends in Spending and Care Delivery |
| B2: | Massachusetts Provider Market: Status and Trends |
| B3: | Prescription Drug Spending |
| B4: | Hospital Utilization |
| B5: | Post-Acute Care |
| B6: | Variation in Spending by Primary Care Provider Group |
| B7: | Alternative payment methods |
| B9: | Demand-Side Incentives |
| B9: | Dashboard |
| C: | Data Sources |
ACKNOWLEDGEMENTS

COMMISSIONERS
Dr. Stuart Altman, 
Chair
Dr. Wendy Everett,  
Vice Chair
Dr. Carole Allen
Dr. Donald Berwick
Mr. Martin Cohen
Dr. David Cutler
Mr. Tim Foley
Ms. Kristen Lepore,  
Secretary of Administration and Finance
Mr. Rick Lord
Mr. Ron Mastrogiavanni
Ms. Marylou Sudders,  
Secretary of Health and Human Services

EXECUTIVE DIRECTOR
Mr. David Seltz

The HPC’s Research and Cost Trends staff led the analysis and preparation for the annual cost trends report: Dr. David Auerbach, Rose Kerber, Lyden Marcellot, Natasha Reese-McLaughlin, Sara Sadownik, Rachel Salzberg, and Cory Stasko. Guidance was provided by Executive Director David Seltz, Dr. David Cutler, Chair of the Board’s Cost Trends and Market Performance Committee, Dr. Stuart Altman, Board Chair, and Dr. Wendy Everett, Board Vice Chair. Other commissioners provided recommendations and guidance.

Many HPC staff contributed significantly to the preparation of this report from each of the HPC’s departments: Executive/Chief of Staff (led by Coleen Elstermeyer), Legal (led by Lois H. Johnson), Accountable Care (led by Katie Shea Barrett), Market Performance (led by Kate Scarborough Mills), and Strategic Investment (led by Kathleen Connolly). Ashley Johnston designed the report. We would also like to thank our fellows and interns, Ben Bigelow, Evelyn Brand, Joshua Hollabaugh, Wilna Paulemon, and Shane Visram.

The HPC acknowledges the significant contributions of other government agencies in the development of this report, including the Center for Health Information and Analysis (CHIA); the Office of MassHealth and the Department of Public Health within the Commonwealth’s Executive Office of Health and Human Services (EOHHS); the Executive Office of Elder Affairs; the Massachusetts Health Connector; the Massachusetts Attorney General’s Office (AGO); and the federal Centers for Medicare & Medicaid Services (CMS).

HPC staff received valuable assistance from many others in government, industry, and the research community, including Dr. Marian V. Wrobel. The HPC would like to thank its Advisory Council and other market participants and stakeholders for insightful input and comments. We gratefully acknowledge our contractor, Mathematica Policy Research, for assistance with the All-Payer Claims Database (APCD).